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Abstract 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disease. The pathological hallmark of PD is the loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc). Common identifiable genetic causes of early 
onset PD (EOPD) are Parkin and PINK1 mutations. Tigarb, the orthologue of human 
TIGAR (TP53–Induced Glycolysis and Apoptosis Regulator), up-regulation was 
demonstrated in a zebrafish pink1-/- model along with dopaminergic cell loss and 
mitochondrial dysfunction (Flinn et al., 2013). Tigarb knockdown rescued the 
dopaminergic neurons and mitochondrial dysfunction. Here, tigarb upregulation 
suggests an involvement in PD neuropathology. Therefore, we investigated whether 
TIGAR is present in the human brain and elucidate its relationship between TIGAR 
protein and the Lewy body pathology. TIGAR was found in the Lewy Bodies and 
Neurites in SNpc of sporadic PD and Dementia with Lewy bodies patients. TIGAR 
protein was not found in the ubiquitylated inclusions of motor neurone disease or 
multiple system atrophy, suggesting a degree of disease specificity. TIGAR role was 
investigated in fibroblasts from PD patients and controls. TIGAR is expressed and 
translated in human fibroblasts. TIGAR gene expression and protein level between 
controls and parkin-mutant fibroblasts was not significantly different. TIGAR cellular 
localisation was not affected in parkin mutant fibroblasts after rotenone toxic and 
cellular stress exposure. TIGAR involvement in autophagy was not found in sporadic 
PD patients. RNAi methods for efficient TIGAR and PINK1 knockdown were 
designed in using HEK 293T cells as host line, where TIGAR and PINK1 deficiency 
showed no significant effect in the ATP production and mitochondrial morphology. 
CRISPR/Cas9 and microRNAs mediated knockdown were investigated to assess 
gene function and to select the best approach with reproducible and reliable results. 
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1. General introduction 
Parkinson’s disease (PD) is a common, progressive neurodegenerative 
disorder. The pathological hallmark of the disease is loss of dopaminergic neurons in 
the pars compacta of the substantia nigra (SN), resulting in the typical clinical PD 
triad of tremor, akinesia and rigidity. The majority of PD cases are sporadic: in most 
populations only ~5-10% of cases are inherited (Pan and Yue, 2014). The exact 
mechanisms leading to the loss of dopaminergic neurons remain obscure, but new 
insights into genetic and molecular pathways will provide us with the required 
knowledge to design disease-modifying therapy for this and, possibly other 
neurodegenerative disorders.   
1.1 Clinical and pathological features 
PD patients usually present with a continuum of motor and non-motor 
symptoms. The age of onset is usually between 5th and 7th decade of life. Clinical 
criteria to diagnose PD include bradykinesia, pronounced muscular rigidity, tremor at 
rest, postural instability and hypomimia (Emre et al., 2007; Palma and Kaufmann, 
2014; Poewe and Wenning, 2002).  
 
At presentation, 50-70% of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc) will have already been lost and the remaining neurons may contain 
Lewy bodies that may be accompanied by thread-like Lewy neurites in the neuropil. 
Lewy bodies and neurites are cytoplasmic protein aggregates composed 
predominantly of alpha-synuclein and are a pathological hallmark in PD (Baba et al., 
1998; Orth and Schapira, 2001). While these inclusions are predominantly found in 
the pigmented nuclei of the brainstem, Lewy bodies can be found in multiple 
subtentorial brain areas and also non-neuronal tissue (Braak et al., 2003) including 
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the cortex, spinal cord, gastrointestinal tract and endocrine organs (Lee et al., 2017; 
Palma and Kaufmann, 2014). The precise location in the brain where these 
inclusions are initially formed remains elusive, both single and multifocal initiation 
sites have been suggested (Freundt et al., 2012; Visanji et al., 2013).  
1.2 Etiology of PD 
1.2.1  Genetics of PD 
PD is a multifactorial disorder: diverse genetic and environmental factors 
contribute to the development of the disease. Most cases are sporadic, but the 
identification of monogenic inherited PD genes has significantly contributed to our 
understanding of PD (Exner et al., 2012). 
 
Studies of genome-wide linkage analysis in PD families have identified a 
number of chromosomal location of genes (loci) associated with PD. These PD loci 
are known as PARK loci, and a number is consecutively assigned for each new 
identified locus (Chung et al., 2011). 
1.2.1.1 Monogenic forms 
Dominant  
The alpha-synuclein (SNCA) gene, encoding the alpha-synuclein protein, was 
the first gene identified as a cause of PD (PARK1 and PARK4) (Farrer et al., 1999; 
Polymeropoulos, 1997; Polymeropoulos et al., 1996; Singleton et al., 2003a). 
However, mutations in this gene are very rare (<1%) (Hoffman-Zacharska et al., 
2013; Lohmann and Klein, 2008; Markopoulou et al., 2008). Mutations in the 
Leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of 
PD (PARK8) (Paisán-Ruíz et al., 2004; Zimprich et al., 2004). The 
Glucocerebrosidase (GBA) gene encodes the β-glucocerebrosidase lysosomal 
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enzyme, homozygous and compound heterozygous mutations which cause of 
Gaucher disease (GD). Heterozygous GBA mutations have been identified as a 
strong risk factor for PD (Aharon-Peretz et al., 2004; Lesage et al., 2011; Neumann 
et al., 2009; Sidransky et al., 2009). The neuropathology from people with PD and 
mutations in GBA is comparable to that of classical, sporadic PD (Aharon-Peretz et 
al., 2004; Ma et al., 2013; Sidransky et al., 2009).  
Recessive  
The Parkin (PARKN) gene is the most common cause of autosomal 
recessively inherited PD with early onset PD (EOPD) (Asakawa et al., 2001; Kitada 
et al., 1998) representing ~50% of mutations occurring in EOPD (Lohmann et al., 
2003; Lücking et al., 2000; Pramstaller et al., 2005). The PTEN-induced putative 
kinase 1 (PINK1; PARK6) gene is the second most common cause (1-7%) of EOPD 
(Valente et al., 2001, 2004). Mutations in DJ-1 (PARK7) are rare and account for 
<1% of PD cases (Alcalay et al., 2010; Bonifati et al., 2004). 
Sporadic 
 PD etiopathology is mainly sporadic (~90%), where no evidence of familial 
history can be found. However, there is a 2-14 fold increased risk for PD for first-
degree relatives of an affected PD patient compared to the general population.  It is 
a complex disorder where a number of factors interact and contribute to the 
development of the disease. One of these factors are genetic variations, with ~28 
independent risk significant loci identified (Nalls, 2014). The majority of the candidate 
risk-related genes and loci have been found by linkage analysis and genome wide 
association studies (GWAS). Some of these candidate genes had been 
demonstrated to be relevant for the disease across different populations and models. 
Here, we will focus in the main candidate genes with strong risk association for PD. 
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Variations within the SNCA gene have been established as one of the main 
susceptibility genes for PD. SNCA mutations in familial PD support its role as a risk 
factor and susceptibility for the disease. More than 800 variations with positive SNCA 
risk association for PD have been reported up to date. Reported SNCA variations 
are: a) single nucleotide polymorphisms (SNP) analysis, which revealed a positive 
association between SNPs within promoter region (REP1), the 3’UTR region (e.g. 
rs356165), 3’ end (e.g. rs356219) and intronic region (e.g. rs2736990) of the gene 
and increased risk for PD across different populations; b) locus duplications and 
triplications and; c) point mutations in the amino-terminal region. The rs256220 SNP 
is the variation that showed the highest reproducibility across different studies 
(Redenšek et al., 2017). Some of the SNPs were reported to have a significant 
impact the SNCA levels in blood, serum, plasma and brain samples. The suggested 
biological effect might be by modifying SNCA expression at transcriptional levels and 
protein aggregation. Few studies investigated the association of SNPs in the clinical 
phenotype (severity and outcome) with inconclusive results. Increased levels of 
SNCA had been associated with increased risk for PD, whereas decreased levels 
were described as protective from the disease (Loureiro and Silva, 2017).  
 
In 1-10% of sporadic PD cases, LRRK2 variations have been associated in 
different populations. LRRK2 variants include from rare high penetrant variants to 
common variants with decreased effect confirmed as a susceptibility gene. The 
biological effect of the reported variants involved endo-lysosomal pathways, 
autophagy and mitochondrial function by affecting LRRK2 function, interaction and 
phosphorylation with binding proteins (Redenšek et al., 2017). The most common 
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reported variation is p.Gly2019Ser (rs34637584), where LRRK2 increased activity 
has been associated with increased risk for PD (Wallings et al., 2015).  
 
MAPT, commonly known as tau, is a protein ubiquitously expressed in the 
neurons and involved in cellular maintenance and organisation. Pathologic 
aggregations have been described in a number of neurodegenerative disorders, 
such as Alzheimer’s Disease (AD), Pick’s disease, and other parkinsonian disorders. 
Tau pathology has been described in PD cases, mostly with LRRK2 mutations (Soto-
ortolaza et al., 2013). It has been confirmed by different studies as a risk factor for 
PD, with up to 40 mutations described. However, variants reported have not been 
replicated. The SNP rs393152 and the inversion locus polymorphism on 
chromosome 17 (900 kb) including several genes besides MAPT, are the ones 
consistently reported with associated risk for PD. Two haplotypes of this locus have 
been described: H1 and H2, where H1 increased MAPT transcription and H2 
decreases it (Peeraully and Tan, 2012). The biological effect has been suggested to 
occur alongside SNCA and hyperphosphorylation of the protein, leading to 
impairment of the microtubule organization, altered cytoskeleton, defective axonal 
transport and impaired autophagy with protein aggregation (Pascale et al., 2016). 
 
The GBA gene was confirmed as a genetic risk factor for PD. Heterozygote 
mutations have been reported to increase the risk for PD in many populations (Li et 
al., 2013). The encoded enzyme is located in the lysosomal membrane, where 
ceramide and glucose are produced after glucocerebrosides had been cleaved. GBA 
mutations decrease the enzymatic activity. 
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Although the GWAS and statistic analysis reported strong association 
between the different genes and the risk for PD, their contribution for the disease 
remains low. The candidate genes and with the highest association are: SNCA, 
MAPT, LRRK2, GBA, Bone marrow stromal cell antigen 1 (BST1), CCDCC2/HIP1R, 
cyclin G association kinase (GAK), diacylglycerol kinase theta (DGKQ), serine 
threonine kinase 39 (STK39) and synaptotagmin XI (SYT11) (Ferreira and Massano, 
2017). 
Environmental factors  
 Some environmental factors have been described as exogenous risk factors 
for sporadic PD. It is suggested that the complex interplay between these and 
susceptibility genes might trigger for the disorder. Epidemiological studies showed 
positive associations between PD and pesticides, including toxins such as paraquat, 
rotenone, organophosphates and organochlorines. Paraquat is a mitochondrial 
Complex I (CI) inhibitor, which also promotes cytosolic oxidative stress and 
apoptosis mediated by caspase-3. Rotenone, also induce mitochondrial dysfunction 
via CI inhibition. Both reagents have been used to study PD-related mechanisms in 
cellular and animal models (Fleming, 2017). 
 
Heavy metals have been also associated with PD development and other 
neurodegenerative disorders. These include iron and manganese as the main 
culprits. Excessive exposure to pesticides and heavy metals lead to PD symptoms 
and cognitive impairment, due to accumulation within the basal ganglia and SN 
mainly (Kwakye et al., 2015; Wang et al., 2016c). Their toxic mechanism remains 
unknown, but it has been suggested to be secondary to oxidative stress, 
mitochondrial dysfunction and impaired protein clearance leading to apoptosis.  
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 Currently, the list of suspected environmental factors is growing, however, 
their role as risk factors remain to be verified. Amongst these are newer pesticides. 
Protective factors such as, smoking and caffeine, have also been reported. However, 
the mechanisms underpinning the apparent protective effect remain to be 
determined (Hernán et al., 2002).  
1.3 Pathogenesis in PD 
1.3.1  Mitochondrial dysfunction in PD 
 There is strong evidence that mitochondrial function plays a key role in the 
disease process. The main mitochondrial functions involved are defects in the 
respiratory chain complexes. The first evidence was found during the 80’s decade in 
drug users in California. They developed parkinsonian symptoms after self-
administration of the synthetic heroin analogue 1 methyl-4-phenyl-1,2,3,6-
tetrahydropiridine (MPTP). Post-mortem studies performed in these people revealed 
dopaminergic neuronal damage within the SN (Langston et al., 1983). Later, it was 
found that MPTP crosses the blood brain barrier, enter to the astrocytes where is 
oxidised to 1-methyl 1-4-phenylpyridinium (MPP+). MPP+ was found to be a 
dopamine receptor substrate. Therefore, when MPP+ is released, it enters the 
dopaminergic neuron. Mitochondrial dysfunction follows when CI is inhibited, leading 
to neuronal death (Langston et al., 1984; Ransom et al., 1987). Further evidence 
was found in the brains of sporadic PD patients, in which CI deficiency was reported 
in the SN and other brain regions (Mann et al., 1992; Mizuno et al., 1989; Navarro et 
al., 2009; Parker et al., 2008; Schapira et al., 1989). Furthermore, CI inhibitors, such 
as MPTP, rotenone and paraquat, recapitulate PD pathology in cells and animal 
models featuring dopaminergic neuronal loss, as well as clinical signs of PD 
(Cochemé and Murphy, 2008; Corona et al., 2010; Decressac et al., 2012; Gille et al., 
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2004; Irwin and William Langston, 1985; Langston et al., 1984; Qureshi and Paudel, 
2011; Sallinen et al., 2010; Sharma and Nehru, 2013; Tanner et al., 2011; Wu et al., 
2011; Yong-Kee et al., 2012). CI deficiency has been consistently demonstrated in 
PD tissue such as human fibroblasts, platelets and lymphoid cells (Krige et al., 1992; 
Mann et al., 1992; Mortiboys et al., 2008, 2013; Parker et al., 1989; Rh et al., 1995; 
Yoshino et al., 1992).  
 
CI inhibition leads to increased reactive oxygen species (ROS) mitochondrial 
production and reduced ATP production, which results in cellular neuronal damage 
and death. Furthermore, CI deficiency induces Ubiquitin proteasome system (UPS) 
impairment, followed by accumulation of misfolded proteins (Reeve et al., 2015). 
Mutant SNCA (Braidy et al., 2013; Chinta et al., 2010; Choubey et al., 2011; Hsu et 
al., 2000; Kamp et al., 2010), PINK1 (Chung et al., 2016; Exner et al., 2007; Hilker et 
al., 2012; Lutz et al., 2009; Morais et al., 2014; Park et al., 2006; Priyadarshini et al., 
2013; Rakovic et al., 2011) and Parkin (Flinn et al., 2009; Grünewald et al., 2010; 
Haylett et al., 2016; Hoshino et al., 2013; Mortiboys et al., 2008, 2013; Müftüoglu et 
al., 2004; Palacino et al., 2004; Rakovic et al., 2010; Seibler et al., 2011; Sethi and 
Kang, 2011; Vergara et al., 2014) deficiency are related to impaired mitochondrial 
morphology, CI dysfunction, increased ROS production and altered bioenergetics 
status of the cell. LRRK2 mutations also lead to increased ROS and oxidative stress, 
CI, II and IV deficiency, altered mitochondrial morphology and mitochondrial 
dynamics by affecting the function of uncoupling and mitochondrial fission proteins 
(Grunewald et al., 2013; Mortiboys et al., 2010a, 2015; Papkovskaia et al., 2012).   
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1.3.2  Autophagy and mitophagy in PD 
Autophagy is the cellular process by which all the damaged/dysfunctional 
organelles and proteins are cleared from the cell. Autophagy is usually triggered by 
different cellular stimuli and can be divided into 3 types depending on the structures 
processed into the lysosomes: macroautophagy, chaperone-mediated autophagy 
(CMA) and microautophagy. The formation of the autophagic vesicle follows 5 steps: 
initiation, nucleation, elongation, fusion and degradation. Macroautophagy is the 
most studied process of all (Yoshii and Mizushima, 2017). 
 
In macroautophagy, the components are sequestered in double-membrane 
vesicles, forming the autophagosome, which fuses the lysosome for degradation. In 
microautophagy, lysosomes are in charge of the uptake and degradation of 
cytoplasmic contents directly without forming the autophagosome. In CMA, the 
process requires the presence of the KFERQ (LysPheGluArgGln) peptide in the 
substrate protein. This substrate protein is then recognised by the chaperone heat 
shock proteins (Hsp70), and brings it to the lysosomal receptor, where it is 
translocated by LAMP2A. The substrate is unfolded and degraded in the lysosome.  
 
Autophagy is a highly regulated process, where a number of molecules are 
required upon stimulation (eg. Nutrient starvation and oxidative stress). Specific 
adaptor proteins p62/SQSTM1 are required for recognition of ubiquilated proteins. 
The autophagy related genes (ATG) are necessary to form the autophagic vesicles 
and autophagosomes. The ATG genes are regulated by: a) the mammalian target of 
rapamycin (mTOR), which inhibits autophagy under physiological conditions; b) 
beclin complex and; c) LC3 lipidation process. LC3-I (cytosolic protein) conversion to 
LC3-II (recruited to the autophagosome membrane) is a hallmark marker of 
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autophagy. Mitophagy is the process in which damaged mitochondria are removed 
and cleared from the cell. This regulated process to maintain the right pool and 
quality mitochondria upon metabolic stress. 
 
Autophagy and mitophagy have been demonstrated to be one of the main 
cellular pathways that might be impaired in PD and contribute to neurodegeneration 
(Redenšek et al., 2017).   
1.3.2.1 The PINK/Parkin Pathway 
Parkin and PINK1 have roles in the same mitochondrial pathway (Pickrell and 
Youle, 2017). Both have been found to be involved in the dynamics and homeostasis 
of mitochondrial function, energy production (ATP), modulation on proteasome 
degradation and clearance of damaged mitochondria (Geisler et al., 2010a, 2010b; 
Ryan et al., 2015; Wild and Dikic, 2010). 
 
It was recently found that PINK1 has a role as an ubiquitin kinase and after 
the mitochondrial membrane potential is lost, it phosphorylates ubiquitin and the 
Parkin ubiquitin-like domain on S65. These events were reported to be required for 
Parkin activation (Aguirre et al., 2017; Schubert et al., 2017). Therefore, when PINK1 
is stabilised on the mitochondrial outer membrane (OMM), it enables Parkin 
translocation to the mitochondria (Wild and Dikic, 2010). In response to 
mitochondrial depolarisation, PINK1 binds, translocates, phosphorylates and 
activates E3 ligase Parkin. PINK1 mutations impede PINK1 importation and 
stabilisation and thus inhibit Parkin binding and translocation to the mitochondria 
(Geisler et al., 2010a, 2010b), as well as PINK1/PARL processing.  
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Following activation and mitochondrial translocation, Parkin polyubiquitinates 
itself and the outer mitochondrial proteins (mitofusins and VDAC) to recruit the 
autophagy adaptor p62 and induce the proteasome/phagophore formation by binding 
Agt8/LC3 to promote autophagy (Geisler et al., 2010a, 2010b). PINK1 is imported to 
the mitochondria and cleaved in presence of a normal mitochondrial membrane 
potential; this enables PINK1 to recruit and translocate Parkin to the mitochondria. 
Activated Parkin can ubiquitinate the proteins of the MOM, voltage dependent anion 
selective channel 1 (VDAC) and p62, which binds LC3. The autophagophore is 
formed promoting autophagy (Wild and Dikic, 2010). Recently, Wang et al. 2017, 
found that LRRK2 is also recruited to the depolarised mitochondria alongside PINK1 
and Parkin. They suggested that the three PD proteins remove RHOT1/Miro (an 
outer mitochondrial membrane protein) to be degraded by the proteasome. This 
leads to mitophagy after the targeted mitochondria is arrested. (Wang, 2017) (Figure 
1.1). 
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Figure 1.1 Schematic representation of the PINK/Parkin pathway. PINK1 is imported to the 
mitochondria and cleaved in presence of a normal mitochondrial membrane potential (MMP). PINK1 
phosphorylates ubiquitin and Parkin ubiquitin-like (Ubl) domain. This enables PINK1 to recruit and translocate 
Parkin to the mitochondria. Activated Parkin can ubiquitinate the proteins of the outer membrane (OMM) VDAC 
and p62, which binds LC3. The autophagophore is formed promoting mitophagy (Aguirre et al., 2017; Schubert et 
al., 2017; Wild and Dikic, 2010).  
Further research has suggested a physical interaction between the Parkin 
RING 1 domain and the p53 (TP53) promoter region. Parkin seems to be a P53 
target gene under both stress and non-stress conditions (Alves da Costa and 
Checler, 2010; da Costa et al., 2009; Zhang et al., 2011). Protein-protein interaction 
between cytosolic p53 and Parkin inhibits Parkin translocation and mitophagy in 
cardiac myocytes from mice (Hoshino et al., 2013). Furthermore, Parkin may act as 
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a p53 target to maintain genome stability by regulating ROS levels (Zhang et al., 
2011).  
1.3.3  Neuroinflamation 
 Neuroinflammation is a further characteristic of PD pathology. However, it is 
unknown whether it is cause or consequence of the disease process. Post-mortem 
studies of brains of PD cases and animal models have shown that pro-inflammatory 
factor levels are increased. One of the main mediators involved in inflammation are 
activated microglia resulting in chronic exposure to ROS and production of cytokines 
within the brain. Mutant SNCA can be recognised as a pathogen by toll-like 
receptors (i.e. TLR2, TLR4), which triggers inflammation through NF-Kb 
translocation and cytokine production, activation and expression. The immune 
response may depend of the conformation of SNCA, where β-sheet conformations 
showed higher sensitivity. Protein aggregates and misfolded SNCA activate 
microglia, which also triggers the production of inflammatory cytokines (TNF-α and 
IL-1β) leading to neurotoxicity and neuronal death (Austin et al., 2011; Béraud et al., 
2011). Despite this, recent findings have demonstrated that microglia can also have 
protective effects by clearing damaged neurons as a result of neurotoxic exposure 
(Gomez-Nicola and Perry, 2014).  
1.3.4  Alpha-synuclein (SNCA) pathology 
As mentioned above, SNCA was the first gene described as a genetic cause 
for familial PD. Subsequently, alpha-synuclein was discovered to be the main 
component of the Lewy bodies and glial cytoplasmic inclusions in PD and related 
alpha-synucleinopathies. Despite this, how SNCA promotes PD pathology and the 
exact physiological function are still unknown (De Franceschi et al., 2017). Alpha-
synuclein is composed of 140 amino acids and expressed in neuronal synaptic 
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terminals (Sengupta et al., 2015). Alpha-synuclein is important for normal synaptic 
function, vesicle trafficking, release and recycling, as well as a regulator of dopamine 
metabolism (release and uptake) (Lautenschläger et al., 2017; Nakata et al., 2012; 
Pelkonen et al., 2013). Several mechanisms for SNCA PD-related pathology have 
been reported, mostly related to toxic effects. Duplications, triplication, gene 
mutations and posttranslational modifications in SNCA inducing its overexpression 
have been related to increased protein aggregation within the neurons in in vitro an 
in vivo models (Bezard et al., 2013). Protein aggregates are resistant to degradation 
due to impaired autophagy, leading to cellular death. Overexpressing SNCA (Wild 
type and mutant) can impair autophagy through different mechanisms: by inhibition 
of the chaperone-mediated autophagy; compromising the synthesis and clearance of 
the autophagosome and UPS pathway; attaching to lysosome receptor LAMP2A, 
preventing its internalisation to the lysosome; and inhibition of lysosomal enzymes, 
such as GBA (Gan-Or et al., 2015). Mitophagy might be also impaired by mutant 
SNCA, due to increased protein aggregation with increased ROS levels. As a result, 
increased levels of oxidative stress promote mitochondrial fragmentation and 
dysfunction, affects MMP and permeability. This entire cascade of events leads to 
impaired mitophagy and clearance (Redenšek et al., 2017; Wang et al., 2016a). 
 
Others suggested that increased levels of alpha-synuclein might impair the 
dynamics and recycling of the synaptic vesicles (Mazzulli et al., 2016). They can also 
impair the interaction with dopamine, induce a conformational change and inhibit the 
degradation of alpha-synuclein through the CMA (Chinta et al., 2010). Additional 
toxic mechanisms include impaired Ca2+ homeostasis; tyrosine hydrolase 
phosphorylation and function. Alpha-synuclein aggregates also lead to increased 
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neuroinflammation in the microglia induced by proteins of the immune response (i.e. 
Major histocompatibility complex and TLR) (Gustot et al., 2015; Luth et al., 2014; 
Venda et al., 2017).  
1.4 TIGAR  
TIGAR (TP53-Induced Glycolysis and Apoptosis Regulator; also known as 
C12orf5) was identified by Bensaad, et al. 2006. The TIGAR locus is on 
chromosome 12p13-3. It has 6 coding exons and two p53 binding sites known as 
BS1 (intron 1) and BS2 (intron 2). It is characterised by a structural and protein 
similarity to the biphosphatase domain of the enzyme 6-phosphofructose-2-
kinase/fructose-2,6-biphophatase (PFK-2/FBPase-2). Both FBPase-2 and TIGAR, 
decrease Fructose-2,6-Biphosphate (Fru-2,6 P2) levels. Fru-2,6 P2 is the substrate of 
Phosphofructokinase-1 (PFK-1), the key enzyme in the glycolytic pathway. By 
lowering the Fru-2,6 P2 levels, TIGAR inhibits the glycolytic pathway and promotes 
the Pentose Phosphate Pathway (PPP). This, in turn, reduces reactive oxygen 
species (ROS) by increasing the production of NADPH and reduced glutathione 
(GSH) (Figure 1.2) (Bensaad et al., 2006).  
Li and Jogl (2009) reported that TIGAR protein also has a similarity to the 
catalytic unit of the Fru-1,6-P2 and F26BPase enzymes. F26BPase is the key 
metabolic activator enzyme of glycolysis and Fru-1,6-P2 is a glycolytic intermediate. 
Due to the shared homology, TIGAR binds the catalytic unit of the F26BPase 
enzyme. Following this event, inhibition of glycolysis occurs due to down-regulation 
of the F26BPase and removal of the Fru-1,6-P2 enzymes. The closest structural 
relation exists between TIGAR and the PhoE phoshphatase (PhoEP) enzyme, 
whose unknown activity might have an additional underlying role in glycolysis (Li and 
Jogl, 2009).  
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Furthermore, Gerin et al., 2014; found that the 2,3-Biphosphoglycerate 
(23BPG), cofactor of the Phosphoglycerate mutase enzyme (PGAM), has a higher 
affinity (~400-fold) for TIGAR compared to F26BP. This suggests an added action of 
TIGAR as a phosphatase, on the grounds of a shared distant homology with the 
histidine phosphatase family (PhoEP) and substrate specificity. However, 23BPG 
has been reported as present and active only in erythrocytes (where it is important 
for oxygen binding to haemoglobin) without any other known functional relevance in 
other cell types (Gerin et al., 2014).  
 
               
Figure 1.2 TIGAR function in the glycolytic and Pentose Phosphate pathway. TIGAR has a shared 
homology to the biphosphatase domain of the PFK-2/FBPase-2 enzyme. Therefore, TIGAR acts by inhibiting the 
glycolytic enzyme PFK1, lowering the F2,6 P2 and F1,6 P2 levels. 3, Phosphoglycerate; G6P (G3P) Glucose-6-
phosphate; Gluthathione (GSH); Hexokinase (HK); 6-Phosphofructo-1-kinase (PFK1); Phosphoglycerate Mutase 
(PGM); Tricarboxylic Acid Cycle (TCA) (Maddocks and Vousden, 2011; Riganti et al., 2012). 
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1.4.1 TIGAR regulators  
The type of TIGAR response (glycolysis and metabolic regulation, ROS 
scavenging, cellular survival and autophagy) within a cell depends on several 
different factors, including stress due to ischaemia or hypoxia; as well as the cell 
type (Bensaad et al., 2009; Cheung et al., 2012; Sun et al., 2015; Zou et al., 2012).    
 
p53. The first identified protein acting as an upstream regulator of TIGAR is 
p53. P53 is a transcription factor that induces different cellular responses depending 
on the cellular physiological demand or damage response. Despite the importance of 
p53-regulation of TIGAR, it is now known that there are several other TIGAR-
mediated mechanisms, which are p53-independent. These are important because 
p53 is not essential to maintain TIGAR basal expression levels (Lee et al., 2015). 
 
p63 and p73. Recent findings have described further molecules that regulate 
TIGAR levels and activity. These include p63 and p73, two other genes from the 
same family of transcription factors as p53 and have been suggested to be upstream 
regulators of TIGAR. A p63- and p73-dependent cellular survival function of TIGAR 
has been demonstrated in intestinal crypts. However, the full details of these 
regulatory mechanisms remains unclear and not fully confirmed (Lee et al., 2015). In 
addition, an inverse correlation has been described between TIGAR expression and 
both p63 and p73, within thymic lymphomas. This mechanisms probably involves 
different P63 and P73 isoforms, which would influence the tumour growth rate 
(Venkatanarayan et al., 2016). 
 
SP-1. SP-1 is a common transcription factor that is responsible for the 
activation or repression of several different genes, affecting a diversity of cellular 
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mechanisms, including, cellular metabolism, cellular proliferation and growth, 
chromatin remodelling and apoptosis (Beishline and Azizkhan-Clifford, 2015; Henson 
et al., 1992). SP-1 has been described in a diversity of cell types, including neuronal 
cells, where it provides a role in neuronal modulation and protection in Huntington’s 
Disease (Qiu et al., 2006). SP-1 has also been suggested to play a role in various 
neurodegenerative diseases, mainly tauopathies: In AD, co-localisation of SP-1 has 
been seen with tau protein in neurofibrillary tangles (NFT), dystrophic neurites, 
threads and plaques. Whereas in other tauopathies, such as Pick’s disease and 
progressive supranuclear palsy, SP-1 is present in neurons, astrocytes and 
oligodendrocytes. Moreover, a negative correlation between Lewy pathology and 
SP-1 has been found in PD and dementia with lewy bodies (DLB) (Santpere et al., 
2006). SP-1-mediated regulatory mechanisms of TIGAR were first demonstrated In 
cancer liver cells, where SP-1 positively interacts with the TIGAR promoter, where it 
modulates TIGAR basal transcription (Zou et al., 2012). 
 
CREB. The highly conserved promoter region of TIGAR contains specific 
sites for many DNA binding-motifs of a variety of transcription factors. Recently, a 
CREB box within this region has been described (Zou et al., 2013). CREB is a 
transcription factor from the leucine zipper family. It is responsible for a number of 
transcriptional responses to different stimuli (e.g. growth hormonal and stress 
signals); (Wang et al., 2016e). CREB expression levels correlate with, and are 
indispensable for, TIGAR expression. However, further transcription factors that 
drive TIGAR expression remain to be elucidated (Zou et al., 2013).   
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PI3-AKT-mTOR. The PI3-AKT-mTOR pathway also has been described as 
an upstream regulator of TIGAR in colonic cancer cell lines. This is an important 
signalling pathway for protein translation by activating eIF4F, an initiation factor that 
induces protein translation (Ahmad et al., 2017) 
 
NSD2. The nuclear receptor-binding SET domain-containing 2 (NSD2) protein, 
also known as multiple myeloma SET domain (MMSET) or Wolf-Hirschhorn 
syndrome candidate 1 (WHSC1), is a H3K36 histone methyltransferase. Some of its 
main functions are via epigenetic gene regulation, NF-Κb and cytokine modulation as 
well as driving expression of oestrogen receptor in breast cancer. NSD2 
overexpression can lead to tumour resistance via glycolytic enzymes and PPP 
pathway induction. The proposed mechanism is by direct stimulation of NSD2 
recruited in the promoter of the glycolytic genes TIGAR, HK-II and G6PD (Wang et 
al., 2016b). 
 
ATM. A possible relation between neurodegenerative disease process via 
upregulation of the ATM-p53-TIGAR pathway has been suggested. The Ataxia-
Telagiectasia Mutated gene (ATM) encodes a key protein involved in DNA-damage 
repair (DDR) to double-strand breaks (DSBs). It acts as an upstream regulator by 
promoting several genes related to cellular proliferation, apoptosis and repair, such 
as p53. Recently, the up-regulation of the ATM gene was found to co-occur with a 
progressive decrease of TIGAR protein levels in patients with AD (Katsel et al., 
2013).  
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HK-II. HK-II (hexokinase II) is prevalent in tissues with high energy demand, 
such as skeletal muscle, heart and adipocytes (John et al., 2011). It also has an 
important role in regulating cellular survival and autophagy under glucose deprivation 
conditions or type of cellular damage (Tan and Miyamoto, 2015). Overexpression of 
mitochondrial HK-II may confer neuronal protection and survival in animal and 
cellular models of PD and neurodegeneration (Corona et al., 2010; Gimenez-
Cassina et al., 2009). Under hypoxic conditions, mitochondrial HK-II is important for 
TIGAR mitochondrial translocation, where both proteins form a complex. This results 
in HK-II stabilization and enhanced activity and interaction with TIGAR upon 
presence of glucose and active HIF-1α. 
1.4.2 TIGAR mechanisms 
Cellular protection and DNA repair. One of the main actions described in 
the p53-TIGAR pathway, is the PPP, which protects cells from damage and aid 
survival by reducing levels of reactive oxygen species and providing cells with 
NADPH and GSH (Bensaad et al., 2006).  
 
In hepatocarcinoma, TIGAR has been suggested as providing cellular 
protection by promoting DDR via a number of mechanisms: Firstly, the PPP pathway 
is involved by providing the cell with nucleotide precursors for DNA synthesis, as well 
as reducing agents (e.g. NADPH and G6PD) to protect against reactive oxygen 
species (Xie et al., 2014). Secondly, in response to cellular hypoxia, TIGAR induces 
nuclear translocation of the oxidoreductase enzyme thioredoxin-1 (TRX1), which is 
important in the DDR pathway (Yu et al., 2015; Zhang et al., 2014). Thirdly, recent 
evidence demonstrates that TIGAR is a modulator of Cdk-5, which is known to 
phosphorylate ATM, consequently triggering the pathway for DDR (Yu et al., 2015). 
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TIGAR role cellular protection during embryogenesis was assessed in mice 
embryos. TIGAR is widely expressed in mouse brain, mainly in the cerebellum, 
olfactory bulb and cortex (Li et al., 2014). It has been suggested that TIGAR levels 
are continuously modified during development from the embryonic stage until adult 
stage in the mouse brain. TIGAR showed to have the highest expression during the 
embryonic and young adult stage. The highest expression of TIGAR in the mice 
brains provided neuroprotection from DNA and cellular damage upon oxidative 
stress and injury by shunting the metabolism to the PPP pathway (Cao et al., 2015). 
 
Cancer. Under adverse metabolic conditions, such as cancer, p53-TIGAR 
and the PPP can contribute to cell survival due to its indirect anti-oxidant effect and 
by providing metabolites, such as ribose-5-phosphate, for DNA biosynthesis and 
repair (Bensaad et al., 2006; Wanka et al., 2012). The property of TIGAR as a ROS 
scavenger and induce anabolism by providing metabolites for DNA synthesis and 
cell growth contribute for the tumour development. TIGAR related mechanisms have 
been described in different cancer types enlisted in Table 1.1. 
 
Another function of the p53-TIGAR pathway is by the regulation of important 
cell cycle genes, which is key to involving tumour progression. When there are low 
levels of cellular stress, p53 induces TIGAR to allow cell repair via the following 
cascade of events: modulation of cell-cycle progression genes and synthesis 
inhibition of cyclins lead to de-phosphorylation of RB-protein. As a result, the RB-E21 
complex is stabilised delaying entry to the S phase of the cell cycle. Consequently, 
better combined therapy via TIGAR mediated-cell cycle arrest with anti-proliferative 
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drugs, can be provided in order to provide a better outcome in some cancers  
(Madan et al., 2012).       
 
The glycoprotein Mucin 1 (MUC1) is a component of epithelial apical surfaces. 
MUC1-C (C terminal subunit of MUC1) and TIGAR, both have been shown to be 
overexpressed in colonic cancer (Al-Khayal et al., 2015; Cheung et al., 2013a; Niv, 
2008) and multiple myeloma (Kawano et al., 2008; Yin et al., 2012a). Inhibition of 
MUC1-C also results in TIGAR down regulation. This is due to the role of MUC1-C 
inhibitors by two mechanisms. First, by preventing AKT phosphorylation and 
therefore, inactivation of EIF4A. This causes reduced TIGAR translation and thereby 
impairing cellular growth and survival (Ahmad, R, 2017). Second, TIGAR reduced 
expression lowers the NADPH and GSH levels, leaving vulnerable the cell to ROS 
damage and mediated cellular death (Yin et al., 2012a, 2014). 
 
Cells depend on energy supply for their maintenance and the glucose uptake. 
This depends on the function of key enzymes, such as glycolytic enzymes. The 
Hexokinase family are enzymes that are responsible for the conversion of glucose to 
glucose-6-phosphate (G-6P). This is a crucial step in the glycolytic pathway and the 
PPP. This family contains four different isoforms of the enzyme: HK-I, HK-II, HK-III 
and HK-IV (also known as glucokinase). HK-I is present in all cellular types, but 
especially in the cerebral tissue and blood cells. It has been suggested that HK-I 
specifically shunts the glycolytic pathway (John et al., 2011; Magrì et al., 2016). HK-II 
stabilization induced the mitochondrial membrane potential and reduced ROS 
production upon hypoxia, which might promote cellular survival and likely contribute 
to tumour progression. The HK-I and HK-II are cytoplasmic proteins that have been 
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previously shown to translocate to the mitochondria through interaction with VDAC 
(Cheung et al., 2012).  
 
NSD2 overexpression induces HK-II, G6PD and, predominantly, TIGAR. 
However, p53 expression is unaffected. Taken together, this suggests a p53-
independent TIGAR function, where NSD2 acts as the key regulator and coordinator 
of the enzymes in the PPP pathway. This provides tamoxifen resistance and poor 
survival rates in some patients with breast cancer (Wang et al., 2016b).  
 
Cancer TIGAR related mechanisms 
MM 
MUC1-C (oncoprotein) inhibition led to a p53-independent reduction of TIGAR 
protein levels, without affecting TIGAR mRNA; suggested to be due to a 
posttranscriptional mechanism (Yin et al., 2012b). 
NCC 
Inhibition of the apoptotic and cell survival regulator c-Met, a tyrosine kinase, 
induced cellular death by lowering p53, TIGAR and NADPH levels. Moreover, 
TIGAR overexpression reversed the growth inhibition by c-Met (Lui et al., 2011). 
Therefore, induced down-regulation of TIGAR has a potential antitumour effect (Lui 
et al., 2010).  
CC 
Reduced apoptotic rate in U2OS cells with TIGAR overexpression, with increased 
ROS induced apoptosis when TIGAR is knocked down (Bensaad et al., 2006). 
Upregulation of TIGAR in colorectal cancer, mainly in advanced stages. This 
suggest to be a good biomarker of colorectal cancer as well as a therapeutic target 
(Al-Khayal et al., 2015). 
BC 
Breast cancer tissue samples of patients with primary invasive breast cancer 
revealed high expression of p53 correlated to low expression of TIGAR, SCO2 and 
COX (Won et al., 2012). Downregulation of Cav- 1 promotes the upregulation of 
TIGAR expression in breast cancer cells, resulting in cancer cell proliferation and 
the suppression of cancer cell apoptosis(Shi et al., 2016) 
GB and 
glioma 
cells 
TIGAR overexpression conferred cell survival. TIGAR shared homology with 
TKTL1 enzyme, which is overexpressed in different neoplasias. TKTL1 inhibition 
suppressed the antioxidant protective and starvation effect of TIGAR. Under 
normoxia, a role of TIGAR preventing apoptosis was proposed. Under hypoxia, 
where ATP production by OXPHOS is limited, suggested to be due to a dual 
modulation of energy production and antioxidant production (Wanka et al., 2012). 
In glioblastoma cells, TIGAR knockdown caused early cell senescence and 
inhibitied cell proliferation, followed by increased sensitization to radiation and 
impaired DNA damage repair (Peña-Rico et al., 2011). 
CLL 
TIGAR expression was related to an increased in cell sensitivity response to the 
cytotoxic agent Fludarabine,  by inducing apoptosis in a caspase-3 dependent 
manner (López-Guerra et al., 2008).  
NSCLC 
TIGAR expression was correlated with FDG-PET results as a marker for evaluation 
of clinical outcome in patients with NSCLC. In patients with NSCLC, positive 
expression of TIGAR was correlated with substantially longer survival rate than 
those with a negative expression  (Zhou et al., 2013).  
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HCC  
TIGAR expression is increased after treatment with epirubicin (anti-cancer agent). 
Knock down of TIGAR led to epirubicin induced apoptosis. In addition, ROS 
production is increased. As a result, cancer cells have enhanced chemosensitivity 
to epirrubicin. A prospective role involving mTOR inhibition has been suggested 
and remains to be elucidated (Xie et al., 2014).  
Table 1.1. TIGAR main mechanisms in cancer. Fluorodeoxyglucose positron emission tomography (FDG-PET); 
Transketolase-like 1 (TKTL1); Cytochrome C oxidase assembly protein (SCO2); Cytochrome c oxidase (COX);  
Non-small cell lung carcinoma (NSCLC); Caveolin 1 (Cav-1); Nicotine adenine dinucleotide reduced (NADH); 
oxidative phosphorylation (OXPHOS); Reactive oxidative species (ROS); Multiple Myeloma (MM); 
Hepatocarcinoma (HCC); Non-small cell lung carcinoma (NSCLC); Chronic lymphocityc leukemia (CLL) 
Glioblastoma (GB); Breast cancer (BC), Nasopharyngeal cancer cells (NCC). 
 
 
Ischemia-reperfusion injury. Hypoxia and ischemic reperfusion injury can 
result in apoptosis in a number of cell types including cardiac myocytes. Main 
detrimental effect is by reperfusion with high volume of oxygenated blood, which 
induce inflammation and oxidative stress. Glycolysis has been described to have a 
vital role for myocyte survival and it seems that maintenance and homeostasis of this 
metabolic pathway is regulated by TIGAR and p53. After myocardial infarction, 
TIGAR and p53 expression were significantly increased. In this context, the 
activation of the p53-TIGAR pathway inhibited glycolysis and energy metabolism, 
which result in apoptosis (Kimata et al., 2010).  
 
On the contrary, TIGAR overexpression in the brain leads to protection 
against brain injury such as ischemia, oxidative stress and oxygen glucose 
deprivation (OGD). This is achieved via reducing levels of reactive oxygen species 
and GSH, and increasing levels of NADPH (Cao et al., 2015). SP-1-mediated 
upregulation of TIGAR is greatly influenced by metabolic hormones that regulate 
glucose and reactive oxygen species. This modulates the TIGAR response to 
ischemia/reperfusion injury in brain tissue (Sun et al., 2015). In addition, SP-1 
regulation of TIGAR has been linked to so-called cerebral preconditioning when 
transient changes occur in the brain in response to ischemic or hypoxic injury, 
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providing tolerance against subsequent lethal ischemic or hypoxic insults. SP-1 and 
TIGAR contribute to this tolerance by regulation of cellular apoptosis and ROS 
scavenging (Zhou et al., 2016). 
 
Interestingly, in testicular ischemia reperfusion injury (TIRI) has also been 
related to TIGAR-p53 pathway activation. TIRI is the considered underlying 
pathology behind testicular torsion and detorsion, which can lead to impaired 
spermatogenesis and testicular function, which could translate into infertility. Here, in 
contrast to the brain, increased expression of the p53-TIGAR pathway promotes 
cellular apoptosis in germinal cells (Al-Maghrebi and Renno, 2016).   
 
Autophagy/Mitophagy and apoptosis. TIGAR has been implicated in 
autophagy through diverse range mechanisms. TIGAR can promote apoptosis by 
inhibiting the glycolytic pathway (Bensaad et al., 2006). Here, a relationship between 
reduced levels of ROS and autophagy inhibition has been suggested (Bensaad et al., 
2009; Ye et al., 2013).  
 
This implies an opposing effect and highlights the complexity of the role of 
TIGAR in regulating ROS levels in response to cellular stress involving both 
apoptotic and autophagy pathways (Bensaad et al., 2009). Increased levels of ROS 
induce p53, which in turn activates transcription of TIGAR, consequently reducing 
autophagy within the cytoplasm (Cheung et al., 2012). Resveratrol is an anti-cancer 
agent that acts by a variety of mechanisms. One of these is via induction of ROS-
mediated apoptosis in cancer cells. Resveratrol inhibits TIGAR and, subsequently, 
autophagy increases in a dose-dependent manner (Hsieh et al., 2015; Kumar et al., 
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2015). Moreover, TIGAR knockdown induced caspase-3 elevation, apoptosis and 
enhanced mitochondrial ROS production in mouse brain tissue from a model of 
ischemia/reperfusion injury (Li et al., 2014). Therefore, neuronal protection against 
DNA and mitochondrial damage has been suggested to be a result of the metabolic 
shift from glycolytic pathway to PPP and oxidative stress reduction (Cao et al., 2015; 
Li et al., 2014). However, in contrast to this, while a protective role through Cdk5-
ATM and the PPP pathway has been suggested for TIGAR, there is also evidence 
for TIGAR-mediated toxicity. In glioblastoma, as mentioned above, cells are 
sensitised by ROS and therefore, made responsive to radiation therapy. As a 
consequence, inhibition of TIGAR produces high levels of ROS, which promotes 
DNA damage and cellular death (Yu et al., 2015).  
 
TIGAR modulates autophagy in a p53-independent manner. Upon metabolic 
stress and nutrient starvation, TIGAR can reduce autophagy, by reducing ROS 
levels. TIGAR has been proposed as a target of the mammalian rapamycin complex 
1 (mTORC1)-related pathway. (Bensaad et al., 2009; Tai et al., 2015; Ye et al., 
2013). This was demonstrated when cells were treated with the mTOR inhibitor 
Rapamycin. Rapamycin result in TIGAR downregulation in the treated cancer cells. 
Furthermore, in cancer cells treated with epirubicin, TIGAR knockdown promoted 
autophagy by inhibiting mTOR and increased ROS production. Here, apoptosis was 
induced by treatment with epirubicin and inhibited autophagy. These findings 
suggest a dual function of TIGAR only as a pro-survival molecule but also as a pro-
apoptotic mediator (Xie et al., 2014). Furthermore, Resveratrol treatment in cancer 
cells downregulation of TIGAR expression suggested to be a result of mTOR 
42 
 
inhibition (Kumar et al., 2015). However, TIGAR ROS-independent function in 
mTOR-mediated autophagy remains to be investigated. 
Mitophagy plays a crucial role in mitochondrial homeostasis in myocytes. 
p53/TIGAR is involved in the Bnip3-mitophagy pathway independent of the 
PINK1/Parkin Pathway. Increased ROS signalling activate Bnip3 which adopts a 
homodimer form in order to promote autophagy and cellular death under conditions 
of severe oxidative stress. (Hoshino et al., 2012). 
 
Early development and regeneration. The effect of TIGAR in development 
was investigated in a mouse model. It was found that development was not affected 
when TIGAR was deficient in mice. In contrast, regeneration of adult intestinal 
epithelium requires TIGAR, particularly after induced damage in rapidly proliferating 
cell types. A lack of TIGAR in damaged intestinal epithelium results in a failure to 
regenerate, reduced tumour size and progression, which could also be contributing 
to tumour progression in cancer cells (Cheung et al., 2013).  
 
Other mechanisms. A number of other p53-independent pathways outside 
glycolysis and the pentose phosphate shunt have been described.  These include a 
role in the regulation of imprinting of genes in the human placenta, possibly related 
to the implantation process (Hamada, 2016). Further mechanisms involve the 
Transforming growth factor β (TGF-β) and human chorionic gonadotropin (hCG), 
which modulate oxidative stress and homeostasis in glioblastoma, one of the most 
common malignant brain tumours. Both proteins share a structural homology. In 
cancer tissues, they regulate cellular survival and oxidative stress. TGF-β treatment 
causes over expression of hCG-β in glioma cells, while inhibition of hCG-β leads to 
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ROS production, thioredoxin (Trx1) expression and thioredutase activity depletion, 
resulting in TIGAR inhibition. Treatment with TGF-β alongside hCG-β inhibited 
TIGAR expression glioma in treated cells. This has been proposed as a new 
therapeutic target for glioblastoma and related malignancies (Ahmad et al., 2015).  
1.4.3 TIGAR and PD 
In a study conducted in a pink1-deficient zebrafish model, researchers from 
our group found that tigarb (the zebrafish homologue of TIGAR) mRNA was 
upregulated. This zebrafish pink1 model, contrary to the PD mice models, displayed 
PD characteristic phenotype with dopaminergic neuronal as well as mitochondrial 
dysfunction and impaired morphology. Microarray expression analysis performed in 
the RNA extracted from the pink1 model showed a 12-fold up-regulation of of TigarB 
mRNA levels. The TigarB upregulation was subsequently confirmed by qPCR. 
Furthermore, in situ hybridization analysis demonstrated a significant increase of 
TigarB expression in the brains of the pink1 mutant zebrafish, which was particularly 
marked in the brain. Moreover, Tigarb knock down in the pink1 deficient model, 
using the morpholino antisense-mediated approach normalised mitochondrial 
function, with normalisation of CI and CIII activity resulting in rescue of the 
dopaminergic neuronal loss (Flinn et al., 2013). These promising results suggested a 
new mechanism in PD mediated by TIGAR unknown mechanisms. Since this 
exciting discovery was performed in a zebrafish model, a confirmation of TIGAR 
mediated mechanisms in PD needed to be undertaken and investigated in a human 
cellular model and PD brain tissue.   
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1.5 Aims and objectives 
In this study, we aimed to determine TIGAR related mechanisms in three 
different models: post-mortem tissue from the brains of people with PD, fibroblasts 
derived from patients with familial and sporadic PD and, a stable inducible cell line 
with TIGAR and PINK1 knock-down.  
• First, we aimed to identify whether TIGAR is present in human dopaminergic 
neurons in healthy brains as well as in the brains of patients with PD and DLB using 
immunohistochemistry. We further investigated whether TIGAR upstream and 
downstream regulators were associated to TIGAR in this context. TIGAR disease 
specificity was investigated by assessing TIGAR expression in another 
synucleinopathy, namely multiple system atrophy (MSA), and a further 
neurodegenerative disease with ubiquitinated inclusions, namely motor neuron 
disease (MND). 
• Second, we aimed to identify if TIGAR was present in human fibroblasts in 
controls and patients with PD mutations. We then determined whether TIGAR 
knockdown can rescue the mitochondrial dysfunction and morphology in parkin-
mutant fibroblasts. TIGAR role in autophagy was also investigated in fibroblasts from 
sporadic PD patients. We further investigated if TIGAR translocates to the 
mitochondria in the parkin-mutant fibroblasts after toxin exposure.  
• Third, we aimed to silence TIGAR and PINK1 via RNAi methods using a 
microRNAs approach. Then, we generated a stable inducible cell line with TIGAR 
and PINK1 deficiency. We subsequently assessed the effect of TIGAR and PINK1 
knockdown on mitochondrial function and morphology in a stable inducible human 
cellular model with TIGAR and PINK1 deficiency. Finally, we compared gene 
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silencing efficacy and efficiency by comparing RNAi conventional methods with 
newer genome editing techniques, namely CRISPR/Cas9. 
1.6 Hypothesis 
We hypothesised that there would be an increased expression of TIGAR in 
the SN of post mortem brains of people with PD. Consequently, TIGAR protein will 
be present in the Lewy bodies. We also hypothesised that up and down stream 
regulators and targets of TIGAR would be altered in PD in post-mortem brains of 
people with PD. 
 
Since fibroblasts from PD patients with known PD-gene mutations display 
mitochondrial dysfunction, we hypothesised that TIGAR expression will be altered, at 
the gene and protein level. This will confirm the findings in the zebrafish model. 
Therefore, TIGAR knockdown will rescue the mitochondrial function in PD fibroblasts 
with known gene mutations. Moreover, TIGAR related mechanisms will be via 
TIGAR mitochondrial translocation upon toxic exposure in PD fibroblasts with 
mitochondrial defect. Another TIGAR related mechanisms will be through autophagy 
impairment in sporadic PD fibroblasts with mitochondrial defect treated with inducers 
(CCCP) and inhibitors (Bafilomycin) of autophagy. Further confirmation of TIGAR 
related mechanisms and its implication in PD, will be through studying TIGAR 
knockdown in a stable inducible human cellular model with PINK1 deficiency. Here 
the mitochondrial phenotype and function will be rescued. TIGAR might be involved 
in the disease by decreasing the glycolytic pathway and the energy supply, by 
affecting the mitochondrial function and the cellular clearance mechanisms. 
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2. TIGAR neuropathology 
2.1 Introduction 
The neuropathological hallmark of Parkinson’s disease (PD) is the loss of 
dopaminergic neurones in the substantia nigra (SN). Another characteristic of the 
disease is the presence of spherical cytoplasmic inclusions in residual neurones 
called Lewy bodies. 
The histological characteristics of classic Lewy bodies in the SN on 
haematoxylin and eosin staining are an eosinophilic hyaline core with a pale halo 
surrounding it. Lewy bodies in the cortex are more pale and lack a halo. (Spillantini 
et al., 1997). Lewy bodies are composed mainly of neurofilaments and ubiquitylated 
proteins, of which alpha-synuclein has been recognised as the main component. 
Immunohistochemistry for alpha-synuclein also reveals neuritic deposits called Lewy 
neurites as well as more diffuse intracellular aggregates, called pale bodies, that lack 
the classical morphology of Lewy bodies. To date, there are about 300 molecules 
that have been identified in Lewy bodies (Leverenz et al., 2007; Wakabayashi et al., 
2013) .   
2.2 Lewy body diseases 
Since Lewy bodies were first discovered, it has been shown that there is a 
spectrum of diseases that also have these inclusions and related alpha-synuclein 
pathology. These disorders are now called synucleinopathies. They are PD, 
dementia with Lewy bodies (DLB), multiple system atrophy (MSA) and Lewy body 
variant of Alzheimer’s Disease (LBAD). For PD and DLB most deposits can be found 
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in neurons, whereas in MSA they are mainly present in glial cells (Ingelsson, 2016; 
Miraglia et al., 2015). 
2.2.1 Dementia with Lewy bodies (DLB)  
DLB is the second most common alpha-synucleinopathy. Clinically, DLB 
presents predominantly with dementia within one year after the onset of motor 
symptoms (Irwin et al., 2017). However, when dementia and the movement disorder 
are present at the same time, it can be very difficult to distinguish between PD and 
DLB. DLB has considerably more cortical amyloid deposits than PD cases 
(Gomperts et al., 2008; Irwin et al., 2017).  
2.2.2 Multiple system atrophy (MSA) 
The pathological hallmark of MSA is the presence of alpha-synuclein positive 
cytoplasmic inclusions in oligodendroglia (McCann et al., 2014). It is a progressive 
neurodegenerative disease with complex variety of clinical symptoms, such as 
parkinsonism, autonomic dysfunction, pyramidal symptoms, and cerebellar ataxia. It 
is a sporadic disorder, which can be associated with other pathological processes, 
including Alzheimer-type, Lewy pathology and entities with other pathological tau 
deposits. Consequently, more than one neuropathological disorder can be present in 
one patient. A neuropathological consensus criteria for a definite MSA diagnosis 
have been agreed. These require the presence of widespread and numerous CNS 
alpha-synuclein positive glial cytoplasmic inclusions, accompanied by pathological 
changes in the striatonigral or olivopontocerebellar regions (Trojanowski and Revesz, 
2007). 
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2.2.3 Incidental Lewy body disease 
Lewy bodies occur in about 10% of normal brain of people older than 65 years 
old (Gibb and Lees, 1988; Klos et al., 2006). This is called “incidental Lewy body 
disease” and can be associated to a reduction of the neuronal population in the SN. 
Further, the nigrostriatal pathology is of intermittent severity between that seen in the 
population with and without PD. There are suggestions that this could be a 
preclinical stage of either PD or DLB (Caviness et al., 2011; DelleDonne et al., 2008). 
2.2.4 Lewy pathology localisation in the brain 
While Lewy bodies are initially confined to the brainstem pigmented nuclei, 
their appearance tends to progress through the brain in a staged manner. This 
corresponds loosely to the clinical severity of the patient (Braak et al., 2003; Luk and 
Lee, 2014). Lewy bodies are found in almost all sporadic and familial PD cases, 
though there are some exceptions, such as some carriers of Parkin mutations 
(Cornejo-Olivas et al., 2015; Farrer et al., 2001; Gouider-Khouja et al., 2003; 
Pramstaller et al., 2005; Yamamura et al., 1998), Pink1 and some with mutations in 
LRRK2 (Gaig et al., 2007; Kalia et al., 2015; Luk and Lee, 2014).  
2.3 Lewy bodies and PD-related genes neuropathology 
Lewy bodies contain mainly alpha-synuclein. However, a large number of 
different molecules have been identified within these inclusions. Some of these are 
proteins link to PD genes, such as DJ-1, LRRK2, Parkin and PINK1. Alongside these 
molecules, other protein constituents of Lewy bodies include are known to have roles 
in: mitochondrial function, the ubiquitin-proteasome system, aggresome formation 
and autophagy (Velayati et al., 2010; Wakabayashi et al., 2013).  
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The genes most commonly associated with familial PD are: Alpha-synuclein 
(SNCA), Leucine Rich Kinase 2 (LRRK2), PTEN (phosphatase/tensin homolog on 
chromosome 10)-induced putative kinase 1 (PINK1), Parkin and DJ-1 (Bonifati, 
2014). The glucocerebrosidase gene (GBA1) encodes a lysosomal enzyme. 
Homozygous mutations of GBA1 are responsible for the metabolic disorder known 
as Gaucher disease (GD). It is now known that heterozygous mutations in this gene 
are one of the main risk factors for developing PD. GBA1 mutations have also been 
associated with DLB and MSA (Gámez-Valero et al., 2016; Mitsui et al., 2015). The 
neuropathology from people with PD and mutations in GBA1 is comparable to that of 
classical, sporadic PD (Aharon-Peretz et al., 2004; Ma et al., 2013; Sidransky et al., 
2009). The main neuropathological features of individuals with mutations of these 
genes, is described in Table 2.1. 
Gene Mutation/substitutions Neuropathological findings 
 
 
SNCA 
A53T 
Severe neuronal loss in SN, LC and Widespread and diffuse LB, 
LN and thread like depositions, rarely GCI and tangles. Rarely, 
TDP-43-positive inclusions. Occasionally plaques A53T+S167N 
PRKN polymorphism with AGD, FTLD.  (Fujishiro et al., 2013; 
Hoffman-Zacharska et al., 2013; Markopoulou et al., 2008)   
E46K Widespread LB pathology(Fujioka et al., 2014; Zarranz et al., 2004)  
A29S LB pathology(Fujioka et al., 2014) 
G51D LB and tau pathology, TDP-53 pathology(Fujioka et al., 2014) 
A30P LB, LN, tau pathology and GCI (Fujioka et al., 2014; Seidel et al., 2010)  
H50Q LB, LN, tau pathology(Fujioka et al., 2014) 
A18T NA (Hoffman-Zacharska et al., 2013) 
A29S LB and LN pathology (Hoffman-Zacharska et al., 2013) 
SNCA locus triplication Widespread LN, some GCI (Singleton et al., 2003b) and  tangles (Fujishiro et al., 2013)  
SNCA locus duplication  LB and tau pathology (Fujioka et al., 2014; Konno et al., 2016)  
PINK1 
N451S het Brainstem and neocortical LB in SN and neocortex. Diffuse Aβ deposits (Gandhi, 2006). 
Y431H het Severe neuronal loss in SN. LB in SN and neocortex. Sparse neurtic plaques (Gandhi, 2006) 
A339T het Severe neuronal loss in SN. LB in SN and neocortex. Diffuse Aβ deposits (Gandhi, 2006) 
C575R het Severe neuronal loss in SN. LB in SN and neocortex. Moderate neurtic plaques(Gandhi, 2006). 
c.1488+1G>A+delEx7 Severe neuronal loss in SN. LB in SN, brainstem and nucleus basalis of Meynert (Samaranch et al., 2010) 
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PARKIN 
R275W, del 40 bp Exon3 Neuronal loss in SN, LB in SN, LC, nBM, amygdala parahipocampal region (Farrer et al., 2001),  
Hom del Ex 3 Moderate loss of neurons of SN and LC (Sasaki et al., 2004) 
delExon7, del1072T Severe neuronal loss in SN and LC, few LB in SN and LC  (Mori et al., 2003) 
Compound het Ex7 
(C924T) 
Neuronal loss in SN. LB in SN, LC and nbM (Schlossmacher et 
al., 2002) 
Compound het 
(Ex7del+1072del) 
SN, locus ceruleus, VNM and NA: Moderete - severe neuronal 
loss, reactive gliosis, neuritic dystrophy and LB. (Pramstaller et al., 
2005) 
Hom del Ex2+del Ex4 LB and LN in SN and LC, amygloid nucleus, VMN, nbM, striatum, anterior cingulate cortex. Tau positive inclusions in ETC 
Compound het: acceptor 
splice site mutation (IVS5-
1G>A) + Ex7del. 
Severe neuronal loss in SN. ETC cortex with NFT and neruritis. 
Negative alpha-synuclein staining and LB no present.(Cornejo-
Olivas et al., 2015; Pramstaller et al., 2005)  
Compound het delEx3/del 
Ex4 
Neuronal loss and presence of LB in SN and LC (Sharp et al., 
2013)  
Hom delEX3/del Ex 7  Severe neuronal loss in SN, less in LC. No LB and LN (Kitada et al., 1998)   
Hom delEx4 
Severe neuronal loss in SN, less in LC. No LB and LN. Tau 
inclusions and NFT, thorn shaped astrocytes (Hayashi et al., 
2000; Mori et al., 2003) 
Compound het 
delEx3/Ex6 transversion 
Severe neuronal loss in SN > LC. No LB and LN. Thorn shaped 
astrocytes (van de Warrenburg et al., 2001) 
Comp het delEx6/delEx7 Severe neuronal loss in SN > LC. No LB and LN .(Mori, 2003) 
Hom delEx2 Severe neuronal loss in SN > LC. No LB and LN (Gouider-Khouja et al., 2003) 
Het C212Y PSP, neuronal loss in SN, striatum, GP, nbM, STN and Thalamus. No LB and LN. (Morales et al., 2002) 
Hom delEx3 
Neuronal loss in SN and LC. No LB. Lewy-like inclusions in the 
anterior horn of the SC, asyn and ubiquitin positive (Sasaki et al., 
2008) 
LRRK2 
G2019S 
Severe-moderate neuronal loss in SN, LC and SI, ETC and VMN. 
LB in SN, LC, SI, amygdala, ETC, VMN, hypothalamus, 
subthalamus, nbM, CG, medulla, BG, transentorhinal and FC. 
Tau-positive inclusions, aggregates of TDP-43 protein, ubiquitin-
only inclusions as well as only dopaminergic neuronal loss without 
inclusions. Mild neuronal loss in SN. α-synuclein negaive LB and 
LN. (Dachsel et al., 2007; Gaig et al., 2007, 2008; Giasson et al., 
2006; Gilks et al., 2005; Gomez and Ferrer, 2010; Rajput et al., 
2006) 
R1441C 
Neuronal loss in SN and degeneration. Diffuse or brainstem LB 
pathology. Tau positive lesions with PSP-like pathology (Wider et 
al., 2010; Zimprich et al., 2004) 
Y1699C Degeneration of SN. Ubiquitin positive inclusions in SN. Neuronal loss in SN and LC (Khan et al., 2005; Zimprich et al., 2004) 
R1441G Neuronal loss in SN and LC, no LB (Marti-Masso et al., 2009) 
R1441R Neuronal loss in SN and LC (Craig, 2008)  
I1371V Neuronal loss in SN and LC (Giordana et al., 2007) 
R793M/L1165P Neuronal loss in SN and LC (Covy et al., 2009) 
N1437H Neuronal loss in SN and LC, sparse NFT and Tau pathology (Puschmann et al., 2012) 
DJ-1 
R98Q polymorphism LB and LN in SN (Bandopadhyay et al., 2004) 
L172Q 
Severe neuronal loss in SN, LC, GP and putamen. Diffuse LB 
pathology. Axonal a-syn positive spheroids and glial inclusions 
(Taipa et al., 2016).  
GBA L444P, N370S, R463C, D409H, R131C, C193E, 
Neural loss in SN and LC. Diffuse LB pathology (Neumann et al., 
2009). 
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RecNcil, RecA456P 
N370S hom; N370S het; 
L444P/D409H+duplication  
Neuronal loss in SN. LB and LN in SN and CA2-4 hippocampus. 
(Tayebi et al., 2003) 
N370S hom, N370S het, 
D409H/L444P+duplication  
Neuronal loss with/without astrogliosis in SN, CA2-4, calcarine 
layer 4b and cortical layer 5. LB inclusions in SN and CA2-4. Gb-
positive LB hippocampal inclusions. (Goker-Alpan et al., 2010; 
Wong et al., 2004) 
N188S/E326K, T369M, 
E326K, N370S, L444P 
Widespread extensive neocortical LB, AD-stages, PD or pure DLB 
(Gámez-Valero et al., 2016).  
Table 2.1 Neuropathology findings in post-mortem brains with PD-related mutations. Amyloid-beta peptide 
(Aβ), Alzheimer’s Disease (AD); Agyrophilic disease (AGD); alpha-synuclein (asyn); Dementia of Lewy bodies 
(DLB); Progressive supranuclear palsy (PSP); Frontotemporal lobar degeneration (FTLD); cingulate gyrus (CG); 
globus palidus (GP); sustantia nigra (SN); locus ceruleus (LC); entorhinal cortex (ETC); subthalamic nucleus 
(STN); glial cytoplasmic inclusions (GCI); Lewy bodies (LB); Lewy neurites (LN); motor nucleus of the vagus 
(VMN); basal nucleus of Meynert (nbM); nucleus ambiguous (NA); sustantia innominata (SI); neurofibrillary 
tangles (NFT); heterozygous (het), homozygous (hom); deletion (del); exon (Ex). 
2.4 Lewy bodies and PD-related proteins 
More recently, one proteomic study has identified over 300 proteins in cortical 
Lewy bodies, some which had been previously described. The total number of 
molecules that constitute the Lewy bodies is not established and continues growing.  
Functional classification of these proteins showed enrichment of the following 
processes: apoptosis (34%), cytoskeleton (19%) metabolism (14%), extracellular 
matrix (10%), protein synthesis and degradation (8%), neurotransmission (2%), 
immune and inflammation (2%) and unknown function (11%). Fully validation of 
these processes through functional analysis is yet to be done (Leverenz et al., 2007).  
 
Alpha-synuclein is the main component of the pathological inclusions found in 
PD and related disorders. It is normally contained in the cytosol and presynaptic 
terminals of the neurons and its physiological function remains unclear (De 
Franceschi et al., 2017). The common pathological aggregation of alpha-synuclein in 
these neurodegenerative disorders classifies them as a group known as  
“synucleinopathies” (Iwai et al., 1995; Jellinger, 2003). The exact mechanisms 
leading to toxicity and pathology in PD and other alpha-synucleinopathies remain 
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elusive. One hypothesis is that different alpha-synuclein isoforms might lead to 
neuroinflammation and neurotoxicity by affecting the protein-protein interactions and 
axonal transport (Nakata et al., 2012; Sekigawa et al., 2015). This process has been 
also suggested to occur alongside the expression different isoforms of parkin and 
synphilin-1, which might result in impaired substrate degradation, protein 
aggregation and clearance (Brudek et al., 2016a; Lonskaya et al., 2013a, 2013b). 
  
PD, DLB and MSA have in common pathological lesions containing alpha-
synuclein. These lesions tend to affect specific vulnerable brain areas, resulting in 
common clinical manifestations features. Therefore, the alpha-synucleinopathies are 
suggested to be part of a single clinicopathological disorder (Galvin et al., 1999; 
Jellinger et al., 2003; Yang and Yu, 2017). A large number of proteins have been 
found in the pathological inclusions from patients with these disorders. Some have 
been suggested to have a functional, cellular and/or structural relation with alpha-
synuclein: LRRK2 (Qing et al., 2009; Volpicelli-Daley et al., 2016), Pink1 (Chung et 
al., 2016), synphilin-1 (Engelender et al., 1999; Xie et al., 2010) and Parkin (Chung 
et al., 2016; Lonskaya et al., 2013a; Schlossmacher et al., 2002). Thus, all appear to 
share a common pathologic pathway.  
2.4.1 PINK1 neuropathology 
PINK1 protein is expressed in the human brain in all cell types mainly in the 
mitochondrial membrane. PINK1 has been found in post-mortem tissue from people 
with sporadic PD, DLB and MSA (Murakami et al., 2007), and with familial PD 
associated to PINK1 heterozygous mutations (Gandhi, 2006). PINK1 expression was 
found in neurons (cytoplasm and axonal processes), glial cells (nuclei surrounding 
rim), endothelial and smooth muscle cells of blood vessels within the SN. PINK1 was 
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not found in cortical Lewy bodies, Lewy Neurites or other alpha-synuclein or tau 
positive inclusions. In contrast, it was found in a small percentage (5-19%) of Lewy 
bodies in the brainstem and SN within the halo and in a small proportion in the core 
of the inclusion. This difference between cortical and brainstem Lewy bodies could 
be explained by the fact that the antibody used for this study recognises only a 
portion of the protein, the insoluble fraction. This might reflect the solubility of PINK1 
might affect the detection. Given that there are morphological differences between 
cortical and brainstem Lewy bodies, this could also reflect different protein contents 
(Gandhi, 2006).  
 
More recent research by Murakami et al. (2007) in contrast, found PINK1 to 
be present in relatively high levels in neurons within the SN. This work used a more 
sensitive antibody that fully recognises the full length and whole fraction (soluble and 
insoluble) of PINK1. This study was also able to show that PINK1 is present in Lewy 
bodies, neurites and glial cytoplasmic inclusions in the SN. Furthermore, PINK1 was 
found in the glial cytoplasmic inclusions of patients with MSA. This suggests a role in 
the development of pathogenic inclusions of both principal alpha-synucleinopathies. 
How PINK1 could be contributing to the pathological progression remains unclear. 
One suggestion is that PINK1 aggregates in inclusions after it becomes misfolded 
and insoluble. Altered PINK1 activity due to misfolding and altered solubility, could 
also lead to protein aggregation alongside its substrates into the inclusions. This 
raises the question of whether PINK1 and alpha-synuclein may act in the same 
pathological pathway and is the subject of further research (Murakami et al., 2007).  
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2.4.2 Parkin neuropathology 
Parkin is expressed in neurones in the human brain under physiological 
conditions, in the same cytosolic and synaptic terminal compartments as alpha-
synuclein (Schlossmacher et al., 2002). It also was found to be expressed in the 
autophagic vacuoles in the cytoplasm within the astrocytes (Lonskaya et al., 2013b). 
In the brain of patients with PD, an insoluble form of Parkin accumulates vacuoles in 
the striatum (caudate nucleus). Parkin has been found to co-localise with Beclin-1, 
an autophagy-related enzyme, in the SN of the normal human brain. In PD patient 
brains, the interaction between Parkin and Beclin-1 appears to be significantly 
reduced. Here, Parkin mutations might affect structural formation, which could lead 
to protein insolubility and affect Parkin enzymatic and protein interactions (Lonskaya 
et al., 2013a, 2013b). This suggests a prospective role of Parkin in the neuronal 
clearance and autophagy through the autophagosomes.  
 
Parkin protein has been identified in the core of Lewy bodies in the SN, 
entorhinal, brainstem and cingulate cortex in brains from patients with PD and DLB, 
where Parkin and alpha-synuclein co-localise (Schlossmacher et al., 2002; 
Wakabayashi et al., 2012). This has lead researchers to suggest a role of Parkin in 
the initiation of Lewy body development. However, the mechanisms leading to this 
process still remain unclear and not fully confirmed (Schlossmacher et al., 2002).  
2.4.3 LRRK2 neuropathology 
In the normal brain, LRRK2 is ubiquitously expressed in neurons especially in 
the cerebral cortex, in striatum and SN (Higashi et al., 2007). However, it has been 
found to be expressed in most brain regions and a diversity of cell types (astrocytes 
and microglia), with a moderate expression in the SN (Miklossy et al., 2006; Vitte et 
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al., 2010). It was found that LRRK2 expression in surviving neurons within the SN 
was extremely decreased in post-mortem brains from people with sporadic and 
familial PD with LRRK2 mutations (Higashi et al., 2007; Vitte et al., 2010). There are 
discrepancies between LRRK2 expression in Lewy bodies. LRRK2 presence is 
controversial; where it is present sometimes in Lewy bodies (but not Lewy neurites), 
in the halo and core in the cortex, SN and Locus coeruleus; absent in cortical Lewy 
bodies in PD and DLB brains (Higashi et al., 2007; Miklossy et al., 2006; Vitte et al., 
2010).  This was more pronounced in brains from PD patients with LRRK2 mutations 
(Vitte et al., 2010).  
 
Patients with the G2019S mutation of LRRK2 have significantly higher levels, 
compared to sporadic PD patients, of phosphorylated alpha-synuclein at serine 129 
(pS129). This difference is principally seen in the dorsal motor nucleus of the vagus. 
Moreover, alpha-synuclein solubility in G2019S patients was found to be altered in 
the Basal Ganglia and limbic cortex (Mamais et al., 2013). 
 
Increased levels of LRRK2 directly correlate with increases in total and 
phosphorylated alpha-synuclein levels in the brains of PD patients. Furthermore, 
LRRK2 protein was found to co-localise with total and phosphorylated alpha-
synuclein in Lewy Bodies and neurons. This co-localisation occurred mainly in the 
cortical regions and in a lesser extent in the brainstem (Guerreiro et al., 2013). How 
LRRK2 interaction with alpha-synuclein leads to pathology remains unclear. 
2.4.4 DJ-1 neuropathology 
DJ-1 is expressed in numerous tissues, including the brain and is localised in 
both the nucleus and the cytoplasm. It is highly expressed in the glia, mainly in 
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astrocytes. It has been found at very low levels if at all in neurons of the frontal 
cortex and SN. It is occasionally present in the halo of Lewy bodies and rarely in 
Lewy neurites within the SN and absent in the Lewy bodies within the frontal cortex 
(Bandopadhyay et al., 2004; Taipa et al., 2016). 
2.5 TIGAR neuropathology 
TIGAR (TP53-induced glycolysis and apoptosis regulator) has been widely 
studied in oncology (Lee et al., 2014a), but very little is known about its role in 
neurodegeneration. It has been suggested that TIGAR is involved in AD (Katsel et al., 
2013): TIGAR protein levels were significantly reduced in patients with severe 
dementia with greater levels of cognitive impairment. However, TIGAR protein levels 
were not found to be related to conventional Braak neuropathology stage or neuritic 
plaque density measurements. Therefore, they suggest that the main role of TIGAR 
here is mainly in the neurobiology of AD and the cognitive impairment. Furthermore, 
in severe dementia and AD neuropathology, ATM (Ataxia-Telangiectasia mutated) 
expression was found to be increased along with some of its downstream genes. 
This, suggests that the regulation of TIGAR might involve the ATM-p53 pathway, 
which responds to stress and damage (see Introduction). TIGAR protein functions to 
provide cellular protection from ROS and to improve cell survival. Consequently, low 
levels of TIGAR hinders these mechanisms and leads to cell death. Interestingly, 
p53 protein levels did not differ between controls and patients, suggesting that post 
translational mechanisms that modify the action of p53, and as result TIGAR levels, 
are involved. This suggests that ATM up-regulation and TIGAR down regulation 
might be characteristic of the development and progression of dementia in AD 
(Katsel et al., 2013). 
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In a study conducted in a pink1-deficient zebrafish model, researchers from 
our group found that tigarb (the zebrafish homologue of TIGAR) mRNA was 
overexpressed compared to controls. This was associated with the loss of 
dopaminergic neurones and mitochondrial dysfunction. Furthermore, TigarB knock 
down normalised mitochondrial function and rescued the dopaminergic neuronal loss 
(Flinn et al., 2013). Both mitochondrial dysfunction and neuronal loss have been 
reported in tissue from patients with PD (Abramov et al., 2011; Ando et al., 2017; 
Chung et al., 2016; Gandhi, 2006; Manzoni et al., 2013a; Murakami et al., 2007; 
Rakovic et al., 2010, 2013; Schapira et al., 1989), as well as cellular models and in 
vivo models that are PINK1 deficient (Anichtchik et al., 2008; Flinn et al., 2013; 
Sallinen et al., 2010).  
 
Several lines of investigation have suggested further PINK1- and TIGAR-
related cellular mechanisms, including oxidative stress and mitophagy may be 
involved in PD pathogenesis. However, to our knowledge, there are no reported 
publications showing the involvement of TIGAR in human PD pathology. Therefore, 
we aimed to identify whether TIGAR is present in human dopaminergic neurons in 
controls as well as patients with PD and DLB using immunohistochemistry.  
Unpublished pilot data from our laboratory suggested that TIGAR protein may be 
present in Lewy bodies:  Immunohistochemistry for TIGAR appeared to be positive in 
Lewy bodies when using an antibody to the C-terminus (Abcam ab129333) but not 
when using an antibody to the central portion of the protein (Millipore #AB10545).  
This may have been due to aberrant cross reactivity by the first antibody, or the fact 
that there is only antigen availability of the C terminus region in Lewy bodies.  
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2.6 Aims and objectives 
The discovery of TIGAR up regulation in the Pink1-deficient zebrafish model of 
Parkinson’s disease suggested a role for TIGAR in PD pathogenesis.  Therefore, we 
aimed to determine: 
a) If TIGAR is present in the human SN and, 
b) Whether TIGAR protein is indeed present in Lewy bodies 
c) Elucidate the relationship between TIGAR protein levels and PD. 
 
To assess this, we used immunohistochemistry to examine the expression 
levels and localization of TIGAR protein in the post mortem brains from people with 
PD, DLB, MSA and controls. While we concentrated on the SN, we also studied the 
hippocampus, a forebrain region that is also affected by alpha-synuclein pathology.  
On finding TIGAR in Lewy bodies, we studied motor neuron disease (MND), another 
disease with ubiquitylated proteinaceous inclusions, to investigate whether TIGAR 
was specific for Lewy bodies or could be seen in other conditions with proteinaceous 
inclusions.  
2.7 Hypothesis:  
We hypothesised that there would be: 
• An overexpression of TIGAR in the SN of post-mortem brains of people with 
PD. 
• TIGAR protein in Lewy bodies detectable using antisera to the C-terminal 
region of the protein.  
• Altered expression of regulators, such as p53 and HK-II, and targets of TIGAR 
in PD. 
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2.8 Materials and methods 
2.8.1  Human brain tissue 
2.8.1.1 Patients and controls 
Sheffield Brain Bank  
Post mortem human brain tissue was obtained from people who donated their 
brains, after obtaining permission from the next of kin. The acquisition of the brain 
tissue by the Sheffield Brain Tissue Bank (SBTB) was performed with ethics 
committee approval by the Scotland A Research Ethics Committee (ref 
08/MRE00/103). Details of the cases are given in Table 2.2 below. 
ID Gender Diagnosis 
Age at 
death 
(y) 
Duration of  
Disease Cause of death PMD 
LP0079/06 M DLB 78 N/A Intraventricular haemorrhage N/A 
LP112/06 M DLB 86 N/A N/A N/A 
LP003/04 F DLB 66 N/A N/A N/A 
LP016/05 M DLB 72 2y Broncopneumonia N/A 
LP097/09 F sPD 84 N/A N/A N/A 
LP052/09 M sPD 76 N/A N/A N/A 
LP015/03 F sPD 74 3 m N/A >100 hrs 
LP087/03 M sPD 71 9 y N/A N/A 
LP073/09 M MSA 69 3 y N/A 34 hrs 
LP120/04 F MSA 63 N/A Broncopneumonia N/A 
LP129/01 M MSA 62 N/A N/A N/A 
LP014/11 M sMND  51 2.3 y N/A N/A 
LP059/09 F sMND  80 8.6 y N/A 50 hrs 
LP072/05 M sMND  66 10 m N/A 8 hrs 
LP094/06 M sMND  71 9 m N/A 53 hrs 
R1208/90 M sMND 48 13 m N/A 8hrs 
LP085/07 F Control 59 - Atypical pneumonia 5hrs 
LP005/07 M Control 63 - N/A N/A 
LP098/07 M Control 67 - Hepatocellular carcinoma 60 hrs 
NA188/96 F Control 82 - N/A N/A 
LP056/90 M Control 51 - Mesothelioma 25 hrs 
LP309/90 M Control 82 - 
Carcinomatosis, 
thoracic cord 
compresion 
36 hrs 
LP335/90 F Control 29 - Acute intermittent porfiria 20 hrs 
Table 2.2. Sheffield Brain Bank Tissue used in this study. Female (F); male (M); sporadic Motor neuron 
disease (MND); Multiple system atrophy (MSA); sporadic Parkinson´s Disease (sPD); Dementia of Lewy Bodies 
(DLB); Post mortem delay (PMD); Not available (N/A); months (m), years (y). 
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Queen Square Brain Bank 
Tissue acquired within the Ethics committee approval Tissue Bank, Queen 
Square Brain Bank for Neurological Disorders (QSBB) and NeuroResource REC Ref. 
08/H0718/54+5. Details of the cases are given in Table 2.3 below. 
ID Gender Diagnosis Age  (years) 
Duration of  
disease Cause  of death 
PMD 
(hrs) 
P2/10 F sPD 82 25y Chest infection 56 
P54/11 M sPD 80 16y Pneumonia 67.30 
P89/10 M sPD 77 16y Ischaemic heart disease 42.55 
P21/12 M sPD 83 6y Heart failure 44.55 
P33/12 M sPD 74 13y Pneumonia 43.10 
P22/12 M sPD 85 10y Urinary tract infection 32.45 
P11/11 M DLB 60 8y Pneumonia 26 
P34/07 M DLB 80 10y Gradual deterioration 45.10 
P28/11 F DLB 86 17y Chest infection 78.40 
P68/10 M DLB 73 12y Chest infection 42.30 
P48/03 F DLB 74 5y DLB 47.45 
P80/10 M DLB 67 7y DLB 40.55 
P72/07 M Control 85 - Multiple system failure 76.50 
P47/11 F Control 79 - Pancreatic carcinoma 78.50 
P75/10 F Control 83 - Squamous cell carcinoma 39.45 
P64/11 F Control 80 - Pancreatic carcinoma 49.10 
P82/10 F Control 87 - Colon carcinoma 84.15 
P78/06 F Control 68 - Breast carcinoma 44.55 
Table 2.3. Queen Square Brain Bank Tissue used in this study. Female (F); male (M); sporadic Parkinson´s 
Disease (sPD); Dementia of Lewy Bodies (DLB); Post mortem delay (PMD); Not available (N/A); years (y). 
2.8.2  Immunohistochemistry  
Immunohistochemical analysis was performed on paraffin-embedded tissue 
from midbrain, hippocampal sections of four cases of sporadic PD, four DLB and four 
matched control cases from the SBTB. Midbrain sections of six sporadic PD, six DLB 
and six matched controls cases from the QSBB were also analysed. Spinal cord 
sections from four MND patients and four controls were also analysed.  
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Paraffin embedded sections of SN, hippocampus and spinal cord tissue were 
used for antibody optimisation. Heat-mediated antigen retrieval of sections was 
carried out using a pressure cooker. Antigen retrieval was performed in either 
Access Citrate (pH6) buffer solution or Access Super (pH8) buffer solution 
(IntelliPATH FLX Detection Kit, Menarini Diagnostics) 20psi for 40s. at 120oC. 
Following antigen retrieval, sections were washed with distilled water and Tris-
Buffered saline (TBS) and incubated for 5 min. with MenaPath Peroxidase Block 
(IntelliPATH FLX Detection Kit, Menarini Diagnostics) to prevent all endogenous 
peroxidase activity. Afterwards, sections were incubated with MenaPath Casein 
Background Blocker (IntelliPATH FLX Detection Kit, Menarini Diagnostics) for 10 min. 
and rinsed with TBS. Sections were then incubated with primary antibody for 1 hr. at 
RT. Following primary antibody incubation, sections were incubated with Universal 
Probe (IntelliPATH FLX Detection Kit, Menarini Diagnostics) for 10 min., washed 
again and incubated with HRP-Polymer (IntelliPATH FLX Detection Kit, Menarini 
Diagnostics) for 15 min. Sections were washed again with TBS and incubated with 
DAB chromogen for 5 min. The slides were then rinsed in deionized water and 
counter stained with haematoxylin. Sections were dehydrated through increased 
concentrations of ethanol (70%, 95%, 100%), cleared in xylene and mounted with 
Dibutyl Phthalate and Xylene (DPX) mountant (Leica). 
2.8.3  Antibody optimisation 
We first attempted to replicate the pilot finding using the antibody recognising 
the C- terminal region of TIGAR. The first aim was to find the best antibody to label 
TIGAR and optimise it to investigate TIGAR protein in the midbrain region. 
Optimisation of the antibody was initially performed in SN, using different 
concentrations of primary antibody (ranging from 1:50 to 1:1000) with antigen 
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retrieval by using a Pressure cooker at pH9 and pH6. A pathologist assessed 
staining and helped to identify the optimal antibody condition for our area of interest. 
From this, rabbit antibody against TIGAR (Thermo Scientific) at a concentration of 
1:400 and a pH 9 was chosen as the best conditions to assess TIGAR presence in 
midbrain sections from the PD and DLB cases and controls. 
Antibody Region Antigen retrieval Dilution/time 
Anti-TIGAR antibody. Millipore 
(AB10545) 
Polyclonal (R) 
KLH-conjugated linear peptide that lies 
in the central region of the protein PC, pH9 1:400 / 30 min 
Anti-TIGAR antibody. ABCAM 
(ab62533) 
Polyclonal (R) 
Synthetic peptide (Human) of 19 amino 
acids from a region near the centre of 
TIGAR 
PC, pH9 1:800 / 30 min 
Anti-TIGAR antibody. ABCAM 
(ab129333) 
Polyclonal (R) 
 
Synthetic peptide corresponding to a 
region within C terminal amino acids 
220-270 of Human TIGAR 
 
PC, pH9 1:750/ 30 min 
*TIGAR Polyclonal antibody 
Thermo Scientific (PA5-
29152) 
Polyclonal (R) 
PC, pH9 1:400 / 1 hr 
Anti-TIGAR  Antibody LS-
C286858 (LifeSpan 
Biosciences) 
Polyclonal (R) 
PC, pH6 1:50 / 1 hr 
Anti alpha-synuclein antibody 
(NCL-L-ASYN) 
Molyclonal (M) 
Prokaryotic recombinant protein 
corresponding to the majority of the full 
length alpha-synuclein molecule 
PC, pH9* 1:1000 / 1hr 
Anti-HK-I [4D7]. ABCAM 
(ab105213) 
Molyclonal (M) 
Recombinant full length protein, 
corresponding to amino acids 1-917. PC, pH9 1:2000 / 1 hr 
Anti-HK-II. Thermo Fisher 
(MA5-14849) 
Molyclonal (R) 
Synthetic peptide corresponding to the 
sequence of human HK-II PC, pH6 1:50 / 1 hr 
Anti-p53 (Bp53-12) sc-263 
Molyclonal (M) 
Antibody raised against recombinant 
p53 of human origin, with epitope 
mapping to the N-terminus part 
PC, pH8 1:200 / 1 hr 
Anti-p53 Dako GA616 
Molyclonal (M) 
Recombinant human wild-type p53 
protein. 
High pH 
Target 
Retrieval 
Solution 
NA+ / 20 min 
Table 2.4 Antibodies tested and optimised for immunohistochemistry in Human brain tissue. Hexokinase I 
(HK-I); Hexokinase II (HK-II); Mouse (M), Rabbit (R); Monoclonal (Mono); Polyclonal (Poly); Non applicable (NA) 
Pressure cooker (PC). * Pre-treatment for 1 hr with formic acid followed by antigen retrieval. +Anti-p53 antibody 
Ready to Use (prediluted). 
2.8.4  Co-localisation with alpha-synuclein 
2.8.4.1 Double staining: Immunofluorescence 
Fluorescent immunostaining against TIGAR in the midbrain was optimised to 
allow double staining to investigate colocalisation with alpha-synuclein. Paraffin 
embedded sections were dewaxed in two washes with xylene, followed by 
63 
 
rehydration, starting with two washes with absolute ethanol, then 95% and 70% 
serially each for 5 min. The tissue was then incubated for 20 minutes in 3% H2O2 in 
fresh methanol. Sections were washed with running tap water. Heat-mediated 
antigen retrieval of sections was carried out using a Pressure cooker in pH8 buffer 
solution (IntelliPATH FLX Detection Kit) for 40 minutes at 120oC. Following antigen 
retrieval, sections were washed with distilled water and Tris-Buffered saline (TBS). 
Subsequently, they were incubated for 15 min in 0.2% glycine and washed three 
times with TBS for 5 min each. The sections were then incubated with rabbit (TIGAR) 
or mouse (alpha-synuclein) blocking serum for 30 min. The excess was removed 
after the 30 min. Sections were then incubated with avidin block for 15 min. and 
rinsed with TBS, then incubated for further 15 min with biotin block and rinsed with 
TBS. They were incubated with primary antibody overnight at 4ºC. After incubation, 
the slides were rinsed three times with TBS for 5 min each and then incubated with 
secondary biotinylated antibody for 30 min. Slides were then rinsed with TBS and 
incubated with secondary fluorescent antibody Alexa Fluor 488 or 555 for 1 hr. at RT 
in the dark. Then slides were rinsed with TBS and incubated in Sudan Black (filtered, 
0.3% sudan black/ 70% alcohol) for 5 min. Slides were then washed with tap water 
and stained with Hoeschst (1:1000) for 10 min and mounted with DPX mountant. 
2.8.4.2 Double staining: DAB immunofluorescence 
Double staining with DAB and immunofluorescence was combined. Firstly, all 
slides were processed for DAB staining as described above, counterstaining with 
haematoxylin and washed for 5 min in Scott’s Tap Water. After this, slides were 
incubated with the appropriate goat serum blocking buffer for 30 min and then 
thoroughly washed and sequentially incubated with avidin and biotin block for 15 min 
each. This was followed by three washes with TBS buffer and incubated with primary 
antibody (TIGAR or alpha-synuclein) at 4º C overnight. After this time, slides were 
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thoroughly washed with TBS and incubated with secondary antibody at RT for 30 
min, followed by three washes with TBS. Then, slides were incubated in the dark 
with secondary fluorescent antibody Alexa Fluor 488 or 555 (1:1000) at RT for 1 hr. 
Slides were then washed three times with TBS and incubated with Hoeschst (1:1000) 
for 10 min. Finally, slides were rinsed with TBS and mounted with DPX mountant. 
 
2.8.4.3 Serial sections: DAB staining 
Co-localisation of TIGAR with alpha-synuclein was also assessed in four PD 
cases from the Sheffield cohort. This was performed by cutting serial sections from 
the midbrain. Staining was performed alternatively for TIGAR (1:400) and alpha-
synuclein (1:1000). Slides were stained using the IntelliPATH FLX™ Automated 
Slide Stainer. The IntelliPATH FLX Detection Kit was used for detection. DAB was 
used for detection and sections counterstained with haematoxylin.  
2.8.5  p53 Immunohistochemistry 
Midbrains from the four PD and four control cases from the Sheffield cohort 
were immunostained with anti-p53 (Bp53-12) sc-263. However, due to heavy 
neuromelanin cross-reactivity with this antibody, an alternative method for 
immunohistochemistry was sought.  We are grateful to Mrs Helen Crowle of the 
Department of Cellular Pathology, Hull and East Yorkshire NHS Trust for performing 
the immunohistochemistry for p53.   
  
Briefly, the slides were stained on the Dako Omnis Automated Slide Stainer 
using the Dako Envision Flex High pH (GV80011) kit. Target retrieval was performed 
by using a high pH Target Retrieval Solution for 30 mins. The p53 is a ready-to-use 
antibody (Dako GA616) and incubation time was 20 mins.  Peroxide blocking was 
65 
 
done for 3 mins, in secondary labelled polymer for 20 mins and substrate chromogen 
for 5 mins.  
2.8.6  Hexokinase I and II immunohistochemistry 
For HKI and HKII study we stained the four PD midbrain cases and four 
midbrain controls slides from the Sheffield Brain Tissue Bank with Anti-HKI (1:2000) 
and Anti-HKII (1:50). All were stained with a Menarini IntelliPATH automated slide 
stainer using the IntelliPATH FLX Detection Kit. DAB was used for detection and 
haematoxylin was the counterstain.  
2.8.7  Image aquisition 
Whole slide images were captured using a Hamamatsu NanoZoomer XR.  
2.8.8  Quantitative histopathology evaluation 
The neuronal and neuritic load of TIGAR labelling was assessed separately.  
For the neuronal load, the digitised whole slide images were scrutinised by two 
pathologists.  The total number of neurones that were positive and negative for 
TIGAR were counted and the percentage of neurones that were positive were 
calculated.   
 
To quantify neuritic pathology, regions of interest were captured from the 
whole slide images at 20x magnification (405 x 721µm). Six regions of interest per 
case were randomly selected by a pathologist from the SN, entorhinal cortex and 
cortex of the occipitotemporal gyrus. Intensely stained neurites were counted by two 
observers who were blind to case identity and diagnosisand the mean count per 
case calculated.    
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HK-I was quantified using image analysis.  A total of 6 fields per case were 
captured from the SN at 40x objective and were analysed with Image J. Each field 
was divided into 100 equal squares and subjected to colour deconvolution to 
separate DAB staining (brown) from haematoxylin staining (blue; Figure 2.1 b). The 
Shanbhag threshold (Shanbhag, 1994) was applied to the DAB-only images. Then, 
the stained area fraction was measured in the pictures submitted to the threshold 
(Figure 2.1 c). The percentage of each image that was positive for DAB staining was 
assessed. The mean of the 10 values across the 6 fields was calculated for each 
case and used in the statistical analysis for each case. 
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Figure 2.1. Image processing method for quantification of HK-I and TIGAR. Representative images showing 
original picture (a) processed with ImageJ. ImageJ color deconvolution plug-in was used to obtain the DAB-only 
images (b). a Shanbhag threshold was applied to the DAB only images, after which unlabelled areas appear in 
brown (not quantified) and labelled areas appear in white (quantified). Scale bar 100µm. 
 
2.8.9  Statistical analysis 
Statistical analysis used for TIGAR included t-Test, Kolmogorov-Smirnov test, 
Mann U-Withney and Levene’s test on Microsoft Excel and SPSS (IBM).  
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2.9 Results 
2.9.1 TIGAR immunohistochemistry in Sustantia nigra 
2.9.1.1 Antibody optimistation 
Antibodies that recognise the central or near the central region of TIGAR protein. 
Every run included positive and negative controls, as well as an isotype 
control that matched the species and the concentration of the antibody. The positive 
showed positive labelling, whereas any signal was detected with the negative and 
isotype controls. Anti-TIGAR antibody (ab62533) (Figure 2.2a, b) and anti-TIGAR 
antibody (ab10545) (Figure 2.2c, d) showed some cytoplasmic neuronal labelling, 
but with significant cross-reactivity to neuromelanin (Figure 2.2). There was 
significant background staining with minimal differentiation between cell and tissue 
types. There was no difference between one PD case (Figure 2.2 b-d) and the two 
controls (Figure 2.2a-c) and no labelling of Lewy bodies (Figure 2.2d).  
 
Figure 2.2 Antibodies central or near central region of the protein. Representative images of TIGAR staining 
in SN. Anti-TIGAR ab62533 one control (a) and one patient (b) and ab10545 in one control (c) and one patient 
(d). Images Showed no difference between controls and patients, granular staining (dark arrow heads) and 
negative Lewy bodies (red arrow). Bar 50µm 
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Consequently, these antibodies were not used for further experiments due to 
the lack of clear immunostaining of TIGAR and poor quality of the stained samples. 
These antibodies were directed against the central portion of the protein, in contrast 
to the antibody used in pilot work, which was directed against the C-terminal region.  
Therefore, we turned to other antibodies that recognised this a specific portion of the 
protein. 
2.9.2  Antibodies that recognise the C-terminal region of TIGAR protein 
Anti-TIGAR antibodies ab129333 (Figure 2.3 a, d), LS-C286858  (Figure 2.3 b, 
e) and PA5-29152 (Figure 2.3 c, f). Trial staining on SN showed a positive neuronal 
labelling, in the cytoplasm and nuclei, as well as a strong labelling of some neurites. 
The three antibodies that label the C-terminus showed positive staining for TIGAR in 
the SN from the controls group. 
 
Positive Lewy body staining was confirmed with three different antibodies to 
the C-terminus. This immunolabelling was interpreted as verification that TIGAR is 
genuinely present in Lewy bodies (Figure 2.3 a-c) and not a result of an artefactual 
cross-reaction of the antibody. There was good quality with minimal background 
staining with lower neuromelanin staining the PA5-29152 antibody (Figure 2.3 c, f). 
This antibody showed homogenous results across all the samples and avoid non-
specific staining, by reducing the concentration of the antibody. Thus, PA5-29152 
antibody was chosen for further experiments. 
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Figure 2.3. Antibodies that recognise the C-terminal region of the protein. Representative images of TIGAR 
staining in SN. Representative images of the controls (a-c) and patients (d-f) stained with Anti-TIGAR antibody 
LS-C286858 (control-a and patient -d); ab129333 (control-b and patient-e) and Thermo Scientific PA5-29152 
(control-c and patient-f). There was positive TIGAR labelling in the Lewy bodies (red arrow) in the PD cases (a-c) 
with some neurite staining (black arrow) in controls (a and c) and patients (d and f). Bar 50µm. 
2.9.3  TIGAR expression in the SN 
2.9.3.1 TIGAR immunohistochemistry in SN: Sheffield Brain bank cohort 
Neurons from controls and patients showed variable levels of cytoplasmic 
labelling: some had pale staining, while others had stronger cytoplasmic labelling 
(Figure 2.4). TIGAR-positive neurites were also seen in the SN from controls and 
patients. TIGAR was present in the Lewy bodies in both PD (Figure 2.4 b) and DLB 
cases (Figure 2.4 c). No Lewy bodies were found in the control group (Figure 2.4 a).  
As noted above, TIGAR expression was seen in Lewy bodies of PD and DLB 
cases.   
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Figure 2.4. Pathological features in the Sustantia Nigra. Representative pictures of TIGAR-positive Lewy 
Bodies (red arrows) in PD (b) and DLB (c) cases. Lewy bodies are absent in the controls (a). Bar 50µm. 
 
2.9.4  Double staining immunohistochemistry 
2.9.4.1 Double staining immunohistochemistry 
TIGAR fluorescence 
Firstly, the stained fluorescent slides were analysed to confirm that the 
antibody worked for fluorescent detection of TIGAR. Neuronal bodies, neurites and 
cytoplasmic inclusions in the PD and DLB cases were present and positive (Figure 
2.5).  
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Figure 2.5.  TIGAR fluorescence in Sustantia Nigra. Representative images of TIGAR fluorescence staining in 
the SN in a control (a), PD (b and DLB (c) cases, showing the presence of TIGAR in Lewy bodies (white arrows), 
neurons (red arrow) and neurites (blue arrow). Bar 50µm. 
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2.9.5  Colocalisation with alpha-synuclein 
2.9.5.1 Double STAINING: DAB/Fluorescence and double fluorescence 
 Double staining with: DAB for TIGAR (Figure 2.6 a, c) and fluorescent alpha-
synuclein (red) (Figure 2.6 b, d); and fluorescent images acquired for TIGAR (green) 
(Figure 2.7 a) and alpha-synuclein (red) (Figure 2.7 b) revealed the colocalisation 
between the two proteins in Lewy bodies and some neurites (Figure 2.6; and Figure 
2.7 d).  
 
 
Figure 2.6. Double staining in SN: DAB/Fluorescence. Microscopic analysis of DAB staining showing TIGAR 
(a and c) and immunofluorescence staining showing alpha-synuclein with AlexaFluor 555 (red) (b and d), from a 
PD (a and b) and DLB (c and d) cases. Acquired images reveal the co-localization of TIGAR and alpha-synuclein 
in the Lewy bodies (white arrow) and neurite (blue arrow). Bar 50µm. 
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Figure 2.7. Double fluorescence staining in Sustantia Nigra. Microscopic analysis of immunofluorescence 
staining showing TIGAR conjugated with AlexaFluor 488 (green) and alpha-synuclein with AlexaFluor 555 (red) 
and, nuclear staining DAPI (blue). Merge image reveals the co-localisation of TIGAR and alpha-synuclein in the 
Lewy bodies and neurites. Original magnification at 40x.   
 
2.9.5.2 Co-localisation: serial sections 
Using the three different detection methods (double fluorescence, 
fluorescence and DAB and DAB in adjacent sections), we confirmed that TIGAR is 
co-localised with alpha-synuclein. Mainly in the Lewy bodies in the SN.  
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Figure 2.8. Aligned adjacent sections in the Sustantia Nigra. Representative images of DAB 
immunohistochemistry for alpha-synuclein (left panel) and TIGAR (right panel) in the SN of a PD case, showing 
the presence of TIGAR in Lewy bodies (red, blue and purple arrows). Bar 100µm.  
2.9.6 Quantification of TIGAR in dopaminergic neurons 
TIGAR quantification in the dopaminergic neurons was carried out by two 
pathologists (JS and RH). This was performed first to assess the inter-rater reliability, 
in which the percentage of neurones that were intensely stained was counted to 
assess TIGAR expression.  There was a 90% inter-rater agreement between the two 
observers. Only data obtained from the blinded pathologist was taken for the group 
comparison. A total number of four controls, four PD and four DLB cases were 
analysed. High levels of neuronal intensity were quantified in the controls 
(mean=34.25 (5.24%), SD=3.04), PD (mean=51.75 (17.52%), SD=5.8) and DLB 
cases (mean=62.75 (15.89%), SD=15.08; Figure 2.9). Neurones of the SN varied in 
their intensity of TIGAR expression across the three groups, but there were a 
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significantly greater proportion of neurones with strong TIGAR expression in PD than 
controls (2-way ANOVA, P=0.2350). The DLB cases showed greater variance and 
no statistical difference compared to the control group (2-way ANOVA, P=0.3166, 
t=1.384, d.f. 6).   
 
Figure 2.9. Neuronal TIGAR expression in PD, DLB cases and controls. Bar graph represents the 
percentage of SN neurones that stain intensely positive for TIGAR in each group. There was a higher TIGAR 
expression in neurones PD (P=0.2350) and DLB (P=0.3166) cases compared to controls, however they did not 
reach statistical significance (2-way ANOVA, Tukey´s test). 
 
After neuronal expression was quantified, we then assessed the density of 
TIGAR positive neurites in the SN from the same group of controls and patients. This 
was carried out by two blinded researchers (LT and KR). Inter-rater reliability 99.8% 
showed agreement between the observers. Thus, the mean of both observer’s 
counts was used for the group comparison as both observers were blind. The same 
group of controls and patients was used to assess the total number of TIGAR 
positive neurites for the controls (mean=4.833, SD=4.771); PD (mean=18.375, 
SD=0.9648) and DLB cases (mean=312.41, SD=61.076). There were also markedly 
more TIGAR positive neurites in both PD (t-test, ***P<0.0005, t=8.277, d.f. 6) and 
DLB (t-test, **P=0.002, t=10.041, d.f. 3.037) cases compared to controls (Figure 
2.10).  
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These quantitative differences suggested that there is a greater neuronal 
cytoplasmic expression and a greater neuritic pathology in PD and DLB cases in the 
SBTB cohort.   
 
Figure 2.10. TIGAR positive staining in neurites in the Sustantia Nigra of the PD, DLB and control cases. 
Immunoreactivity in representative control (a), PD (b) and DLB (c) cases. The percentage of SN neurites that 
stain intensely positive for TIGAR is significantly higher in DB cases (t-test, ***p<0.0005) and slightly higher in PD 
cases (t-test, **P=0.002) compared to controls.  
2.9.7 TIGAR immunohistochemistry in SN: Queen Square Brain Bank Cohort 
We then aimed to expand our patient cohort and further characterise TIGAR 
in PD and DLB cases from another source, the Queen Square Brain Bank (QSBB) in 
an attempt to validate these findings.  Again, we found TIGAR-positive Lewy bodies 
and neurites in the six PD and six DLB cases (Figure 2.11). Neurones and neurites 
from the controls, PD and DLB cases varied in the intensity of the staining.  
 
Therefore, we next proceeded to examine the TIGAR expression in this group.  
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Figure 2.11,  Immunohistochemical staining in Sustantia Nigra. Immunostaining for TIGAR by peroxidase 
substrate DAB counterstained with haematoxylin (a-c). Representative picture of a control (a), PD (b) and DLB (c) 
cases from QSBB, cases confirming the presence of TIGAR in Lewy bodies (red arrow) and neurites. Bar=50µm.  
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2.9.8 Quantification of TIGAR expression in SN  
 TIGAR neuronal staining protocols were performed by the same researchers 
using the same methods as with the SBTB cases. The percentage of neurones that 
were intensely TIGAR-positive was assessed by one blinded pathologist (JS) in six 
controls (mean=360.8 (52.37%), SD=31.71), six PD (mean=115.5 (29.38%), 
SD=17.74) and six DLB (mean=198.5 (49.04%), SD=27.29) cases (Figure 2.12) 
 
The neurones of the SN varied in their intensity of TIGAR expression, but 
there were not significantly difference regarding the proportion of neurones with 
strong TIGAR expression between PD (t-test, P=0.160, t=1.55, d.f. 7.851) and DLB 
(t-test, P=0.849, t=0.195, d.f.10) patients when compared to controls.   
  
Figure 2.12. TIGAR positive staining in neurones and neurites in the SN of the PD, DLB and control cases 
from QSBB.  The percentage of neurons in entire SN (a) positive for TIGAR relative to total number of neurons 
per field. The analysis showed no difference between the PD (t-test, P=0.160) and DLB (t-test, P=0.849) cases 
compared to controls.  
 
We then quantified the number of TIGAR positive neurites in the SN from the 
same group of controls and patients. The Inter-run sections used for comparing both 
cohorts were the same control sections. Quantification of TIGAR positive neurites 
was carried out by one blinded researcher in controls (mean=90.88, SD=82.55), PD 
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(mean=27.833, SD=26.16) and DLB cases (mean=63.833, SD=32.31).  This also 
showed no difference between both PD (t-test, P=0.125, t=1.784, d.f. 5.99) and DLB 
(t-test, P=0.481, t=0.748, d.f. 6.49) cases compared to controls (Figure 2.13). 
 
 
 
Figure 2.13. TIGAR positive staining in neurites in the SN of the PD, DLB and control cases. Bar graphs 
representing the percentage of TIGAR positive neurites in the controls and diseases cases. No significant 
difference was found in PD (t-test, P=0.125) and DLB (t-test, P=0.481) cases compared to controls. 
 
We found that TIGAR was present in the Lewy bodies in the SN in the PD and 
DLB cases, and absent in the control group from the QSBB. This corroborates with 
the previous results obtained with the SBTB. However, we did not find TIGAR 
quantitative differences between controls and PD and DLB cases from the QSBB as 
we did we the SBTB.   
2.9.9 p53 in SN 
To elucidate the mechanism in which TIGAR might be involved in PD 
pathogenesis, we wanted to know if any other proteins that are upstream or 
downstream of TIGAR might be dysregulated in PD brains. For this reason, we 
proceeded to determine p53 localization in the SN in four PD, one DLB cases and 
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four controls from the Sheffield Brain Tissue Bank. Initial staining with the Anti-p53 
sc-263 antibody heavily stained melanin and failed to get a good staining (data not 
shown). Therefore, p53 staining was performed in the Department of Cellular 
Pathology, Hull and East Yorkshire NHS Trust.  
 
 The positive control showed positive labelling of cell bodies (neoplastic tissue). 
There was no p53 expression in either the control (Figure 2.14 a) or the PD (Figure 
2.14 b) and DLB (Figure 2.14 c) disease group, suggesting no up regulation in the 
expression of the p53 protein in the SN. Moreover, Lewy bodies were negative for 
p53 (Figure 2.14 b, c). In this study and with our methods, we did not find p53 
involvement.  
 
Figure 2.14. p53 staining in the Sustantia Nigra. Immunoreactivity in representative control (a), PD (b) and 
DLB (c) cases showing negative p53 expression within neurons and absence in Lewy bodies (arrows) from PD (b) 
and DLB (c) cases.  NB the brown pigment shown is neuromelanin-not DAB-labelled TIGAR Bar=25µm. 
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2.9.10 Hexokinase I and II in SN 
In addition to p53, Hexokinase I (HK-I) and II (HK-II) are well known to be 
regulators of TIGAR. Therefore, we wanted to investigate if there was an association 
with TIGAR expression in the SN. We assessed HK-I and HK-II expression in four 
controls and four Parkinson’s disease cases. HK-II, which is more abundant in 
muscle and liver, was not found or was found in very low levels. Moreover, we had to 
use high antibody concentration, which gave a considerable amount of non-specific 
background staining (Figure 2.15).  HK-II was not found in the Lewy bodies in the 
patient group (Figure 2.15 b-c). 
 
Figure 2.15. HK-II immunohistochemistry in Sustantia Nigra. Representative images of HKII DAB staining in 
SN in a control (a), PD (b) and DLB (c) cases showing non-specific labelling. There was no difference between 
cases and controls. HKII was not found in Lewy bodies (red arrow). Bar=100µm. 
We could only find positive expression of one of the hexokinase isoforms, HK-
I, which is well known to be abundant in the brain (Aleshin et al., 1998). HK-I staining 
showed a strong cytoplasmic expression in granular pattern in neurons and glia 
(Figure 2.16). This pattern varied within controls (Figure 2.16 a) and disease cases 
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(Figure 2.16 b-c). HK-I was not found in the Lewy bodies of the disease cases 
(Figure 2.16 b-c). 
 
 
Figure 2.16. HK-I immunohistochemistry in SN. Immunoreactivity in representative control (a), PD (b) and 
DLB cases (c). Images show varied neuronal cytoplasmic staining with slightly higher expression in the PD cases 
(b). Bar = 100µm. 
Each captured imaged from the SN from four controls and 4 PD cases was 
analysed with ImageJ. The DAB-only images, which were subjected to the threshold, 
gave the stained area fraction and measured. Overall, a total number of HK-I positive 
neurones were quantified for the controls (mean=61.99, SD=1.73); PD cases 
(mean=67.85, SD=1.03). Neuron intensity of ten fields from ten regions of the SN 
revealed a slightly increased HK-I expression in the PD cases compared to the 
controls (t-test, *P=0.0259, t=2.942, d.f. 6) (Figure 2.17). 
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Figure 2.17. HK-I positive staining in neurones in the SN of the PD and control cases. Bar graphs represent 
the percentage of neurons that stain positive for HK-I. HK-I showed slightly higher expression in PD cases (t-test, 
*P=0.0259) compared to controls. 
 
2.9.11 TIGAR expression in mesial temporal lobe 
Alpha-synuclein pathology has been found in the hippocampus in PD and 
DLB cases (Galvin et al., 1999). Thus, we aimed to look for TIGAR expression in the 
cohort of controls, PD and DLB cases in hippocampal tissue, both anterior and 
posterior, from the SBTB. Since we previously found TIGAR presence in the Lewy 
bodies in the SN in the PD and DLB cases, we wanted to determine whether TIGAR 
colocalization in Lewy bodies was also present in the hippocampus in the patient 
group. The presence of alpha-synuclein pathology had been confirmed previously in 
these cases and the paraffin-embedded tissue blocks were already available.  
 
TIGAR showed variable neuronal expression in the hippocampus in the 
controls and diseases cases (Figure 2.18 b-c). Some showed strong labelling in the 
region of the perforant processes pathway in the CA2 (Figure 2.18 c). 
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Figure 2.18. TIGAR staining in Hippocampus. Representative image of TIGAR presence in hippocampal 
regions CA2 in a control (a), PD (b) and DLB case (c). TIGAR expression showed to be variable in the pyramidal 
cells in controls (a) and disease cases (b-c). There was also some intense labelling in the performant pathway in 
some cases (c).  Bar=100µm 
 
TIGAR labelling in pyramidal neurons from the entorhinal and 
occipitotemporal regions appeared to have slightly higher expression in the disease 
group (Figure 2.19 c-f) when compared to the controls (Figure 2.19 a-b). However, 
not every cell showed to be affected, some showed higher expression, others do not. 
Therefore, we next proceeded to quantify TIGAR positive neurons in these regions.  
86 
 
 
 
Figure 2.19. TIGAR staining in entorhinal and occipitotemporal cortex. Representative image of neurones of 
the entorhinal (left panel: a, c, e) and occipitotemporal cortex (right panel: b, d, e) in mid layers from controls (a, 
b), PD (c, d) and DLB (e, f) cases. Images showed variable TIGAR neuronal expression in controls (a-b) and 
disease cases (c-f) in both regions. Some cells and processes appeared to have higher TIGAR expression in the 
disease cases (c-f) compared to the controls (a-b). Bar 100µm. 
 
2.9.12 Quantification of TIGAR staining in occipitotemporal cortex and 
entorhinal cortex. 
Three regions of interest were captured at 20x from the occipitotemporal and 
three from the entorhinal cortices from digitised whole slide images of sections at the 
level of the posterior hippocampus from one control, one PD one DLB cases were 
assessed.  Two blinded researchers counted the number of TIGAR-positive neurons 
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and neurites. There was no correlation between the two independent researchers 
(occipitotemporal cortex count correlation=63.3%; entorhinal cortex count 
correlation=21.22%)  (Figure 2.20 a, b); therefore this assessment method was 
aborted.  
 
As an alternative, image analysis was used to assess, based on the 
proportion of the image that was positive for TIGAR was performed by ImageJ 
analysis.  This did not detect any statistical difference (Mann U-Whitney, P=0.800) 
between the control (mean=44.28; SD=7.47), PD (mean=50.41; SD=16.74) and DLB 
cases (mean=50.40; SD=13.96) (Figure 2.20 c, d).     
 
Thus, we found that TIGAR was not involved in PD pathology in other areas 
different outside the SN. These suggest a specific role of TIGAR in PD and DLB 
disease process in the SN. There was no labelling of neocortical or hippocampal 
bodies. 
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Figure 2.20. Quantification of TIGAR in hippocampus. Scatter charts showed no correlation between the two 
independent researchers in counts from the occipitotemporal cortex (OTC) (63.3% correlation) (a) and the 
entorhinal cortex (EHC) (21.22% correlation) (b). Bar graphs represent the percentage of TIGAR positive neurons 
processed and quantified by Image J for the OTC (c) and the EHC (d); no statistical difference was found 
between controls and patients (Mann U-Whitney, P=0.800).  
2.9.13 TIGAR in MSA 
We then assessed TIGAR expression in another synucleinopathy, namely 
MSA. We wanted to determine whether TIGAR had a disease specificity for PD or 
whether it was also present in other synucleinopathies. In the SN, many neurons 
showed apparent intense neuronal cytoplasmic and neurite staining. TIGAR-positive 
glial cytoplasmic inclusions were not seen (Figure 2.21 a-b).  
2.9.13.1 Quantification of TIGAR in MSA 
We then analysed the variability of TIGAR expression in neurones and 
neurites between controls and MSA cases (Figure 2.21 a-b). We assessed the levels 
of these by using the same methods as for the PD and DLB cases above. The 
proportion of TIGAR positive neurones was quantified for controls (mean=52.37, 
SD=31.71) and MSA cases (mean=29.42, SD=4.42). TIGAR positive neurites were 
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also quantified in controls (mean=90.88, SD=82.55) and MSA cases (mean=43.77, 
SD=24.01). We found no significant difference in TIGAR expression in neurones (t-
test, P=0.138, t=1.73, d.f. 5.377) and neurites (t-test, P=0.241, t=1.29, d.f. 6.37) 
between the controls and the MSA patients (Figure 2.21 c-d).  
 
There was no other significance evidence between the control and patient 
group, likewise we did investigate further regions involved in its pathology.  
 
Figure 2.21. TIGAR staining in SN from MSA cases. Immunostaining for TIGAR by peroxidase substrate DAB 
counterstained with haematoxylin in control (a) and MSA cases (b). Images showed variability in TIGAR 
expression between the controls (a) and patients (b). Controls and patients showed a diverse range of 
immunoreactivity within the SN. Bar graphs represent the proportion of TIGAR positive neurones (c) and TIGAR 
positive neurites (d) between controls and patients. No statistical difference was found in neurones (c) (t-test, 
P=0.138) and neurites (d) (t-test, P=0.241) expression between the controls and patients. Bar 100 µm 
2.9.14 TIGAR in spinal cord: Motor Neurone Disease 
We proceeded to assess the presence of TIGAR in the ubiquitylated 
inclusions in neurones of another neurodegenerative disorder: The lower motor 
neurons of motor neurone disease (MND).  
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In contrast to its presence in Lewy bodies, TIGAR protein was not found in the 
TDP-43 positive cytoplasmic inclusions typical of MND. However, TIGAR 
immunostaining in spinal cord showed that TIGAR is present in motor neurons and 
neurites (Figure 2.22 b). Thus, results suggest TIGAR disease specificity for 
brainstem neuronal Lewy pathology of PD and DLB.  
 
Figure 2.22. TIGAR presence in Spinal cord. Microscopic analysis of TIGAR immunoreactivity in Spinal cord 
from a control (a) and ALS patient (b). TIGAR was not found in the TDP-43 positive inclusions of MND cases. A 
variable pattern of TIGAR positive immunoreactivity was observed in the nuclei and neuronal bodies in both 
controls and patients. Bar 50µm. 
2.9.15 Quantification of TIGAR in spinal cord in MND  
We investigated TIGAR expression in a different neurodegenerative disease 
with ubiquitinated inclusions, such as MND, to assess TIGAR disease specificity. It 
was noted that motor neurons from the spinal cord varied in their intensity of TIGAR 
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expression in both the control and patient groups. Therefore, we decided to assess 
the proportion of TIGAR positive and negative motor neurons in controls and MND 
cases by using the same methods as above.  
  
Quantification of TIGAR positive neurones was carried out by one blinded 
researcher. The percentage of TIGAR positive neurites was obtained for controls 
(mean=37.55, SD=26.04) and MND cases (mean=22.04, SD=20.07). However, there 
was no significant difference between the proportion of neurons with strong TIGAR 
expression in controls and MND cases (t-test, P=0.354, t=1.01, d.f. 7) (Figure 2.23 a-
c). Thus, results suggest a TIGAR specific role for PD and DLB. 
 
 
Figure 2.23. TIGAR-positive neurons in the spinal cord of controls and MND cases. Immunoreactivity in 
representative control (a), and MND cases (b). The percentage of neurons in the spinal cord that stain intensely 
positive for TIGAR (red arrows) was not significantly different in the MND cases compared to the controls. (t-test, 
P=0.354). Bar=50µm. 
92 
 
 
Therefore, we then assessed TIGAR positive neurites in the same groups. 
This was carried out by two blinded researchers. Inter-rater reliability 99.6% showed 
agreement between the observers. Thus, the mean from both observer’s counts was 
used for the group comparison. A total number of TIGAR positive neurites were 
quantified for the controls (mean=64.27, SD=71.81) and MND cases (mean=4.83, 
SD=2.92).  There was also no difference of TIGAR-positive neurites between 
controls and MND cases (t-test, P=0.196, t=1.654, d.f. 3.008) (Figure 2.24 a-c).  
 
 
Figure 2.24. TIGAR positive staining in neurites in the Spinal cord of the MND and control cases. 
Immunoreactivity in representative control (a), and MND cases (b). The percentage of neurites in the Spinal cord 
that stain intensely positive for TIGAR (red arrows) was not significantly different in the MND cases compared to 
controls. (t-test, P=0.196). Bar 100µm.  
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2.10 Discussion  
2.10.1 Antibody confirmation 
The present study addressed the normal and pathological TIGAR-related 
characteristics in the human brain in PD and related disorders. Although TIGAR 
expression has been characterised before by Western blot, Immunohistochemistry 
and microarray analysis in the superior temporal gyrus in normal brain and in 
patients with Alzheimer’s Disease (AD). Here, TIGAR gene and protein expression 
was reduced in patients with severe dementia (Katsel et al., 2013). Therefore, we 
wanted to assess it in the PD and related disorders DLB and MSA cohort. We also 
wanted to look in another neurodegenerative disorder characterised by pathological 
inclusions, such as MND, to determine if TIGAR was also present in other disease 
with ubitiquinated inclusions. Here, we demonstrated the presence of TIGAR in 
neurons in the normal and pathological brain. We could confirm that the obtained 
findings were true and reproducible by using three different antibodies that showed 
the similar result across the stained brains.  
2.10.2 TIGAR presence in human brain  
There was TIGAR widespread expression in the midbrain and hippocampus, 
as well as the spinal cord.  This result suggests that TIGAR function is important for 
the normal cellular metabolism across different regions of the CNS and cellular types. 
This could be due to its role in the Pentose Phosphate Pathway (PPP), which 
provides antioxidant defence against ROS, cellular stress and hypoxia, as well as 
providing the nucleotides for DNA synthesis (Bensaad et al., 2006). In neurons, the 
PPP has been suggested to be essential for glucose metabolism and for antioxidant 
function via glycolysis inhibition (Herrero-Mendez et al., 2009). Neurons seem to be 
susceptible to continued damage from oxidative stress (Herrero-Mendez et al., 2009).  
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Therefore, TIGAR function by lowering ROS production, maintaining NADPH and 
glutathione could be indispensable for the maintenance and antioxidant protection of 
the neurons preventing permanent damage (Bolaños and Heales, 2010).   
 
NADPH is produced in high levels in response to stress and is an important 
reducing cofactor that counters oxidative stress. It is produced from the metabolised 
glucose from the PPP and generated by the enzyme glucose-6-phosphate 
dehydrogenase (G6PD). Glutathione (GSH) is an anti-oxidant and cofactor alongside 
NADPH, which combats oxidative stress after it is converted into its reduced form by 
the glutathione reductase (Zuo and Motherwell, 2013). A recent study by Dunn et al., 
2013; characterised the activity of the PPP across different regions of the brain in 
Alzheimer’s disease (AD), PD and normal control tissue by measuring levels of 
NADPH in post-mortem brain tissue. In the cerebral cortex and putamen of AD and 
severe and moderate PD groups NADPH and G6PD were increased; whereas in the 
mild PD group there was a decrease in G6PD. The mild group was related to be an 
early stage of PD, whereas the moderate/severe group was related to later stages of 
the disease. This evidence showed that an impairment of glucose metabolism and 
PPP inhibition leaves neurons vulnerable and exposed oxidative stress, which has 
been suggested to be a feature of an earlier stage in the development of PD (Dunn 
et al., 2013). Furthermore, oxidative stress has been suggested to have a role in the 
formation of Lewy bodies at early stages of the disease (Dias et al., 2013). 
 
NAPDH is produced through the PPP and utilised by glutathione in the redox 
cycle to decrease ROS levels (Ramos-Martinez, 2017). It has been reported that 
neurons have been reported to be deficient in the SN from brain tissue of patients 
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with PD (Fitzmaurice et al., 2003; Perry et al., 1982; Sofic et al., 1992). Therefore, it 
is important to produce glutathione through the recycling via the PPP and NADPH to 
prevent damage from oxidative stress insult. In this study NADPH levels were 
reduced in the putamen and cortex of early stage PD patient, suggesting a defect in 
the sensing or inhibitory mechanisms that prevent NADPH production and inability to 
recycle glutathione. A number of studies have suggested a dysregulation of the PPP 
pathway and glucose metabolism is one of the earliest events occurring in the 
pathogenesis of neurodegeneration (Bouzier-Sore and Bolaños, 2015; Dunn et al., 
2013; Hilker et al., 2012). 
2.10.3 TIGAR expression in the SN in PD, DLB and MSA  
In a previous study performed in post-mortem tissue, studying TIGAR mRNA 
and protein levels in the superior temporal gyrus from brains of AD patient group and 
compared to controls. Microarray data and protein levels obtained by western 
blotting showed reduced levels of TIGAR in the AD patient group compared to 
controls. However, no difference was found between patients and controls tissue 
expression performed in the superior temporal gyrus, one of the most affected brain 
areas in AD. This suggested that TIGAR was probably involved in the functional 
cognitive process rather than the neuropathology seen in the later stages of the 
disease (Katsel et al., 2013). Initially in our study, TIGAR expression was moderate-
high in the PD and DLB group compared to the control group from the first cohort 
studied (Sheffield Brain Tissue Bank). This initially suggested TIGAR upregulation in 
the SN of the disease cases groups, and a possible role in dopaminergic cell 
degeneration leading to disease development. However, when we attempted to 
replicate this with a second cohort (from the Queen Square Brain Bank) no 
significant difference was found. These can be due to the fact that 
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immunohistochemistry is a method in which specific subtle changes of proteins might 
not be detected.  
 
In immunohistochemistry, there are several critical factors that influence the 
outcome of the results of the protein of interest. These include: uncontrollable 
variables from the patient (disease duration and severity, case-case variation, diet, 
age, treatments and surgery, comorbidities, cause of death), quality of tissue, how 
the tissue was obtained, handled (post-mortem delay, ambient temperature, storage, 
mode of inactivation), fixed, processed (storage medium and conditions) and 
interpreted (observer variability and subjectivity). In our study, tissue was obtained 
from two different sources, which might have had an impact on the quantification. 
For example, paraffin processing at very high temperatures, could have an impact in 
the tissue adhesion and result in loss or impaired antigenicity. Immunohistochemistry, 
as a quantitative measure, DAB-based immunohistochemistry is generally not ideal, 
due to the amplification steps involved. Therefore, more accurate quantitation 
methods, such as Enzyme Linked Immunosorbent Assay (ELISA), are required to 
fully assess TIGAR protein levels in the brains from controls and disease patients. 
Therefore, TIGAR suspected neuronal upregulation in PD can be further assessed.   
 
TIGAR role in PD was initially suggested by findings from our group in a 
zebrafish pink1-deficient model (Flinn et al., 2013). TIGAR up-regulation may be a 
feature of PINK1-related disease only and not sporadic disease. In sporadic cases 
the combination of different environmental and genetic factors may have a 
considerable influence. Then, TIGAR expression might be altered only in a subset of 
cases. This is also true for some of the different genes described in sporadic PD. 
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Post-mortem studies in PD patients with PINK1 mutations are rare and difficult to 
obtain. However, it would be interesting to see if what was reported in the zebrafish 
brain can be confirmed in the human brain with Pink1 mutations. 
 
Alpha-synuclein aggregates are different in MSA when compared with PD and 
DLB (Yang and Yu, 2017). The main pathologic features of MSA is the presence of 
glial cytoplasmic inclusions alongside striatal and olivopontocerebellar degeneration 
(Miraglia et al., 2015). In this study we characterised TIGAR presence in the SN of 
MSA patients. We did not find TIGAR-positive glial cytoplasmic inclusions or 
differences in TIGAR expression. However, our cohort was relatively small (3 
patients).  
 
A recent study in MSA showed that neuronal loss, gliosis and glial 
cytoplasmic inclusions are mainly found in the motor, supplementary motor cortex, 
postcentral somatosensory cortex and temporal lobe neocortex (Salvesen et al., 
2015). Here, significant neuronal loss as a consequence of changes in cell density 
rather than cortical tissue volume, was found in the parietal and temporal neocortex. 
In addition, they found that glial cells were more abundant in these regions, which 
compensated for loss of neurones resulting in a normal cortical volume (Salvesen et 
al., 2015). If there is a TIGAR-related pathologic mechanism in MSA, the main 
affected regions, such as neocortex, need to be evaluated. Furthermore, double 
staining immunohistochemistry for TIGAR and alpha-synuclein should be performed 
in order to assess more robustly for co localisation in glial cytoplasmic inclusions. 
TIGAR-related pathology in MSA remains inconclusive following our study. In order 
to assess in a more robust method, such as immunoelectron microscopy or laser 
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capture microdissection (LCM), and a larger cohort should be assessed, not only 
looking at the SN, but other affected regions of the brain. 
2.10.4 TIGAR and alpha-synuclein: co-localisation in Lewy Bodies  
Alpha synucleinopathies are a group of disorders that share many 
neuropathological characteristics, principally the aggregation of alpha-synuclein. In 
the normal human brain alpha-synuclein is present in presynaptic terminals of the 
neurons (Galvin et al., 1999; Iwai et al., 1995; Murphy et al., 2000; Wang et al., 
2014). Although the synucleins have different isoforms, only the alpha isoform has 
been found to be accumulated in the synaptic terminal and involved in the formation 
of pathological oligomeric aggregates in the SN (Dimant et al., 2013). Many theories 
have suggested different mechanisms for this including: increased levels of alpha-
synuclein and toxic gain-of-function; protein misfolding leading to aggregation and 
neurotoxicity; mitochondrial dysfunction; impaired vesicle dynamics; defective 
synapsis and impaired intracellular trafficking. Moreover, two clearance mechanisms, 
the lysosomal autophagy system (LAS) and the ubiquitin-proteosome system (UPS), 
are also suggested to be impaired in PD (Bang et al., 2016; Beilina and Cookson, 
2015; Xilouri et al., 2016). This would impede the degradation of abnormal 
aggegates.  
 
TIGAR localisation in the regions studied in the brains of people with PD 
showed no difference from normal human brain. Interestingly, we found that TIGAR 
is present in Lewy bodies in the SN in PD and DLB, which was not found in the 
controls.  We found co-localisation of TIGAR with alpha-synuclein in Lewy bodies. 
This result reinforces the suggested association of TIGAR with PD pathology. To our 
99 
 
knowledge, this association has never been reported before in humans. It is still to 
be elucidated if TIGAR has a role in the formation of Lewy bodies.   
 
PD-related proteins such as LRRK2, PINK1 and Parkin; have also been found 
in Lewy bodies. Their role in Lewy body formation is still elusive. Interestingly, 
TIGAR was first linked to PD in a zebrafish pink1 deficient model, and both proteins 
were found to be in the Lewy bodies in the SN. Therefore, the suggested shared 
distribution within the brain and pathological inclusion would suggests that there may 
be a common involvement of both PINK1 and TIGAR in the development of Lewy 
pathology.  
 
Lewy body pathology could be the result of a cellular self-defence mechanism 
that disposes of and restricts cytotoxic proteins (Fecchio et al., 2013) Thus, the 
inclusion of TIGAR in Lewy bodies could be the result of the same cellular 
mechanism. This suggests an acquired cytotoxic property of TIGAR.   
 
Both, TIGAR and alpha-synuclein, have been described to have a role in 
autophagy impairment, so it is possible that both proteins, when produced in excess, 
impair autophagy and therefore promote protein aggregation. Alternatively, alpha-
synuclein overexpression and aggregation, might be promoting TIGAR sequestration 
and subsequent aggregation. There is already evidence for the capacity of alpha-
synuclein to sequester proteins: Alpha-synuclein aggregates interact with 
mitochondrial complex I, promoting mitochondrial dysfunction and alpha-synuclein 
tends to aggregate in the mitochondria in the SN and basal ganglia of post-mortem 
tissue (Devi et al., 2008).  
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As noted above, TIGAR promotes apoptosis by inhibiting glycolysis in some 
models. A correlation between ROS level reduction and autophagy inhibition has 
been suggested (Bensaad et al., 2009; Ye et al., 2013). This implies that TIGAR 
opposes autophagy (Bensaad et al., 2009).  
2.10.5 TIGAR, p53 and the Hexokinases 
To elucidate the mechanism that might be implicated in the TIGAR-related 
pathology, we looked at p53 expression in the SN of the PD patients compared to 
the normal controls: p53 is a good candidate as is an upstream regulator of TIGAR 
and has it’s a suggested role in neurodegeneration.  
 
Our results demonstrate p53-independent expression of TIGAR in the 
pathologic inclusions in the SN from brains of patients with PD and DLB. If there is a 
direct relationship between p53 and TIGAR, it is possible that this was not evident in 
our work due to the changes affecting p53 structure and function, before and after 
the cellular insult. There is also a possibility that p53 structural and functional 
changes are transient and no longer evident at autopsy. Wild type alpha-synuclein 
promotes p53 down regulation (Alves et al., 2016; Duplan et al., 2016). Therefore, as 
alpha-synuclein is altered in PD, MSA and DLB this may have reduced p53 
expression such that no changes could be seen in the present study. Very low levels 
of expression p53 in normal aged brain has been reported previously, where 
significantly increased p53 expression was detected in brains from AD patients (de la 
Monte et al., 1997). Previously, transcriptional regulation of p53 by parkin in familial 
PD was demonstrated and suggesting a potential involvement of p53 in PD 
pathology. Here, brains from patients with parkin mutations showed significantly high 
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p53 mRNA and protein levels in the striatum. However, the study was carried only in 
two patients with familial PD (Du et al., 2009). Therefore, p53 levels in the SN might 
be difficult to assess and it only could be detected when it is overexpressed and in 
particular conditions. Such very low levels of p53 expression suggest that related 
mechanisms and pathways need further evidence and might not have a pathological 
relevance.     
 
Another possibility is that p53-independent pathways are involved in the 
pathogenesis of PD. In order to further characterise other possible TIGAR regulators, 
we looked at hexokinase I (HK-I) and hexokinase II (HK-II) expression in the SN of 
the PD cases and controls. Our results showed no difference in HK-II expression 
between normal controls and PD patients in the SN. This is likely to be due to low 
levels of HK-II normally expressed in the human brain (John et al., 2011).  
 
HK-I is structurally similar to HK-II, but, in contrast, is expressed principally in 
the brain. Like HK-II, HK-I is important for promoting the glycolytic pathway shunt 
(John et al., 2011; Magrì et al., 2016). Our results revealed only a very slight 
increase in HK-I expression in the SN in PD compared to our controls.  
2.10.6 TIGAR in hippocampus 
The hippocampus and mesial temporal lobe is one of the brain areas that can 
be affected and susceptible to Lewy body pathology (Fujishiro et al., 2013; Jellinger 
et al., 2003). There is a diversity of pathological changes in this area. More frequent 
findings are hippocampal atrophy, Lewy bodies and Lewy neurites, senile plaques 
and phospho-tau pathology. Less frequent findings are the presence of glial 
cytoplasmic and nuclei inclusions, neuronal loss and Pick body-like inclusions (Dalfó 
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et al., 2005; Gaig et al., 2007; Galvin et al., 1999; Klos et al., 2006; Rohan et al., 
2015; Yang and Yu, 2017). The relationship of hippocampal pathology with dementia 
and severe cognitive decline is controversial (Elder et al., 2017; Tanner et al., 2017). 
Lewy pathology is mainly found in the entorhinal cortex, amygdala and CA2/CA3 
regions of the hippocampus. The CA1 region, fusiform gyrus and dentate gyrus are 
only rarely affected. In DLB a correlation between hippocampal atrophy and impaired 
cognition has been reported (Elder et al., 2017; Foo et al., 2016; Gazzina et al., 
2016). This finding is not consistent, however: other studies have not found a 
correlation between cognitive decline and Lewy pathology. This could be explained 
by the different approach from the different studies; where the investigation was 
undertaken in post-mortem tissue and reports (retrospective study), MRI and 
ongoing prospective studies in patients with PD only, MSA only or PD, DLB and AD 
as a group. Moreover, the disease duration varied amongst the different populations 
study, as well as the neuropsychological assessment (Koga et al., 2016; Tam et al., 
2005; Tanner et al., 2017). TIGAR expression in the entorhinal and occipitotemporal 
cortices as well as the hippocampus, did not showed any difference between 
controls and PD and DLB patients. We also did not find TIGAR-positive Lewy bodies. 
Overall, TIGAR pathology involvement in the neuronal alpha synucleinopathies 
seems to be confined to the SN. The limitation of the current study is the small 
number of patients studied. Further research need to be conducted including 
patients that developed dementia.   
2.10.7 TIGAR and MND 
 One of the main pathological characteristics of MND is the presence of 
proteinaceous cytoplasmic inclusions in affected motor neurones, which are positive 
for antibodies to the transactive response DNA binding protein-43 (TDP-43) and 
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ubiquitin(Arai et al., 2006; Ciryam et al., 2017). Given that both PD and ALS are both 
neurodegenerative diseases and have intracellular neuronal inclusions, it is possible 
that these two diseases share some neuropathological processes. Therefore, it was 
important to determine whether the inclusions of both diseases were positive for 
TIGAR. Previous gene chip analysis of mRNA expression of TIGAR in our laboratory 
(Highley et al., 2014) has suggested  a 1.65 fold reduction in TIGAR mRNA in motor 
neurones in ALS (P=0.0008). However, we found that while TIGAR is present in the 
neurones of the spinal cord, there was no significant difference between controls and 
patients.  
 
In this study we looked for TIGAR at the protein level, compared to Highley et 
al. 2014, that looked at the mRNA levels. The discrepancy between the results could 
be due to the fact that immunochemistry is not a good method for quantitation, 
therefore more sensible and specific techniques (ELISA, LCM, western blotting, etc.) 
are required to confirm the results. Post-transcriptional modifications and regulatory 
processes occur at any time during the protein lifetime in response to cellular activity 
demands. Therefore, these modifications offer an alternative explanation for the 
discrepancy between the mRNA and protein TIGAR levels obtained and affect the 
function of the protein. These modifications could be transient or permanent, which 
can affect the expression of the protein in situ. Post-transcriptional modifications 
have been suggested to have a role in PD pathology and related diseases, affecting 
related proteins such as alpha-synuclein (Guhathakurta et al., 2017) and potentially 
TIGAR. If the latter is true, future research needs to address this issue by studying 
the proteomics by specific techniques such as, mass spectrometry or proteomic 
arrays, in situ. Another explanation could be that the data obtained by Highley et. al, 
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2014; were false-positive results due to variability of the platforms and procedures 
used. Validation studies, such as qRT-PCR or enzyme-linked assays, which is a 
useful technique frequently used to confirm the possible biological relevance 
obtained by microarrays.  
 
As consequence, it was concluded TIGAR-positivity in ubiquitylated inclusions 
in PD and DLB but not in ALS inclusions, seems to have a disease-specificity for 
pathology occurring in neuronal PD and DLB in the SN. This is in contrast to p62, 
ubiquitin and many other proteins that are present in the inclusions of other diseases. 
The related proteins, p53 and HK-II, did not show altered expression on 
immunohistochemistry in our study. However, further studies are needed to elucidate 
the suspected role of TIGAR in the human brain pathology. Specifically, it is 
necessary to assess whether its localisation in pathologic inclusions are merely due 
to recruitment or the result of other events involved in PD and DLB development.  
2.11 Conclusion 
  
We have found that TIGAR is present in Lewy bodies in the SN of PD and 
DLB patients where it co localises with alpha-synuclein. This suggests a potential 
role of TIGAR in the formation of Lewy bodies and neurodegeneration more 
generally. The TIGAR-positive pathological inclusions were only found in the SN and 
thus seemed to be restricted to this area.  No TIGAR-positive inclusion was found in 
the spinal cords of patients with MND, or in the glial cytoplasmic inclusions of cases 
of MSA. This suggests specificity for Lewy-type pathology and no involvement in 
other neurodegenerative diseases. There was no difference of p53 localization and 
expression when comparing the PD cases to controls. Further cellular and post-
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mortem tissue studies need to be conducted to elucidate the TIGAR-related 
pathological mechanisms and pathways leading to neurodegeneration. 
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3 TIGAR in PD cellular model 
3.1 Introduction 
3.1.1  Cellular models for Parkinson’s research 
Different cellular models have successfully reproduced neuronal degeneration 
occurring in PD. Important disruptions and alteration in cellular biochemical 
pathways have been found in these models and suggested as part of the 
etiopathology. Cellular models have been widely used to study mainly protein 
aggregation and the mechanisms of cellular death leading to neuronal loss of the 
dopaminergic cells in the SN pars compacta (SNpc). In this study we focused on the 
utility of human fibroblasts from patients with familial and sporadic PD. 
3.1.2 Mitochondrial dysfunction in Parkinson’s disease from patient skin 
tissue 
Mitochondrial dysfunction linked to Complex I (CI) deficiency has been 
reported in several tissues from patients with PD and has a key role in the 
pathogenesis.  Several compounds have been described as neurotoxins, acting by 
inhibiting CI activity and the mitochondrial respiratory chain. 1-methyl 4-phenyl, 1, 2, 
3, 6 tetrahydropyridine (MPTP), the 1-methyl 4-phenyl pyridium ion (MPP+), and 
rotenone are some of the widely used toxins to create PD cell models (Gerlach and 
Riederer, 1996; Tanner et al., 2011). MPTP is recognised as a toxin that induces cell 
death specifically in the SN and causes PD symptoms in humans and animal models. 
Oxidative stress and ROS production have also been linked to PD pathogenesis, the 
oxidative stress inducer Paraquat, another CI mitochondrial inhibitor is also used in 
current models of PD (Cochemé and Murphy, 2008; Tanner et al., 2011). One of the 
difficulties for studying neurodegenerative diseases, such as PD, is the 
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inaccessibility to the affected areas in patients to study the different biological 
mechanisms and processes.  
3.1.3  Skin fibroblasts 
 Skin fibroblasts derived from biopsies taken from a diagnosed PD patient 
have been widely used in PD research as a non-neuronal cell model, as well as in a 
wide range of systemic diseases. They are a representation of primary human cell 
culture, reflecting the influence of the individual genetic background and environment 
in the disease process. This model offers the advantages of robustness, easy 
storage, transport and availability.  
 
 The 2mm punch biopsies are taken from the skin usually from the forearm, set 
up for culture from which fibroblasts can be isolated. Initially it is a culture containing 
keratinocytes and fibroblasts, which can be then be purely separated after the third 
passage. Since these cells come from the skin, they can be easily contaminated with 
Mycoplasma, for which they need to be regularly tested to prevent any deleterious 
effect due to the infection. Subsequent fibroblasts cultures will be consisting of a 
diverse population of mitotic and post-mitotic cells (Bayreuther et al., 1991). There 
are numerous cell repositories and laboratories from which skin fibroblasts, from 
patients with sporadic PD and with mutations in PD related genes, can be obtained: 
Coriell Institute (https://www.coriell.org) and The NINDS human cell and data 
repository (https://nindsgenetics.org) (Wray et al., 2012). Fibroblasts express PARK 
genes at endogenous levels. Furthermore, they display the important similar cellular 
contact interaction, comparable to neurons and response to trophic signals. Unlike 
tumour cell lines, glycolysis does not occur at maximal glycolysis. They also reflect 
additive cellular damage according to the patient age (Auburger et al., 2012). 
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Notably, they can be converted to induced pluripotent stem (iPS), induced neurons 
(iN), induced dopaminergic neurons (iDA), induced neural progenitors (iNP) and/or 
induced neural stem (iNS) cells by reprogramming and applying differentiation 
methods (Badger et al., 2014; Gopalakrishnan et al., 2017; Momcilovic et al., 2016; 
Xu et al., 2017).  
3.1.4  Skin fibroblasts from patients with PARK gene mutations 
3.1.4.1 Alpha-synuclein 
Alpha-synuclein is the main component of the pathological hallmark of PD, the 
Lewy Body. This was the first identified gene in familial cases of PD, the function of 
which remains unknown. Several studies have suggested that it is expressed in 
peripheral tissues from living patients, such as skin, stomach and colon. Post-
mortem studies have reported its expression in peripheral ganglia, plexus, glands, 
etc. (Tolosa and Vilas, 2015). Healthy fibroblasts can take up recombinant alpha-
synuclein, which aggregates and potentially forms inclusions in these cells. It occurs 
in a time dependent manner and is linked to an enhancement of the cellular oxygen 
consumption and apoptosis (Braidy et al., 2013). However, endogenous levels of 
alpha-synuclein expression in these fibroblasts have been repeatedly reported to be 
undetectable (Ambrosi et al., 2014; Braidy et al., 2013; Sanchez-Martinez et al., 
2016).  
3.1.4.2 LRRK2  
Skin fibroblasts from patients with LRRK2 mutations have mitochondrial 
dysfunction (Grunewald et al., 2014; Mortiboys et al., 2010a, 2013, 2015; 
Papkovskaia et al., 2012) and more specifically complex III (CIII) and IV (CIV) defect 
in fibroblasts with LRRK2G2019S mutations (Mortiboys et al., 2015). LRRK2G2019S 
fibroblasts from PD patients displayed increased autophagy, where pharmacological 
inhibition in the MEK/ERK pathway induced a reduction in autophagy (Bravo-San 
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Pedro et al., 2012, 2013; Yakhine-Diop et al., 2014). In fibroblasts, LRRK2 protein 
levels was not affected by the G2019S mutation, but the LRRK2 kinase activity was 
increased (Bravo-San Pedro et al., 2013). Mortiboys et al., 2015; demonstrated that 
mitochondrial function is rescued after LRRK2 siRNA mediated knockdown, which 
suggest that the mitochondrial defect is secondary to the mutation rather than due 
LRRK2 haploinsufficiency or a nonspecific downstream effect (Mortiboys et al., 
2015). Altered lysosomal morphology has been also documented in LRRK2G2019S 
fibroblasts (Manzoni et al., 2013b). The Two-pore channel 2 (TPC2) proteins, which 
regulate the Ca2+ signalling dynamics and trafficking, were linked to altered 
mitochondrial morphology in LRRK2G2019S fibroblasts (Hockey et al., 2015). Co-
immunoprecipitation of LRRK2 and TCP2 was demonstrated and suggested that 
LRRK2 possibly acts by phosphorylation of TCP2. TPC2 in LRRK2-PD related 
mutations are suggested to be due to interaction and modulation of autophagy in this 
cells (Hockey et al., 2015). LRRK2G2019S mutation fibroblasts were reported to 
display excessive fission due to constant phosphorylation and activation of Drp-1, a 
fission protein, by LRRK2 (Mortiboys et al, 2010; Su and Qi, 2013). Increased 
mitochondrial uncoupling proteins (UCP2 and UCP4) expression lead to an 
enhancement of the mitochondrial proton leak, linked to LRRK2 kinase activity in 
patient fibroblasts (Grunewald et al., 2013; Papkovskaia et al., 2012). 
 
Our group also assessed mitochondrial function and morphology in G2019S 
manifesting (M) and nonmanifesting (NM) carriers. Similar defects in the 
mitochondrial function, basal mitochondrial oxygen consumption and maximal 
respiration and a CIV defect in both groups were found. Coupled respiration and CIII 
were both lower in both groups, but more markedly in the G2019S-M than in the 
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G2019S-NM. (Mortiboys et al., 2015). Ursodeoxycholic acid (UDCA) rescues 
mitochondrial function in people with LRRK2G2019S mutations (M and NM). This cell 
model provided a new reliable platform for drug testing. (Mortiboys et al., 2013, 
2015). 
LRRK2 fibroblasts with different pathogenic mutations within the kinase and 
ROC domains demonstrated that the cytoskeleton, and cellular adhesion remain 
unaffected after the kinase activity is inhibited (Garcia-Miralles et al., 2015). However, 
another study by Caesar, et al. 2015, demonstrated that LRRK2G2019S fibroblasts 
harbour cytoskeletal alterations due to a direct effect in actin dynamics and 
depolymerisation (Caesar et al., 2015). Fibroblasts harbouring mutations within the 
core portion of the LRRK2 protein (R1441G, Y1699C and G2019S), located in the 
ROC, COR and kinase functional domains, showed impaired autophagic response, 
mTORC1 independent, upon starvation. Here, impairment of the 
autophagy/lysosomal pathway was suggested as one of the leading disease 
mechanisms and highlights the importance of studying a variety of disease related 
mutations (Manzoni et al., 2013a). Moreover, fibroblasts from patients with LRRK2 
R1441C and G2019S mutations, displayed enhanced basal mitophagy and 
autophagy (Smith et al., 2016; Su and Qi, 2013; Yakhine-Diop et al., 2014). 
Increased autophagy with mitochondrial dysfunction in the G2019S fibroblasts has 
been suggested to be activated via increased mitochondrial recruitment of dynamin-
related (Drp-1), a protein involved in the mitochondrial fission (Su and Qi, 2013).   
3.1.4.3 PARKIN  
Fibroblasts from patients with parkin mutations have been widely used as a 
PD cellular model investigating the biochemical, functional and physiological 
mechanisms implied in the development of the disease (Grünewald et al., 2010; 
Haylett et al., 2016; Lobasso et al., 2017; Mortiboys et al., 2008, 2013, Rakovic et al., 
111 
 
2010, 2011; Vergara et al., 2014; Zanellati et al., 2015). Parkin belongs to the 
Ubiquitin E3 ligases family of proteins involved in the mitochondrial fusion and fission. 
As an E3 Ubiquitin ligase, Parkin acts in a diversity of cellular functions by modifying 
substrates and proteins, which leads to protein stability, regulation, modification, 
localisation and functionality (Panicker et al., 2017).  
 
Defective cytoskeletal proteins in parkin-mutant fibroblasts, cause irregular 
cellular shape and impaired elasticity, via actin regulation (Vergara et al., 2014). 
Parkin mutations impair the cellular bioenergetics status, mitochondrial function, 
respiration and morphology (Grünewald et al., 2010; Mortiboys et al., 2008; Pacelli et 
al., 2011) alongside biomechanical and molecular alterations as some of the 
principal causes of PD (Pacelli et al., 2011; Vergara et al., 2014). Parkin-mutant 
fibroblasts have a CI defect (Mortiboys et al., 2008; Pacelli et al., 2011), defective CI 
biogenesis  and  lower ATP production (Grünewald et al., 2010; Mortiboys et al., 
2008). However, CI deficiency was inconsistent in other parkin-mutant cell lines, 
where activity remained similar between controls and patients (Grünewald et al., 
2009; van der Merwe et al., 2014). Reduced CIV and citrate synthase enzyme were 
found in parkin-mutant fibroblasts (Pacelli et al., 2011). Oxidative stress may also be 
present in Parkin mutant fibroblasts (Grünewald et al., 2010; van der Merwe et al., 
2014; Mortiboys et al., 2008, 2013; Pacelli et al., 2011). These defects were present 
in fibroblasts with parkin knockdown, which support reports that the effect is due to 
parkin deficiency (Mortiboys et al., 2008). The peroxisome proliferator-activated 
receptor gamma coactivator 1 alpha (PGC-1α), a protein with several functions, 
pathway is dysregulated in Parkin deficient fibroblasts. This protein play a role in PD 
pathology by protecting the cells against oxidative stress and promoting 
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mitochondrial biogenesis (Pacelli et al., 2011). Resveratrol treatment rescues CI 
activity, where the rescue effect was suggested to be a mediated-mechanism via CI 
mitochondrial biogenesis or/and post-transcriptional modifications (Ferretta et al., 
2014). 
 
Drug screens performed by Mortiboys et al, 2013, showed that the natural 
compound ursolic acid, and the licensed drug ursodeoxycholic acid, rescued 
mitochondrial dysfunction in parkin-mutant fibroblasts. Here, enhanced Akt 
phosphorylation followed by the activation of the glucocorticoid receptor is crucial for 
the rescue effect (Mortiboys et al., 2013).  
 
Mitofusins (Mitofusin 1 and 2), located in the OMM, maintain the balance 
between mitochondrial fission and fusion (Schrepfer and Scorrano, 2016). Parkin-
deficient fibroblasts showed impaired Mitofusin 2 ubiquitination, which was rescued 
in by overexpressing Parkin (Rakovic et al., 2011). Impaired mitochondrial fusion and 
fission in parkin-deficient fibroblasts, but not in partially deficient cells, result upon 
cellular stress (Mortiboys et al., 2008). Impaired mitophagy has been related to 
parkin loss of function, which alters the PINK1/Parkin mitophagy pathway. Parkin 
mediated ubiquitination and mitophagy was impeded by ubiquitin-specific protease 
15 (USP15), a deubiquitinating enzyme. USP15 knock-down in parkin deficient 
fibroblasts rescued the mitophagy pathway, suggesting USP15 as new therapeutic 
target for PD (Cornelissen et al., 2014).  
 
Further research investigated the lipidome profile of parkin-deficient 
fibroblasts. Results showed a reduced phospholipid and glycosphingolipid content 
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and proportion; whereas high levels of phosphatidylinositol, phosphatidylserine and 
gangliosides were detected (Lobasso et al., 2017). These results suggested an 
unknown connection leading to inflammation, defective autophagy, mitochondrial 
function and morphology. 
3.1.4.4 PINK1  
After mitochondrial depolarization in PINK1-mutant fibroblasts with missense 
and nonsense mutations, PINK1 accumulates in the mitochondrial membrane and is 
effective but not essential to induce Parkin mitochondrial translocation upon stress, 
polarizing and non-depolarizing (Rakovic et al., 2010). Specific mutations alter 
PINK1 function at different stages. Different mutations can affect in a different 
manner the mitochondrial membrane potential (MMP) and biochemical properties, 
where missense mutations appear to be more deleterious (Grünewald et al., 2009). 
PINK1 expression and mitochondrial accumulation, but impaired stabilization in the 
outer mitochondrial membrane (OMM), were found in PINK1 mutant fibroblasts with 
missense mutations (See general introduction).  
 
PINK1 deficient fibroblasts displayed reduced parkin expression; in addition to 
a high susceptibility to proteasomal stress upon caspase activation (Klinkenberg et 
al., 2010). LRRK2 was found to be dysregulated in PINK1 mutant fibroblasts and 
corroborated in iPSC-derived neurons lines with PINK1 mutations. PINK1 
overexpression in control and mutant cell lines led to LRRK2 down-regulation; 
whereas in mutant tissue only, its dysregulation increased LRRK2 protein levels. It 
has been suggested that PINK1 might be inhibiting LRRK2 at the transcriptional level 
(Azkona et al., 2016). 
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A loss of PINK1 kinase activity, possibly secondary to ATP-binding site 
alteration, leads to proteasomal inhibition and Parkin translocation impairment (Ando 
et al., 2017; Exner et al., 2007; Siuda et al., 2014).  PINK1 p.G411S heterozygote 
mutation was described as a variant of risk for PD. Fibroblasts  harbouring the 
mutation showed a partial dominant-negative effect, where mutant PINK1 
heterodimerizes with wild-type PINK1, leading to impaired function and reduced 
kinase activity (Puschmann et al., 2016). Enzymatic kinase activity of PINK1 is 
important for Ubiquitin phosphorylation in the S65 residue (p-S65-Ub), which was not 
found in fibroblasts with PINK1 mutations. Nevertheless, the physiological relevance 
and pathology remain unknown (Fiesel et al., 2015).  Increased glycolysis, 
mitochondrial function and bioenergetics status, decrease levels of CI and CIV and 
enzyme activities of the respiratory chain were reported to be inconsistent in 
fibroblasts with PINK1 mutations and suggested to be mutation-dependant (Abramov 
et al., 2011; Azkona et al., 2016; Exner et al., 2007; Grünewald et al., 2009; Lopez-
Fabuel et al., 2017; Siuda et al., 2014). Mitochondrial morphology was reported 
altered in fibroblasts with missense mutations (Grünewald et al., 2009) and in PINK1 
deficient fibroblasts and rescued when wild-type PINK1 and Parkin are transfected, 
where a protective mechanism against stress has been suggested (Exner et al., 
2007). 
Ubiquitination of mitofusins was altered in Parkin and PINK1 mutationt 
fibroblasts, where the suspected leading mechanism is the degradation of the 
Mitofusins by the Ubiquitin Proteasome System (UPS) (Rakovic et al., 2011).  
   
3.1.4.5 Sporadic PD  
Ambrosi et al. reported that the proteasome catalytic subunit 20S and the 
polyubiquitinated proteins were higher in fibroblasts from sporadic PD patients. 
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Parkin protein levels were increased in sporadic PD fibroblasts and demonstrated to 
be the result of proteasomal impairment (Ambrosi et al., 2014). Sporadic PD 
fibroblasts also showed increased sensitivity to rotenone exposure, enhancing the 
proteasome mechanisms in response, rather than activate autophagy. Also, basal 
mitochondrial respiration may be reduced in the sporadic PD patients (Ambrosi et al., 
2014; Winkler-Stuck et al., 2004) and after rotenone exposure (Ambrosi et al., 2014; 
WIEDEMANN et al., 1999). 
3.2 Aims and objectiives 
TIGAR PD-related mechanisms have yet to be determined in a human cellular 
model. Pink1 and Parkin share common pathways in mitochondrial function and 
mitophagy.  
 
In this study, we aimed to determine TIGAR related mechanisms in fibroblasts 
from sporadic and familial PD patients. By knocking down TIGAR in this model we 
wanted to assess whether TIGAR knockdown can rescue the mitochondrial 
dysfunction.  
• Characterize TIGAR gene expression and protein level in human fibroblasts to 
determine differences between controls and patients. 
• Correlate TIGAR and Parkin protein levels in fibroblasts from controls and 
patients with parkin mutations. 
• Optimise effective and efficient transfection in human fibroblasts.  
• Achieve effective TIGAR knockdown in fibroblasts and assess the effect in 
mitochondrial function and bioenergetics status in controls and patients with 
PD mutations. 
116 
 
• Assess TIGAR cellular localisation in fibroblasts from controls and patients 
with Parkin mutations under normal conditions and upon toxin exposure 
• Determine whether TIGAR is involved in autophagy in fibroblasts from 
controls and patients with sporadic PD, which were previously identified to 
have mitochondrial defect.  
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3.3 Materials and methods 
3.3.1  Cell tissue culture 
3.3.1.1 Fibroblasts  
 
Fibroblast cell lines were obtained from two sources; from punch skin biopsies 
from control healthy individuals, patients with compound heterozygous or 
homozygous mutations in the parkin gene, one LRRK2G2019S and two sporadic PD; 
and Coriell Cell Repositories (Camden, NJ) (Table 3.1). All biochemical and 
morphological experiments were performed in fibroblasts from passage 7-12.  
 
Patients  
Case ID Mutations Gender AB (y) 
Parkin 
patients 
P1 
202_203delAG 
(X2) 
Del X4 F 48 
P2 
202_203delAG 
(X2) 
Del X2 F 38 
P3  
202_203delAG 
(X2) 
202_203delAG 
(X2) 
F 39 
ND31618 (P4) ARG42PROhet -- F 63 
ND30171 (P5) ARG42PRO Del X3 M 54 
ND37731 (P6) Del X3 40bp Del X3-X4 F 64 
LRRK2 
patients 
NPF-008(Pt-1) G2019S manifesting M 65 
Sporadic 
patients 
OB137 (Pt-a) Sporadic  M 50 
OB194 (Pt-b) Sporadic  M 61 
Table 3.1. Parkin, LRRK2 mutant and sporadic fibroblasts from patient biopsies. AB, Age at biopsy; y, 
years; X, exon; Del, deletion; het, heterozygote; hom, homozygous; M, male; F, Female. 
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Controls 
Case ID Gender AB (y) 
GM08400 F 37 
GM02153 F 40 
GM00730 F 45 
GM02189 M 63 
GM23967 M 52 
GM07924 M 63 
ND29510 F 55 
OB183 M 50 
OB153 M 61 
Table 3.2. Fibroblasts from healthy controls biopsies. AB, Age at biopsy; y, years; M, male; Female. 
 
3.3.1.2 Cell culture  
Skin fibroblasts 
Primary fibroblasts cells were maintained in T75 cell culture flasks and 
incubated in a humidified atmosphere with 5% CO2 at 37ºC. Skin fibroblasts from 
parkin, LRRK2-mutant patients and matched controls, were grown in Minimum 
Essential Medium with 10% Biosera Fetal Bovine Serum (FBS), 5 ml (1%) of 
Penicillin/Streptomycin, 0.1mM non-essential amino acids, 1mM Sodium Pyruvate, 
50ug/mL uridine and 1x MEM vitamins. Sporadic PD patients and matched controls, 
were grown in DMEM (Invitrogen) with 10% FBS (Sigma), 5 ml (1%) of 
Penicillin/Streptomycin, 1mM Sodium Pyruvate and 50ug/mL uridine. Media was 
stored at 4ºC and warmed to RT before use for cell culture and experiments. Cell 
passaging was performed when cells were >80% confluent. Fibroblasts were sub-
cultured at a ratio of 1:3.  
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Other cell lines 
HEK, HeLa and SH-SY5Y cells were grown in DMEM (Invitrogen) 
supplemented with 10% FBS (Sigma) and 5ml of Penicillin/Streptomycin. Media was 
stored at 4ºC and warmed to RT before use for cell culture and future experiments.  
3.3.2  TIGAR characterisation in human fibroblasts 
3.3.2.1 Sample preparation 
Cells were pelleted and lysed to obtain proteins without cell debris. At 70-80% 
confluency, cells were trypsinised and centrifuged at 400rcf for 4 min. The 
supernatant was discarded and the cell pellet was washed twice with 5mL of PBS. 
After the washes, the pellet was left to dry for 5 min and stored at -80ºC for future 
experiments. 
3.3.2.2 TIGAR gene expression 
To evaluate the TIGAR gene expression, Real-Time qPCR was performed in 
fibroblasts from healthy age-matched controls and parkin-mutant patients. Total RNA 
was extracted from cell pellets, using QIAGEN RNeasy kit (Qiagen) and cDNA was 
synthesised using SuperScript III cDNA first strand-synthesis Kit (Invitrogen), 
following the manufacturer’s instructions. Reaction mixtures were prepared at 20nM 
in a 20µl mix using 10µM of each primer forward and reverse, 10µl 2 X Brilliant III 
Ultra Fast SYBR master mix (Agilent), DNAse-RNase free water and 1 µl of cDNA 
added to a well in a 96 well PCR plate (Biorad), sealed with plastic caps. DNA 
amplification was performed by thermal cycling: initial denaturation at 95ºC for 10 
min, followed by 40 cycles of 95ºC for 30 sec and 60ºC for 1 min, then 60ºC for 1 
min in a PCR detection system (CFX96 Real-Time System, Biorad). Target gene 
expression level was normalised using GAPDH and β-actin as reference genes. 
Primer sequences are given in Table 3.3. 
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The gene quantitation was done relative to the reference genes by subtracting 
the cycle threshold (Ct) of either β-Actin or GAPDH, from the Ct of TIGAR (∆∆Ct=∆Ct 
gene of interest-∆Ct reference gene). The resulting value of Ct (∆Ct) was then 
normalised to control, then the exponent of the base 2 (2-∆∆Ct) was calculated to 
obtain the fold change. This was represented as the fold difference of template for 
the genes (Table 3.3). Five 5-fold serial dilutions of cDNA template were prepared 
and their threshold cycle value was determined. The threshold value versus the 
dilution factor was plotted in a base10 semi-logarithmic graph to obtain a straight line. 
The correlation coefficient (R2) was 0.999. Efficiency of the qPCR reactions of all 
gene primers were calculated based on the slope of the standard curve, where the 
closer slope to 100% is -3.32. The efficiency of all the qPCR reactions was 95-99%. 
For the knockdown expression, the normalised relative TIGAR gene expression was 
first calculated for each condition and then normalised against the untreated control. 
The knockdown percentage was calculated by subtracting the normalised ∆∆Ct 
expression of the control and multiplying by 100. The following formula was used in 
Excel for the calculation: (Power(10,-((∆Ct target-∆Ct reference)/3.333)))*100. 
Gene Sense Sequence 5’-3’ 
TIGAR 
A1 
 F CGGCATGGAGAAACAAGATT 
R TCCTTTCCCGAAGTCTTGAG 
B2 
F CCAAAGCAGCCAGGGAAGAGTG 
R CCGCTTCTTTCAGGATTAGTTGAC 
C3 
F CTCCAGTGATCTCATGAGGACA 
R TGACTCAAGACTTCGGGAAAG 
β-Actin 
F GATGCAGAAGGAGATCACTGC 
R ACTCTGCTGGAAGGTGGAC 
GAPDH 
F CTGACTTCAACAGCGACACC 
R ATGAGGTCCACCACCCTGT 
Table 3.3. Primers used for TIGAR characterisation. All primers were used for TIGAR gene expression by 
qPCR   1(Bensaad et al., 2006). Glyceraldehide 3-phosphate deshydrogenase (GAPDH); Primer forward (F); 
Primer reverse (R). 
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3.3.2.3 Western blotting  
TIGAR and Parkin protein determination 
Western Blots were performed to compare the levels of TIGAR protein 
between controls and parkin-mutant fibroblasts, and determine whether the different 
attempts to knock TIGAR down using the siRNA antisense strategy had the desired 
effect. We also looked if there was a correlation between the protein levels of TIGAR 
and Parkin, involving the pathologic process in PD. The fibroblast cell pellet was re-
suspended in Lysis Buffer containing RIPA (Radio-Immunoprecipitation Assay) 
buffer (Sigma Aldrich, USA) and diluted phosphatase inhibitors (1% v/v) (Sigma 
Aldrich, USA) and phosphatase inhibitors cocktail (1% v/v) (PIC). Cell lysates were 
incubated on ice for 30 min and centrifuged at 15871 g at 4°C. Supernatant was 
collected and total protein concentration was measured using the Bradford assay to 
select the appropriate amount of protein. 
 
The Bradford assay is a colorimetric assay, which enables the determination 
of the protein concentration from the cell lysates. A standard curve was obtained by 
preparing various protein concentrations of Bovine serum albumin (BSA) as 
standards. BSA concentrations (µg/ml) of the standards used were: 100, 125, 250, 
500, 750, 1000, 1200 and 1500. The same volume of three serial dilutions of the 
samples and standards were loaded in a 96 well plate in triplicate and 250 µl of 
Coomassie Blue reagent (Biorad) was added to each well. The absorbance was 
measured immediately at 595 nm and the standard curve was prepared. The protein 
concentration was calculated using the linear equation (Figure 3.1).  
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Figure 3.1. BSA standard curve. The absorbance obtained for each standard was plotted in a linear regression 
graph, where each measurement is theoretical to its concentration. A straight line is obtained and expressed in 
the equation “y=mx+b”; where y = absorbance (595nm) and x=protein concentration. Each sample represents the 
average of three replicates. Protein concentration was calculated after the measured absorbance for each 
sample was obtained  
The volume of cell lysate was determined and mixed with 2x Laemmli buffer 
(4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol blue and 
0.125 M Tris HCl). Samples were heated for 3 min at 100°C and centrifuged for 1min 
at 2347 g. The same amount of protein from each sample was loaded on a 12% 
polyacrylamide gel (SDS-PAGE) (Table 3.4). 
 
 
Resolving gel 12% Stacking gel 5% 
Reagent  Vol Reagent  Vol 
30% Bis/Acrylamide 4 mL 30% Bis/Acrylamide 1.7mL 
1.5M Tris HCL / 13.9 mM SDS / 
pH 8.8 2.5 mL 
0.5M Tris HCL pH6.8/ 13.9 mM 
SDS / pH 6.8 2.5 mL 
dH2O 3.5 mL dH2O 2 mL 
10% Ammonium Persulfate 
(APS) 100 µL 10% Ammonium Persulfate (APS) 50 µL 
N, N, N’, N -Tetramethyl-
ethylenediamine (TEMED) 10 µL  
N, N, N’, N -Tetramethyl-
ethylenediamine (TEMED) 20 µL 
Table 3.4. Composition of resolving and stacking polyacrylamide gels.  
Gels were assembled in a Mini-PROTEAN Tetra Vertical Electrophoresis cell 
(Biorad). The pre-stained protein marker (Precision Protein Dual Colour Standard 
(Biorad)) was loaded, followed by samples into each well. Stacking (separating) gels 
were run at low voltage (50 V) and running gel at a higher voltage (120 V) in a 
running buffer (Table 3.5). The process was complete when the dye front ran off the 
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bottom of the gel. Proteins were transferred applying a wet electrophoretic transfer 
(Table 3.5) to a PVDF membrane for 1.5 hours at 250 mA.  
 
Buffer  Reagents  Buffer Reagents Buffer Reagents  
Running 
buffer  
25 mM Tris 
Transfer 
buffer  
25 mM Tris 
TBS-T 
pH 7.6 
150 mM NaCl 
190 mM 
Glycine 
192 mM 
Glycine 20 mM Tris 
0.1% SDS 20% v/v Methanol 
0.1% Tween-
20 
Table 3.5. Solution and Reagents used for Western Blotting. 
The membranes were blocked with 5% non-fat dried milk (Mavel) diluted in 
TBS-T (Table 3.5), after which, membranes were incubated overnight at 4ºC with 
primary antibodies against TIGAR (Santa Cruz) and Parkin (Cell Signaling) (Table 
3.6). Then, membranes were incubated with secondary antibody horseradish 
peroxidase (HRP) (Table 3.6). Membranes were washed three times in TBS-T at RT 
for 15 min. Then, membranes were incubated with enhanced chemiluminescence 
(ECL) in a 1:1 ratio of solution 1 (Luminol Enhancer) and solution 2 (Peroxide 
solution) for 1 min before imaging. Bands were detected using a G-Box (Syngene). 
Actin and α-Tubulin were used as loading controls. Quantification was done by 
densitometry analysis using G-Box Syngene Image software. 
Antibodies Catalogue number Company Dilution 
Molecular 
weight (kDa) Host 
 Primary antibodies 
Anti-Actin antibody 
ACTN05 (C4) ab3280 Abcam 1:1000 42 R 
TIGAR antibody 
TIGAR(G2)  sc-74577 
Santa Cruz 
Biotechnology 1:1000 30  M  
Monoclonal anti-α-
Tubulin T9026 Sigma 1:10000 50  M 
Monoclonal Parkin 
antibody CST-4230* 
Cell signaling 
Technology 
1:1000 52 M 
Monoclonal Parkin 
antibody(Prk8) CST-4211 
Cell-signaling 
Technology 
1:1000 50  M 
Secondary antibodies 
Anti-rabbit HRP IgG 1706515 Biorad  1:5000 - G 
Anti-mouse HRP IgG 1706516 Biorad 1:10000 - G 
Table 3.6. Antibodies used for TIGAR characterisation and Parkin detection. Goat (G), Mouse (R); Rabbit 
(R), *discontinued. 
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3.3.3  Comparison with other common cell lines in research 
 For future assays in a suitable and different cellular model system, we 
characterized TIGAR and Parkin protein levels in HEK, HeLa, SHSY-5Y and 
LUHMES (Lund human mesencephalic). LUHMES cell lysates were provided by Prof. 
Stephen Wharton’s group (SITraN). All cell pellets were prepared as mentioned in 
sample preparation.  
3.3.4 TIGAR immunofluorescence 
 Immunofluorescence was performed to assess the effects on TIGAR 
localization and expression after inducing cellular stress. First, we tested different 
TIGAR antibodies (Table 3.7). Fibroblasts were seeded at 1.3 x 104 cells/well in a 
24-well plate containing a glass coverslip and grown for 48 hrs. Wells were rinsed 
with PBS and fixed with 4% paraformaldehyde (PFA) for 10 min. Cells were then 
rinsed with PBS and permeabilised using 0.3% Triton-X. Followed by incubation with 
5% BSA in PBS (Blocking buffer) for 1 hr at RT to block non-specific binding. Cells 
were then rinsed with PBS and diluted primary antibody (Table 3.7) in blocking buffer 
was applied to all the wells and incubated overnight at 4ºC. Cells were rinsed with 
PBS and incubated with fluorescent secondary antibody (Table 3.7) diluted in 
blocking buffer for 1 hr in the dark at RT.  
 
Antibody Company Dilution  Region Host 
Primary antibodies 
Anti-TIGAR 
antibody. (AB10545) 
Polyclonal  
Millipore 1:500 
KLH-conjugated linear 
peptide that lies in the 
central region of the protein 
R 
Anti-TIGAR 
antibody. (ab 
129333) 
Polyclonal 
ABCAM 1:800 
Synthetic peptide raised 
against the 19 aas from a 
region near the central 
region of the protein 
R 
TIGAR Polyclonal 
antibody (PA5-
29152) 
Polyclonal 
Thermo Scientific 1:1500 Synthetic peptide 
corresponding to a region 
within C terminal amino 
acids 220-270 of the protein 
R 
Anti-TIGAR  
Antibody (LS-
C286858) 
LifeSpan 
Biosciences 1:500 R 
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Polyclonal 
Anti-TIGAR 
antibody1 
Monoclonal 
 
(Bensaad et al., 
2006) 1:300 
Antibody raised against 
peptide corresponding to 
aas. 256-270 in exon 6-
encoding region of the 
protein. 
M 
Anti-TOM20 (FL-
145) 
Monoclonal 
Santa Cruz 
Biotechnology 1:500 
Antibody raised against aas 
1-145 representing the full 
length of the protein. 
R 
Anti-TOM20 
Monoclonal BD Biosciences 1:1000 
Antibody raised against aas. 
47-145 M 
Secondary antibodies 
Alexa Fluor 555a Invitrogen  1:1000 γ-IgG H and L R  
Alexa Fluor 488b Invitrogen  1:1000 γ-IgG H and L M 
Table 3.7. Antibodies used for TIGAR immunofluorescence. Mouse (M); Rabbit (R); aa., aminoacids; gamma 
immunoglobulins (γIgG). Antibody donation from Dr. Karen Vousden (Bensaad et al., 2006).  
3.3.5  RNAi mediated TIGAR knockdown: siRNA transfection 
3.3.5.1 Transfection efficiency  
Transfection reagents  
For transient TIGAR siRNA knockdown, we first assessed the transfection 
efficiency using different reagents and cellular densities in order to achieve the best 
knockdown effect. Lipofectamine 2000 (Invitrogen) is a cationic liposome formulation, 
which permits the introduction of the genetic material by cell membrane electrostatic 
repulsion. EndoFectin™ Max (GeneCopoeia) and DharmaFECT 1 and 3 
(Dharmacon, GE) are both cationic lipid-based transfection reagents. These 
transfections reagents form complexes with nucleic acids and facilitate their delivery 
into a wide range of commonly used mammalian and primary cell lines. 
Transfection procedure 
Initially, a suitable dose and concentration was assessed in a 96-well plate 
format in order to obtain the highest efficiency and least toxicity. After fibroblasts 
were 70% confluent, one day prior to transfection, cells were seeded at 2-5x103 
cells/well in 100 µl antibiotic-free media in a 96 well plate. 
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On the day, transfection complexes were prepared using Opti-MEM® I to 
dilute transfection reagent, and FITC labelled scramble siRNA (Ambion) control 
separately. Each mixture was incubated for 5 min at RT. The diluted amounts for 
each reagent are detailed in the (Table 3.8). Then, mixtures were gently mixed and 
incubated for 10 min at RT. Opti-MEM was added to the mix for a final volume of 
100µl of transfection medium. Cell culture medium was removed from the plates and 
replaced with transfection medium for each transfection reagent/siRNA complex.    
    
Transfection reagent 
(TR) 
Tube 1: diluted TR Tube 2: diluted siRNA 
Volume of TR Opti-MEM® Volume of 20µM siRNAa Opti-MEM® 
Lipofectamine 2000 0.1, 0.2, 0.5, 0.75 µl 9.5 µl  
0.3 µl 
9.5 µl 
DharmaFECT 1 0.1, 0.3, 0.5 µl 
9.5 µl 9.5 µl 
DharmaFECT 3 0.1, 0.3, 0.5 µl 
Endofectin™ Max 0.2, 0.35, 0.5 µl 5 µl 5 µl 
Table 3.8. Conditions for transfection of fibroblasts for each Transfection Reagent. Reagents tested at 
different concentrations for cell toxicity and transfection efficiency. *Final concentration 30nM in 200µl of serum-
free media  
Media was replaced 6 hrs after transfection to avoid cell toxicity and obtain 
the best transfection efficiency, except for Endofectin.  
Self-transfecting Accell siRNA  
Dharmacon Accell siRNA® transfection system (Dharmacon, GE) is a new 
method designed for delivery into cells difficult to transfect. The system uses a 
naked and chemically modified siRNA, without requiring the use of transfection 
reagents, virus or any other instrument used in standard RNAi methods. Therefore, 
lower toxicity without secondary viral effects can be achieved. In the present study, 
we tested this new method and compare it with conventional RNAi methods here 
assessed.  
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Accell siRNA transfection in fibroblasts, was optimised by assessing the effect 
in human fibroblasts treated with positive and negative controls. Negative controls 
(Table 3.9) are non-sequence-specific siRNAs with minimal targeting of known 
genes in human cells and should not have a specific cellular response. Negative 
controls are useful for siRNA delivery assessment and to determine the effect with 
siRNA-treated samples. Positive siRNA controls (Table 3.9) target highly expressed 
and non-essential cellular genes; therefore, viability is not affected when they are 
knocked-down. Positive controls are useful to optimise experimental conditions.  
Accell siRNA preparation 
Accell siRNAs work at 1µM, which is a higher concentration compared to 
standard siRNA. First, 5x siRNA buffer (Dharmacon, GE) was diluted in 4 volumes 
of RNase-fee water to obtain 1x siRNA buffer. All siRNAs (Table 3.9) were then 
diluted and prepared at 100µM in the 1x siRNA buffer, pipetted then 3-5 times up 
and down avoiding bubbles. Finally, the solution was placed in a shaker for 90 min 
at 37ºC, centrifuged, collected, aliquoted and stored at -20ºC for future experiments.  
Controls Company / catalogue number 
Unit 
size Description 
Accell Non-
targeting siRNA #1 
Dharmacon / D-001910-
01-05  
5 nmol 
Specific negative control, without targeting 
any gene product.  
Accell cyclophilin B Dharmacon / D-001920-01-05 Specific positive control for silencing.usually 
known to achieve high levels of knockdown  
Accell GAPD siRNA Dharmacon / D-001930-01-05 
Accell red Non-
targeting siRNA 
(Dy-547-labelled) 
Dharmacon / D-001960-
01-05 
Assessment of siRNA uptake by fluorescent 
microscopy to dye-labelled siRNA. Filter 
Cy3 (Rhodamine) 
Table 3.9. Accell siRNA controls. 
Accell siRNA delivery 
Briefly, control fibroblasts were seeded at different densities from 2.5-4 x 103 
cells/well in 100µl Accell Delivery Media and incubated overnight at 37ºC with 5% 
CO2. Then, 24 hrs after plating, growth media was removed and replaced with 100µl 
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Accell Delivery media containing with or without 1µM siRNA for each control (Table 
3.9). Cells were incubated then for 48hrs; after which, medium was replaced with 
glucose-free galactose medium and further incubated to assess ATP at 96 and 
72hrs. mRNA and protein knockdown were assessed at 72hrs. 
 
Cytotoxicity was assessed for all the RNAi methods. First, with ATP assays 
measurements (See Section 3.3.6.1) at ~70% confluency and viability for: a) each 
transfection reagent alone; b) with Accell siRNA treated positive and negative 
controls. A comparison of each condition was performed by testing a range of 
cellular densities. Efficiency was then assessed by using either FITC scramble 
siRNA or Accell Red Non-targeting siRNA (Dharmacon, GE Healthcare) then 
imaged using the InCell Analyzer 2000 (GE Healthcare) and analysed with the 
InCell Developer Toolbox 1.9.2 Software. The image analysis was performed by 
image segmention to find nuclei and siRNA fluorescent signal according to intensity, 
shape and size per cell.   
 
Culture 
Vessel 
Surf. 
Area 
(cm2) 
Cell 
seeding 
density 
Vol. of 
plating 
medium 
Dilution 
medium of  
transfection 
siRNA 20 
µM 
Lipofectamine 
2000 
96-well 
plate 0.32 3.5 x 10
3 200 µl 2 x 100 µl 0.2 µl 0.1-0.75 µl 
6-well 
plate 10 1.6 x 10
5 2.5 ml 2 x 500 µl 1.5 µl 3.5 µl 
T25 flask 60 3 x 106 4 ml 2 x  1 ml 6 µl 20-30 µl 
Table 3.10. Scaling up and down transfections. Example of vary amounts of transfection reagents, medium, 
cells and nucleic acids required in different tissue culture formats. 
 
3.3.5.2 TIGAR siRNA sequences 
TIGAR expression was inhibited by transfection with small interfering RNAs 
(siRNAs) against TIGAR from 3 sources: TIGAR siRNA (h) (Santa Cruz); ON-
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TARGETplus Human C12orf5 siRNA SMARTpool (Dharmacon, GE Healthcare) and 
SMARTpool from Accell siRNA (Dharmacon, GE Healthcare) (Table 3.11).   
To knock down TIGAR expression and avoid off-target effects, transfection 
conditions were modified to assess increasing concentrations of siRNAs. We first 
tested the siRNA pool targeting the exon 6 within the 3’UTR region to check TIGAR 
know-down efficiency. 
siRNA against 
TIGAR Target specific sequence 
Santa cruz biotechnolology 
TIGAR siRNA (h)  
sc-76662A Sense: CCACUUGCUUCUUAUCUAAtt Antisense: UUAGAUAAGAAGCAAGUGGtt 
sc-76662B Sense: GGAAGCACAUAAAGUAAGAtt Antisense: UCUUACUUUAUGUGCUUCCtt 
sc-76662C Sense: CCAUCAAUUUGGAAGUACAtt Antisense: UGUACUUCCAAAUUGAUGGtt 
Dharmacon  
ON-TARGETplus Human C12orf5 siRNA - SMARTpool 
siRNA J-020597-09 GUAGAAGGCAAAGCGCUAA 
siRNA J-020597-10 GUUAAUUCAGACAGCGGUA 
siRNA J-020597-11 GCAUGGAAUUUUGGAGAGA 
siRNA J-020597-12 GUAUGAACCUACAGGAUCA 
Dharmacon 
Accell SMARTpool siRNAC12orf5 
siRNA A-020597-13 CUAACAUGUUUUACGUAUA 
siRNA A-020597-14 GUAUGAACCUACAGGAUCA 
siRNA A-020597-15 UCUUAUUAUUUUAUGGUUA 
siRNA A-020597-16 GUAUAUCCCUGCAAUUUUA 
Table 3.11. TIGAR siRNA pool sequences. The complete target sequences from each of the siRNA contained 
in each pool from the 2 different sources used in this study.  
                                
Figure 3.2. TIGAR gene schematic representation. The 6 predicted exons of TIGAR gene are in represented 
in purple and the UTR regions are represented in violet. The targeted regions from the first siRNApool against 
TIGAR (Santa Cruz) act are in the 3’ UTR region of exon 6 (arrows). The second SMARTpool siRNA against 
TIGAR (Dharmacon) act within the exons 4, 5 and 6 (asterisks). The third Accell SMARTpool siRNA against 
TIGAR (Dharmacon) act within the exon 6 and its 3’ UTR region (stars). 
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Levels of TIGAR mRNA were quantified and normalised to β-actin and 
GAPDH. For western blots, cells were collected from 10 cm petri dishes, after 48hrs 
of transfection. We then check whether the second siRNA SMARTpool, targeting the 
exons 4, 5 and 6, had the desired knock-down effect in human fibroblasts. Western 
blots were performed after 48 hrs of transfection from T25 flask. 
3.3.6  Mitochondrial function assessment 
3.3.6.1 ATP assays 
Cultured fibroblasts typically generate their ATP through glycolysis if grown in 
glucose-rich medium. When the medium is changed to galactose, they rely on the 
oxidative phosphorylation pathway to produce ATP (Mortiboys et al., 2008). The ATP 
assays were performed over 3 consecutive passages as biological triplicates. 
Galactose media components: DMEM without glucose (Invitrogen) suplemented with 
0.9 mg/ml galactose, 10% FBS (Sigma), 5 ml (1%) of Penicillin/Streptomycin, 1mM 
Sodium Pyruvate, 1X MEM vitamins and 50ug/mL uridine.  After reaching 70-80% of 
confluency, cells were trypsinised and re-suspended with 1 mL of media. Cells were 
counted by taking 10 µl of cell suspension and using a haemocytometer. Cells were 
resuspended in 200 µl of normal glucose or galactose media and seeded at a 
density of 2.5-5x103 per well into 96-well plates according to the assay. ATP cellular 
level was measured using the ATPliteTM Luminescence Assay System (Perkin Elmer 
Inc).  
 
ATP production was assessed under different conditions. 24 hrs after of 
plating, media was exchanged for glucose-free galactose media. Cells were further 
incubated for 24 or 48 hrs. Reagents were warmed to RT before starting the assay. 
Lyophilised substrate was reconstituted with 25 mL of substrate buffer solution and 
gently agitation. Cells were removed from the incubator and media aspirated. In 
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order to remove any remaining media, 2 washes with 100 µl of PBS were performed, 
after which 100µl of PBS was added with 50 µl of mammalian cell lysis solution per 
well and the plate was placed on a plate shaker at 700 rpm for 5 min. This allows 
cells to lyse fully and to stabilise ATP levels. Then, 50 µl of substrate solution was 
added and plate was shaken for further 5 min at 700 rpm. The plate was then left to 
adapt to the dark for 10 min. and assessed using a FLUOstar Omega microplate 
reader (BMG LABTECH) at 520 nm, Gain 3600 5% adjustment on luminescence 
mode.  
3.3.6.2  CyQUANT measurement 
Cell density was measured with CyQUANT Cell Proliferation Assay Kit (Life 
technologies, USA). To prepare the HBSS buffer 1x, the 5x HBSS buffer was diluted 
with deionised water. The 1x dye binding solution was prepared by adding 
CYQUANT dye reagent (1:500 dilution of stock reagent provided) to the 1x HBSS 
buffer. After ATP was measured, 50 µl of prepared dye solution were added per well 
and incubated for 1 hr at 37ºC. The fluorescence was measured at 480/530 nm 
Ex/Em using a FLUOstar Omega plate reader. The normalised data was obtained 
when the total ATP was divided by the CyQUANT measurement per well in triplicate. 
Averages from controls were taken as a 100% and the ratio corresponding to 
patients was calculated. 
3.3.6.3 Seahorse assays: Oxygen consumption (OCR) and extracellular 
acidification rates (ECA) measurements. 
PD-mutant fibroblasts and controls 
The Seahorse XF24 Analyzer (Seahorse Bioscience) was used to assess the 
intact cellular endogenous respiration rates and glycolysis at the same time. 
Mitochondrial respiration was measured as the rate of oxygen consumption (OCR) 
and glycolysis by the extracellular acidification (ECAR). Basal OCR and ECAR were 
measured under basal conditions and upon sequential administration of 
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mitochondrial inhibitors: oligomycin, Carbonyl cyanide m-chlorophenyl hydrazine 
(CCCP), rotenone and antimycin A (Table 3.12). ATP-linked respiration was 
obtained from the difference between OCR at baseline and respiration after 
oligomycin injection. Mitochondrial OCR is measured by the difference of OCR after 
antimycin A addition and basal OCR. Oxygen consumption due to proton leak was 
obtained from the difference between antimycin A and oligomycin. Maximal OCR is 
the measurement resulting from OCR after CCCP administration, subtraction from 
OCR induced by CCCP. Spare respiratory capacity is obtained by the difference 
between maximal OCR and basal OCR. The obtained difference OCR after rotenone 
and antimycin A administration was measured as Non-complex I. Coupling efficiency 
was obtained from the fraction of ATP synthesis OCR divided by basal mitochondrial 
OCR. The respiratory cell ratio (RCR) was calculated by dividing maximal OCR by 
oligomycin-insensitive OCR. 
 
The seahorse assays represent two sets of experiments. First, mitochondrial 
respiration OCR and ECAR were assessed in two controls and two parkin-mutant 
fibroblasts in triplicate. Second, TIGAR knockdown effect was performed in one 
control and one LRRK2G20192-mutant fibroblasts.  
Seeding cells in XF24 Cell Culture Microplates  
Seahorse culture plates were prepared by coating with gelatine 48 hrs before 
plating, covered and stored at 4° C overnight.  Seahorse plates were set up 24 hrs 
previous the assay. Gelatine was removed from all the wells and then rinsed with 
sterile dH20. All liquid was removed carefully from the plate and left to dry. Cells 
were seeded at 3.5 x 104 cells/well in 200 µl of galactose media in a 24-well 
Seahorse culture plate. Cells were placed in the incubator for 1-2 hrs, to let cells to 
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attach to the plate. Once cells were attached, 300 µl of galactose media was added. 
Plate was incubated at 37o C overnight.  
XF assay media preparation 
XF assay media was prepared 24 hrs before assay. 48.5µl of XF DMEM 
media was aliquoted and heated to 37o C; followed by addition of 0.5 ml of 0.1g/ml of 
glucose, 0.5 mL of 2-mM glutamine and 0.5 µl of 1-mM Sodium Pyruvate. XF DMEM 
Media pH was adjusted to 7.4 by diluting NaOH, passed through a sterile filter and 
stored at 4oC overnight.  
Sensor cartridge hydration 
The sensor cartridge contains a set of probes, which are important to detect 
pH and O2 changes. The day before the assay, XF Flux plate was prepared by: 1) 
removing the sensor cartridge from the utility plate, 2) 1 ml of calibrant solution was 
added to each well of the utility plate and, 3) return sensor cartridge onto the utility 
plate and sensors submerged in XF calibrant solution. Plate was incubated without 
CO2 at 37o C overnight.  
Running XF assay 
On the day, the XF assay media was warmed up to 37o C. Media from the 
blank wells was removed and replaced with 100µl assay media, which served as 
guidance. Media contained in wells with cells was removed leaving only 100µl by 
using guides in blank wells. This was followed by 900µl of XF assay media careful 
administration to the top of each well, without disturbing the cellular layer. Finally, 
900 µl of media was again removed and replaced with 575 µl of fresh XF assay 
media. Seahorse culture plates were then placed at 37ºC without CO2 for 1 hr to 
allow temperature and O2 calibration.  
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Loading the XF24 Cartridge plate with compounds 
During Seahorse culture plate incubation, the XF24 Cartridge plates were set 
up with the mitochondrial inhibitors drugs listed in Table 3.12. The drugs were 
injected sequentially in the injection ports (A-D) to determine the OXPHOS function. 
The XF24 Cartridge plates were carefully transferred to the Seahorse XF24 flux 
analyser to allow calibration before the assay. XF24 Cartridge plates were then 
replaced with XF24 Cell culture plates to run the assay. Each OCR measurement 
consisted of: 3 min mixing; 2 min wait time and 3 min of continuous measuring of O2 
levels. Basal OCR and ECAR were obtained previous to the addition of Oligomycin, 
CCCP, Rotenone and Antimycin A. The effect on the mitochondrial respiration and 
ECAR was measured for 3 min for each component. 
Cellular normalisation 
For normalisation after cells had been analysed in the Seahorse, Cyquant 
reagent (1:500) was added to the wells and incubated without CO2 for 30 min. 
Normalization was performed by nuclear count after imaging fluorescent nuclei using 
the Incell Analyzer 2000 (GE Healthcare) and analysed with the InCell Developer 
Toolbox 1.9.2 Software. 
 
Injection Compound Action 
Assay 
Conc 
(µM) 
Injection 
Conc (µM) 
Stock 
Conc 
(mM) 
Dilution 
Factor 
Vol into 
3mLs 
(µL) 
A Oligomycin Inhibit CV 0.5 5 10 1:2000 1.5 
B CCCP Uncoupler 2.5 25 10 1:250 7.5 
C Rotenone Inhibit CI 0.5 5 2 1:250 7.5 
D Antimycin Inhibit CIII 0.5 5 2.5 1:200 6 
Table 3.12. Mitochondrial inhibitors used in this study. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP); 
complex I (CI); complex III (CIII); complex V (CV); Concentration (Conc). All compounds were diluted in XF Assay 
media before being loaded in the sensor cartridge. 
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3.3.7  TIGAR knockdown effect in fibroblasts 
Transfection conditions and efficiency of RNAi mediated TIGAR knockdown 
were optimised and assessed in control fibroblasts. Cells were transfected with 
either 30nM siRNA TIGAR or Scramble siRNA using Lipofectamine 2000. 
Mitochondrial respiration and glycolysis was assessed in the knockdowns after 48 
hrs using the Seahorse XF24 Analyzer to measure the OCR and ECAR in the 
derived fibroblasts from one control and one LRRK2G2019S patient. Normalisation was 
done by nuclei count. 
3.3.8  Cellular stress: Rotenone toxic exposure  
One hypothesis of the causes leading to neuronal cell death in PD suggests an 
inhibition of the mitochondrial CI activity. One of the important inhibitors of 
mitochondrial CI, currently used in PD research, is rotenone. In order to assess the 
effect on TIGAR expression and cellular localisation upon cellular stress, cells from 
controls and parkin-mutant fibroblasts were treated with 25nM rotenone. We 
assessed four different conditions: 1) glucose only, 2) glucose with rotenone, 3) 
galactose only and, 4) galactose with rotenone. Cells were seeded at 1.2 x 104 
cells/well in a 24-well plate containing a glass coverslip. Media was removed from 
wells and replaced with: normal MEM glucose media, normal MEM media with 25nM 
rotenone, galactose media and galactose media with 25nM Rotenone. Cells were 
exposed for 48 hrs and fixed with 4% PFA as described earlier (TIGAR 
immunofluorescence) for immunofluorescence. We used two different TIGAR 
antibodies and compared the results. Primary visualization was performed using a 
Leica SP5 confocal microscope system with a x40/1.3 oil immersion objective lens. 
TIGAR (Leica/566) and TOM20 (Leica/488), within a high resolution (246.27 x 
246.27 microns per image, 1024 x 1024 pixels) z-stack made up of images 0.5 µm 
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intervals. Then, images were captured in a wide-field system using a Nikon inverted 
T1 microscope with dual camera. Eight Images per field per condition per patient 
were captured and deconvolution software was used to improve stacked images (Z-
sectioning). This avoided the need of lasers usually employed in confocal imaging. 
The quantitative colocalisation analysis of TIGAR and Tom20 signals was assessed 
with ImageJ and JACoP plug-in (BOLTE and CORDELIÈRES, 2006) to determine: 
a) Pearson’s coefficient; which measures dependency of pixels in dual-channels 
and plotting two images values in grey against each other. It estimated the 
approximation between the signals. It ranges from 1 (complete positive 
colocalisation) to -1 (no colocalisation)    
b) Mander’s coefficients; which is based on Pearson’s correlation coefficient 
where intensity average is taken out of the mathematical expression. It ranges 
from 0 (no overlap) to 1 (complete positive colocalisation). 
Both coefficients are used to measure the linear correlation of two variables 
(Pearson´s) and the proportion of intensity coming from fluorescent pixel colocalising 
signals coming from different colour channels (Mander´s) (Dunn et al., 2011). Since 
both coefficients were good indicator of concurring signals; TIGAR and Tom20 
signals were used to assess colocalisation.  
3.3.9  TIGAR and autophagy 
We then investigated whether TIGAR is implicated in autophagy and/or 
mitophagy. Current treatments for mitophagy activation use high doses of carbonyl 
cyanide m-chlorophenylhydrazone (CCCP), which is a mitochondrial uncoupler. 
CCCP promotes the dissipation of the mitochondrial membrane potential, which 
promotes mitochondrial PINK1 accumulation with subsequent Parkin recruitment. 
Finally, it is believed the process promotes mitochondrial clearance by mitophagy. 
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Bafilomycin in a lysosomal inhibitor, which acts by inhibiting the vacuolar type H(+)-
ATPase and prevents lysosomal acidification. Here, we assessed the effect in 
fibroblasts from two controls and two patients with sporadic PD.  
 
Each treated cell lysates were provided by MSc Rebecca Burger. Shortly, 
provided cell lysates were from four different pre-treatment conditions for 4 hours: a) 
untreated, b) 100nM bafilomycin, c) 10µM CCCP and, c) CCCP with bafilomycin.  All 
cell pellets were then assessed by WB for TIGAR protein levels as described earlier 
(TIGAR and Parkin protein determination) and compared between controls and 
patients.  
3.3.10 Statistical Analysis 
Unless specifically stated otherwise, experiments were done in triplicate and 
values were expressed as means and Standard Deviations (SD). The data was 
analysed using the software GraphPad Prism 7. Statistical test included: unpaired t-
test and non-parametric tests with Bonferroni correction (Mann-Whitney U), and 
ANOVA with multiple comparisons. For TIGAR colocalisation analysis, Image J 
software and JaCoP plug-in were used for Pearson’s and Manders coefficients.  
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3.4 Results 
3.4.1  TIGAR gene expression 
First we investigated TIGAR gene expression in primary fibroblasts of the two 
groups. TIGAR mRNA levels were compared between the six patients with parkin 
mutations (P1-P6) and six matched healthy controls (C1-C6). Overall, there was no 
significant difference, with TIGAR expression being similar in the parkin-mutant 
patient fibroblasts and controls (Figure 3.3). TIGAR mRNA levels were slightly higher 
in the patients (mean=1.217, SD=0.1) compared to the controls (mean=1.067, 
SD=0.81), but this did not reach statistical difference (Mann-Whitney U, P=0.3095) 
(Figure 3.3).  
 
Figure 3.3. TIGAR gene expression in fibroblasts from controls and patient fibroblasts with Parkin 
mutations. Bar graphs represent the fold change of TIGAR expression between controls (mean=1.067, SD=0.81, 
n=6) and patients (mean=1.217, SD=0.1, n=6). Analysis showed no statistical difference between controls and 
patients (Mann-Whitney U, P=0.3095). Results are expressed as the mean +SD of samples from 3 independent 
experiments.  
3.4.2  TIGAR and Parkin protein level 
We then investigated TIGAR protein expression in primary fibroblasts from 
controls and parkin-mutant patients. Initially, controls were used to optimise the 
protein amount and antibody concentration for the group comparison. Next, we 
investigated whether TIGAR protein levels were different between controls 
(mean=0.7483, SD=0.1552, n=6) and parkin-mutant patients (mean=0.8386, 
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SD=0.297, n=6). No significant difference was found between controls and patients 
when a group comparison was undertaken (Mann-Whitney U, P=0.8182). However, 
one parkin-mutant fibroblast cell line (P1) had an almost 2-fold overexpression 
(Figure 3.4 b) compared to the controls and the other parkin-mutant patient lines 
(Figure 3.4 a-b). Therefore, we decided to investigate whether Parkin protein levels 
were correlated to TIGAR protein levels in the fibroblast lines. 
 
Figure 3.4. TIGAR protein levels in fibroblasts from controls and patients with Parkin mutations. WB 
image (a) and densitometry analysis (b, c) using Tubulin as loading control. b) One patient-mutant patient line 
showed almost a 2-fold increased TIGAR protein levels compared to the controls and other parkin-mutant patient 
lines (2-way ANOVA, *P=0.0334). c) However, group analysis showed no difference between controls (n=6) and 
patients (n=6) (Mann-Whitney U, P=0.8182). Bars represent the mean values +SD, from three independent 
experiments.  
 
Parkin protein levels were quantified in primary fibroblast cell lines from the 
six controls and six patients with parkin mutations by performing WB. As shown in 
(Figure 3.5), Parkin and b-actin protein levels were determined and quantified by 
densitometry. WB analysis demonstrated that Parkin was significantly decreased in 
one patient (P1) (Figure 3.5 a-b), compared with the rest of controls and patients, 
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where Parkin protein levels remained similar between them (Figure 3.5 a-b). 
However, when analysed all the controls (mean=0.5922, SD=0.1912, n=6) and 
patients (mean=0.5018, SD=0.179, n=6), there was no statistical significance (Mann-
Whitney U, P=0.9372) (Figure 3.5 c).  
.  
Figure 3.5. Parkin protein in fibroblasts from controls and patients with parkin mutations (right bottom 
panel). WB image (a) and densitometry analysis (b) using b-actin as loading control. b) Parkin protein levels 
between controls (mean=0.5922, SD=0.1922, n=6) and patients (mean=0.5018, SD=0.179, n=6) were variable. c) 
No statistical difference was found between parkin-mutant patients and controls (Mann-Whitney U, P=0.8182). 
Bars represent the mean values +SD, from three independent experiments. 
 
Only one patient (P1) showed increased levels of TIGAR protein correlated 
with reduction of Parkin levels. Since controls and fibroblasts have low similar Parkin 
levels, only TIGAR increase in P1 remained significant. In order to assess whether 
TIGAR high levels have a pathological effect in parkin deficiency, further functional 
analysis remain to be performed in this patient. Due to the limited availability of the 
tissue, these assays could not be performed in the present study. 
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Figure 3.6. TIGAR and Parkin protein levels in fibroblasts from controls and parkin-mutant patients. 
Correlation of TIGAR and Parkin protein levels in controls and parkin-mutant patient lines. Only one patient 
demonstrated TIGAR protein increased levels correlated with reduced Parkin levels (2-way ANOVA, 
****p<0.0001). The ratio of TIGAR and Parkin protein levels is highlighted in the right panel. Bars represent the 
mean+SD from three independent experiments.  
3.4.3  Assessment of mitochondrial function in Fibroblasts 
3.4.3.1 ATP assays 
First, total cellular ATP levels were assessed in fibroblast cell lines from six 
controls and six parkin-mutant patient lines. Transfection optimisations were 
performed in two control and two parkin-mutant cell lines. Then, we assessed TIGAR 
knockdown effect in the mitochondrial function in one LRRK2G2019S mutant fibroblasts 
and matched control. 
 
ATP levels were assessed in four controls and four parkin-mutant cell lines. 
Reduction of ATP cellular levels was seen in four patients: P1 (48%, **P=0.007), P4 
(33%, P=0.108), P5 (48%, **P=0.009) and P6 (37%, *P=0.0279) compared to 
matched controls. Overall, a significant decrease in the ATP production was seen in 
the parkin-mutant fibroblast group by ~41.5% (Mann-Whitney U, *P=0.0286) (Figure 
3.7). We then determined whether the ATP defect was associated to a defect in the 
bioenergetics status. The assays were then performed in two of the six parkin-
mutant patient lines (P4-P6) due to the limited availability of the other cell lines.  
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Figure 3.7. ATP assays in controls and parkin patients. ATP cellular levels were compared between four 
controls and four patients. Cellular ATP levels are reduced by ~41.5 % in parkin-mutant patient lines compared to 
controls (Mann-Whitney U, *P=0.0286). Bars represent the mean and +SD from three independent experiments.  
3.4.3.2 Mitochondrial respiration. Seahorse assays  
Controls and patients  
Parkin-mutant patients  
A great proportion of cellular ATP is produced by mitochondrial oxidative 
phosphorylation, which plays an important role in cellular survival. To assess the 
mitochondrial bioenergetics in parkin-related PD, we measured the mitochondrial 
respiration (OCR) and acidification (ECAR) using the Seahorse XF24 Analyzer.  
 
Bioenergetic parameters were calculated in two controls (C4-C5) and two 
parkin-mutant patient lines (P4-P5). Previous basal ATP assays from both patients 
showed a significant reduction, thus we assessed if it was related to a defect in the 
bioenergetics status, mainly in the respiration committed to ATP synthesis. The 
obtained respiratory measurements were normalised to cell number and are 
illustrated individually (Figure 3.8). Individual data showed a similar trend in controls 
and patients in all the measurements (Figure 3.8).  
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 CONTROLS PATIENTS P value 
NORMALISED COMPONENTS OCR 
Baseline C4=0.032 + 0.003 C5=0.042 + 0.008 
P4=0.0294 + 0.001 
P5=0.035 + 0.004 
0.928 
0.547 
Mitochondrial OCR C4=0.023 + 0.003 C5=0.034 + 0.006 
P4=0.022 + 0.003 
P5=0.027 + 0.004 
0.997 
0.586 
Proton leak C4=0.006 + 0.0007 C5=0.009 + 0.002 
P4=0.005 + 0.002 
P5=0.010 + 0.005 
0.995 
0.995 
ATP-linked C4=0.016 C4 + 0.003 C5=0.024 + 0.004 
P4=0.017 + 0.001 
P5=0.017 + 0.004 
>0.999 
0.440 
MRC *C4=0.120 + 004 C5=0.071 + 0.015 
*P4=0.046 + 0.006 
P5=0.083 + 0.014 
****<0.0001 
0.058 
SRC *C4=0.088 + 0.001 *C5=0.029 + 0.0009 
*P4=0.017 + 0.004 
*P5=0.047 +0.010 
****<0.0001 
**0.001 
Non-Complex I C4=0.001 + 0.0004 C5=0.002 + 0.0009 
P4=-0.0002 + 0.0007 
P5=0.002 + 0.0005 
0.975 
>0.999 
Coupling efficiency C4=0.726 + 0.015 C5=0.726 + 0.02 
P4=0.777 + 0.089 
P5=0.626 + 0.173 
0.931 
0.674 
RCR *C4=27.111 + 6.117 C5=9.844 + 3.823 
*P4=10.081 + 3.822 
P5=14.599 + 9.190 
*0.022 
0.668 
NORMALISED COMPONENT ECAR 
Baseline  *C4=0.001 + 0.0004 *C5=0.004 + 0.0008 
*P4=0.003 + 0.0003 
*P5=0.002 + 0.0006 
*0.0165 
**0.004 
MC *C4=0.002 + 0.0009 *C5=0.007 + 0.001 
*P4=0.005 + 0.0002 
*P5=0.002 + 0.0006 
****<0.0001 
****<0.0001 
SC C4=0.0005 + 0.0004 C5=0.003 + 0.0006 
P4=0.002 + 0.0004 
P5=0.001 + 0.0003 
0.059 
**0.001 
Table 3.13. Bioenergetics parameters from two parkin-mutant cell lines and two matched controls. 
Maximun respiratory capacity (MRC); Spare respiratory capacity (SRC); Maximum capacity (MC); Spare capacity 
(SC) Values measured are expressed as mean + SD from three independent experiments. 2-way ANOVA.  
Overall, data showed a reduction in the basal, mitochondrial OCR, ATP-
synthesis, mitochondrial maximal capacity, spare capacity, coupling efficiency and 
respiratory cell ratio in parkin-patients (Figure 3.8 a, d). Statistical analysis showed 
apparent significant difference only between patient and matching control, however it 
did not when taken as a grouped data (Table 3.13). Glycolytic function was assessed 
by the ECAR measurements (Table 3.13). The ECAR measured under basal 
conditions in individual cases showed a huge variability between individuals (Figure 
3.8 e) and overall, grouped data showed no significance between controls and 
patients (Table 3.13). Therefore, respiratory bioenergetics status needs to be 
assessed in more patients with parkin mutations.  
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Figure 3.8. Mitochondrial respiration and glycolysis in individual controls and parkin-mutant patients. 
Representation of the measurement of a) Normalised component oxygen consumption rate (OCR), b) Coupling 
efficiency, d) Cell Respiratory Ratio (CRR), e) Normalised OCR trace and e) Normalised component ECAR 
representative of glycolysis. OCR rate was measured in XF medium under basal conditions followed by 
sequential injections of Oligomycin, CCCP, rotenone and Antimycin A. Baseline (B), Mitochondrial (M), Proton 
Leak (PL), ATP-linked (ATP-L), Maximum Capacity (MC), Spare Capacity (SC), Non-Complex I (NC-I). Data 
represent the mean+SD from three independent experiments.   
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3.4.4  TIGAR RNAi mediated knockdown optimisation 
3.4.4.1 Transfection optimisation in fibroblasts. Lipofectamine 2000 
 TIGAR knockdown was first aimed at specific siRNA transfection in three 
fibroblasts control cell lines. Transfection efficiency was initially evaluated by using 
Lipofectamine 2000 and FAM-labelled negative control siRNA. We found a 
transfection efficiency of 62%, 77% and 84% using the 0.1, 0.25 and 0.5 µl of 
Lipofectamine respectively (Figure 3.9 a). At the 48 hrs post-transfection, cellular 
toxicity was assessed visually by checking cells under the microscope. Toxicity 
ranged from 10% with the lowest amount of Lipofectamine and 20% with the highest 
(data not shown). Therefore, we found that 0.25 µl of Lipofectamine was the lowest 
amount with the highest transfection efficiency and the lowest toxicity. Secondly, to 
avoid off-target effect and select the best time course and correct siRNA TIGAR 
concentration, transfections at three different time points and increased siRNA 
TIGAR concentrations were assessed. Thirdly, for protein expression, cell pellets 
and lysates were collected and studied after 48 hrs post-transfection.   
 
Figure 3.9. Transfection optimisation with Lipofectamine 2000. a) Transfection efficiency at three different 
concentrations. b) Representative images of Scramble siRNA transfection captured and analysed. c) Image 
representation of transfection efficiency per field using 0.25µl Lipofectamine. Transfected cells were analysed 
and counted individually (blue and white arrows). Scale bar 50 µM. 
146 
 
3.4.4.2 siRNA against TIGAR optimisation assessment: qPCR 
TIGAR expression was measured after 24, 48 and 72 hrs post-transfection in 
three different control cell lines. Results from the real-time qPCR data showed 
decreased and increased TIGAR expression in the three different experiments. 
Moreover, the expression was different when normalised to the two reference genes 
(Figure 3.10). At the same time point, when normalised against B-Actin, TIGAR 
mRNA appeared increased, but down regulated when normalised against GAPDH 
(Figure 3.10).  
 
Figure 3.10. siRNA against TIGAR 24, 48 and 72 hrs. Real-Time qPCR data obtained from: a) three fibroblast 
control cell lines (C1, C2, and C3) transfected with either Scramble siRNA or siRNA against TIGAR (siRNA 10nM, 
25nM, 50nM and 70nM) for 24 hrs. siRNA against TIGAR at 70nM was used only in two control cell lines;  b) 
three fibroblast control cell lines (C1, C2, and C3) transfected with either Scramble siRNA or siRNA against 
TIGAR (siRNA 10nM, 25nM, 50nM and 70nM) for 48 hrs. siRNA against TIGAR at 70nM was used only in two 
control cell lines and; c) from two fibroblast control cell lines (C2 and C3) transfected with either Scramble siRNA 
or siRNA TIGAR (siRNA 10nM, 25nM, 50nM and 70nM) for 72 hrs. siRNA against TIGAR at 70nM was used only 
in one control cell line. Untreated (UT), Lipofectamine only (L), scramble siRNA (Scr). Results using both 
reference genes are expressed as the percentage mean of TIGAR expression normalised against the untreated 
control of one experiment for each cell line.    
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Due to the inconsistent results of the qPCR experiments, we decided to 
assess the effect of the chosen siRNAs against TIGAR at protein level using a 
different house-keeping control.  
3.3.4.3 siRNA against TIGAR optimisation assessment. WB 
WB were performed 48 hrs post-transfection using siRNA against TIGAR at a 
concentration of 50nM. Despite several attempts in different control cell lines, TIGAR 
knockdown was unsuccessful. Furthermore, TIGAR protein levels in the condition 
with only Lipofectamine, were consistently affected (Figure 3.11, a).  
 
 
Figure 3.11. WB siRNA against TIGAR. a) After 48 hrs scramble siRNA and siRNA TIGAR treatments, protein 
extracts from cell lysates were used for WB using Tubulin as loading control. b) Densitometry quantification of 
TIGAR Proteins levels, normalised against Tubulin and presented as percentage relative to untreated (UT) 
control. Results are expressed as the mean +SD of samples from three different experiments. 
As the knockdown experiments with siRNA continued to have inconsistent 
results we decided to stop the experiments and tested new siRNAs for TIGAR 
knockdown. 
  
A different pool of siRNA against TIGAR, which targeted 4 coding regions of 
the last 2 exons of the TIGAR gene (Figure 3.2) was tested. Shortly, one control and 
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one parkin-mutant fibroblasts were transfected to compare efficacy between different 
cell lines. Due to previous inconsistency assessing gene knockdown with qPCR, we 
decided to check knock-down efficacy at the protein level. WB were performed 48 
hrs post-transfection using 30nM of siRNA against TIGAR. At the 48hrs, ~70% of 
TIGAR knockdown was successfully achieved with transient transfection mediated 
by siRNA against TIGAR. This siRNA-mediated knockdown was consistent in the 
control and the parkin-mutant fibroblasts (Figure 3.12).  
 
Figure 3.12. WB siRNA against TIGAR. a) After 48 hrs scramble siRNA (Scr) and siRNA TIGAR (siTIGAR) 
treatments, protein extracts from cell lysates, from a control (left side) and a parkin-patient cell lines (right side1) 
were used for WB using Tubulin as loading control. b) Protein levels of TIGAR were normalised to Tubulin, 
quantified by densitometry and presented as percentage relative to untreated (UT) control. Overall, a knockdown 
effect of ~70% was achieved in both cell lines. Results are expressed as the mean + SD of samples from three 
different experiments (ANOVA, **P=0.0036)   
Due to the successful TIGAR knockdown, we then decided to assess if it 
rescues the mitochondrial function in patient cell lines with a known defect in this.  
3.4.5  RNAi mediated knockdown mitochondrial function 
Parkin-mutant patient cell lines were unavailable when this study was 
performed, thus TIGAR knockdown effect in the mitochondrial function in PD patient 
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tissue with a known mitochondrial defect was assessed in the LRRK2G2019S patient 
cell line available. This was investigated by performing ATP and Seahorse assays.  
3.4.5.1 ATP assays 
TIGAR knockdown in LRRK2-mutant fibroblasts 
 We undertook mitochondrial ATP production assays to determine whether 
TIGAR knockdown had a rescue effect in the mitochondrial function in the LRRK2-
mutant patient fibroblasts when compared to a matched control. Basal cellular ATP 
levels were decreased in the patient by ~30% compared to the matched control. 
 
ATP levels of the transfected fibroblasts were assessed at the 48 hrs and 
compared with the untreated and the control conditions. Data showed no difference 
between control and transfected cell lines in both, control and patient. ATP levels 
were consistently increased with both conditions. The transfection reagent had a 
marked effect alone, which made difficult to assess the effect of TIGAR knockdown 
(Figure 3.13).  
 
We concluded that since the ATP assays performed in knockdown 
experiments with siRNA continued to have inconsistent results we decided to stop 
the experiments and tested other method to evaluate the mitochondrial function.  
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Figure 3.13. Mitochondrial ATP production in LRRK2 mutant fibroblasts. Basal mitochondrial ATP 
production is decreased in the LRRK2G2019S mutant fibroblasts. Mitochondrial ATP production was increased in 
the control and the patient cell line after treatment with Lipofectamine alone and in the TIGAR knock-downs.  
Results are expressed as the mean + SD of samples from three different experiments (2-way ANOVA, *p<0.05). 
 
3.4.5.2 Seahorse assays: mitochondrial respiration 
TIGAR knockdown in LRRK2 fibroblasts.  
An ATP defect and mitochondrial OCR, maximum and coupled respiration 
were reported previously and present in this patient (Mortiboys et al., 2015). 
Therefore, we assessed the effect of TIGAR-knockdown in the bioenergetic status in 
the LRRK2G2019S mutant patient and control cell line. We hypothesised that TIGAR 
might be implicated in PD pathology, and when silenced, it can rescue the 
mitochondrial function in cells with the underlying pathology.  
 
Decreased basal (38.5%), mitochondrial (43.9%), ATP-linked OCR (54.7%) 
and coupling efficiency (55.6%) was observed in the patient (Table 3.14. When 
TIGAR was knocked down, all these parameters showed an increase, which was 
less pronounced the lipofectamine treatment was observed (Figure 3.14 a). Due to 
high variability between treatments, this results where no significant.  
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 CONTROL PATIENT 
NORMALISED COMPONENTS OCR 
Baseline 
UT a 1+ 0.0 a 0.615 + 0.370 
L 0.994 + 0.11 0.782 + 0.3642 
siTIGAR 30nM 0.875 + 0.045 a 0.978 + 0.137 
OCR (M) 
UT a 1 + 0.0 a 0.561 + 0.428 
L 1.079 + 0.124 0.788 + 0.486 
siTIGAR 30nM 1.212 + 0.219 a 1.015 + 0.264 
Proton leak 
UT a 1+ 0.0 0.927 + 0.178 
L 1.045 + 0.113 1.002 +  0.219 
siTIGAR 30nM a 1.312 + 0.073 1.083  +  0.179 
ATP-L 
UT 1 + 0.0 a 0.435 + 0.522 
L 1.098 + 0.142 0.706 + 0.547 
siTIGAR 30nM 1.182 + 0.270 a 1.017 + 0.250 
MRC 
UT a 1 + 0.0 a 1.061 + 0.296 
L 1.183 + 0.149 0.907 + 0.727 
siTIGAR 30nM a1.484 + 0.261 a 1.590 + 0.304 
SC 
UT *1 + 0.0 *1.928 + 0.389 
L *1.342 + 0.225 *1.035 + 1.262 
siTIGAR 30nM *2.015 + 0.328 *2.411 + 0.575 
Non-Complex I 
UT 1 + 0.0 1.219 + 0.159 
L 1.231 + 0.256 0.859 + 0.064 
siTIGAR 30nM 1.401 + 0.466 0.975 + 0.621 
Coupling 
efficiency 
UT 1 + 0.0 0.444 + 0.514 
L 1.007 + 0.033 0.724 + 0.416 
siTIGAR 30nM 0.829 + 0.252 0.997 + 0.015 
RCR 
UT 1 + 0.0 0.667 + 0.747 
L 1.179 + 0.129 0.810 + 0.673 
siTIGAR 30nM 1.059 + 0.627 1.74 + 0.298 
NORMALISED COMPONENTS ECAR 
Baseline 
UT *1 + 0.0 *1.78 + 0.626 
L *0.973 + 0.128 *1.66 + 0.367 
siTIGAR 30nM *1.120 + 0.105 *1.25 + 0.184 
Max 
UT 1 + 0.0 1.261 + 0.199 
L 0.854 + 0.0792 1.203 + 0.0348 
siTIGAR 30nM 0.793 + 0.030 0.946 + 0.120 
SC 
UT 1 + 0.0 0.581 + 0.304 
L 0.660 + 0.174 0.426 + 0.594 
siTIGAR 30nM 0.271 + 0.132 0.455 + 0.103 
Table 3.14.  Bioenergetic parameters in a control and LRRK2 patient fibroblasts. Oxygen consumption rate 
(OCR), Mitochondrial (M); ATP-L (ATP-linked); Maximum respiratory capacity (MRC); Spare Capacity (SC); 
Respiratory Cell Ratio (RCR); Untreated (UT); Lipofectamine only (L); siRNA TIGAR (siTIGAR). *Measurements 
with statistical difference between control, patient and siRNA treatment. aMeasurements where a difference 
between control and patient were obtained under basal conditions and where siRNA treatment showed an effect. 
Values measured are expressed as mean + SD, normalised to control (UT) from three independent experiments. 
 
Maximal respiratory capacity (MRC) showed increased levels when TIGAR 
was knocked down, in both control (2-way ANOVA, P=0.569) and patient (2-way 
ANOVA, P=0.471); however, apparent statistical difference was not significant due to 
inconsistency between the different treatments and huge variability in the patient 
(Figure 3.14 a). Spare respiratory capacity (SRC) OCR from the patient showed a 
152 
 
significant increase under basal conditions (2-way ANOVA, *P=0.261) and when 
TIGAR is knocked down when compared to the control under basal conditions (2-
way ANOVA, ****P<0.0001). Here, Lipofectamine had the opposite effect in the 
patient, where it showed reduced levels (Figure 3.14 a). Lipofectamine seemed to 
continue displaying a slight effect in the control (2-way ANOVA, P=0.852), but not 
the patient, where it showed significant reduction (2-way ANOVA, P=0.523) (Figure 
3.14 a). 
 
 Spare respiratory capacity (SRC) relies on glucose and fatty acids as its main 
source, suggesting that OCR and SRC are modulated by distinctive metabolic 
regulators. After knocking down TIGAR in the LRKK2G2019S mutant-patient glycolysis 
is enhanced. This correlates with glycolysis measured by ECAR (Figure 3.14 e), with 
a significant increase in levels under basal conditions in the patient (2-way ANOVA, 
**P=0.007); which decreased when treated with Lipofectamine (2-way, ANOVA, 
P=0.992) and TIGAR knockdown (2-way ANOVA, P=0.139). The spare capacity (SC) 
in the control was notably reduced when TIGAR is knocked down (2-way ANOVA, 
*P=0.014).   
 
Overall, we found some differences in the LRRK2-mutant patient. However, 
these assays were performed in only one patient of one genotype, where a different 
gene from a different pathway and particular mutations are involved, which influence 
the overall result. Further assays need to be conducted in a larger group of patients 
to investigate the potential role involving the PD related genes. 
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Figure 3.14. TIGAR knockdown effect in a control and a LRRK2 mutant fibroblast. Mitochondrial respiration 
(OCR) and glycolysis (ECAR).  Representation of the measurement of a) Normalised component oxygen 
consumption rate (OCR) b) Coupling efficiency, c) Respiratory Cell Ratio (RCR), d) Normalised OCR trace and e) 
Normalised component ECAR representative of glycolysis. OCR rate was measured in XF medium under basal 
conditions followed by sequential injections of Oligomycin, CCCP, rotenone and Antimycin A. Oxygen 
consumption rate (OCR), Mitochondrial (M); ATP-L (ATP-linked); Maximum capacity (Max); Spare Capacity (SC); 
Respiratory Cell Ratio (RCR); Untreated (UT); Lipofectamine only (L); siRNA TIGAR (siTIGAR); Control (Ctl); 
Patient (Pt).  Data represent the mean + SD, normalised to control from three independent experiments (2-way 
ANOVA, **p<0.005; *p<0.05).   
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3.4.6 Transfection reagents optimisation 
To assess the effect of TIGAR knockdown in fibroblasts, without being 
masked by the effect from the transfection reagent in cells, we further optimised 
different transfection reagents by measuring ATP levels upon different conditions. 
For this, we tested a control and a patient cell line. First, the different concentrations 
of transfection reagents at the 48 hrs (Figure 3.15 b) showed to be more stable 
compared to the 24 hrs (Figure 3.15 a). Alongside ATP assays, transfection 
efficiency was assessed with transfected cells with Scramble fluorescent siRNA 
plated alongside ATP assays under the same conditions. Cells were visualised using 
the InCell Analyzer 2000 and analysed with the InCell Developer Toolbox 1.9.2 
Software. All the compared transfection reagents showed an efficiency of between 
60-80%, where the 48hrs showed the best results and more comparable with the 
untreated condition between the two cell lines.  From these experiments, we chose 
the lowest concentrations for each transfection reagent and continued optimisation 
assessing different cellular densities at the 48hrs.  
155 
 
 
Figure 3.15. Transfection reagents optimisation in fibroblasts. ATP levels at different concentrations of 
transfection reagent in a control (C4) and a parkin patient (P4) at the 24 (a) and 48hrs (b). Transfection efficiency 
in both cell lines with the different concentrations of transfection reagent using scramble siRNA 30nM at the 24 (c) 
and 48 (d) hrs. Untreated (Ut); DarmaFECT (DF); Endofectin (E) Data represent the mean +SD from one 
independent experiment. 
 
Four different cellular densities were assessed at the 48 hrs in one control 
fibroblast line. The lowest (2,000 cells/well) and the highest (4,500 cells/well) cellular 
densities showed the highest variability in the ATP level with all the transfection 
reagents. ATP levels seemed steadier between the 2,500-3,5000 cells/well in all the 
conditions (Figure 3.16). Since patient fibroblasts showed to have a higher variability 
of ATP levels when it is transfected, we decided to test the transfection reagents in 
two patient fibroblasts cell lines.   
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Figure 3.16. Transfection reagents in one control fibroblast. ATP levels in a control fibroblast at four different 
cellular densities using 0.1µl DharmaFECT 1 (DF1), 0.1 µl DharmaFECT 3 (DF3), 0.2µl Lipofectamine and 0.2 µl 
Endofectin.  
 
 Experiments were performed in the two patient cell lines at the 48 hrs, 
assessing cellular densities ranging from 2,500-3,500 cells/well. The patient 4 (P4) 
showed steadier ATP levels between the three different cellular densities (Figure 
3.17 a), whereas patient 5 (P5) showed a high variability within the three different 
cellular densities (Figure 3.17 b). However, in both cell lines, 3,000 cells/well, 
showed a minimal variability between them and within the different transfection 
reagents. Therefore, we decided to test it further to see if this remained when both 
cell lines were compared with matched controls with the same conditions.  
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Figure 3.17. Transfection reagents in parkin-mutant fibroblasts. ATP levels in two parkin-mutant fibroblasts, 
P4 (a) and P5 (b). Three different cellular densities were assessed using 0.1µl DharmaFECT 1 (DF1), 0.1 µl 
DharmaFECT 3 (DF3), 0.2µl Lipofectamine (L) and 0.2 µl Endofectin (E) and compared with the untreated (Ut) 
condition at 48hrs.    
 Finally, we decided to test one control (C4) and one parkin patient (P4) 
fibroblasts alongside transfection efficiency in the control and the patient and see 
whether transfection remained efficient at a higher passage. At 2,500 and 3,500 
cells/well, C4 and P4 (Figure 3.18) showed slight reduction of ATP levels, except 
from Endofectin, were the levels were significantly lower than the untreated condition. 
C4  (Figure 3.18, a) showed comparable levels to the untreated condition across all 
the samples, whereas P4 (Figure 3.18, b) showed a tendency to an increase in all of 
them. Transfection remained effective with an overall reduction of <10%, where 
Endofectin efficiency remained comparable to previous results (Figure 3.18 c, d, e). 
However, basal ATP levels from the P4 started to be similar to the control cell line, 
which reflected that both cell lines were probably affected due to higher passage and 
constant stress. Since after a numerous failed attempts to optimise the transfection 
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using conventional RNAi methods, we decided to stop this experiments. A new 
method of RNAi delivery was approached and tested, where the need of a 
transfection reagent was avoided.      
 
Figure 3.18. Transfection ATP levels and efficiency in one control (C4) and one patient (P4) fibroblasts. 
ATP levels in a C4 (a) and patient (P4) fibroblasts after 48hrs of transfection. Control (C4) cell line showed less 
variability between 3,000 cells/ well, P4 (b) showed increased levels at 3,000 cells/ well with all the transfection 
reagents. c), d) and e) Representation of the different transfection efficiencies obtained at the 48hrs, where 
Endofectin showed the highest efficiency. Scale bar 50µM  
3.4.7  Accell siRNA transfection 
  Conventional RNAi methods used knockdown TIGAR failed to assess its 
effect in human fibroblasts due to the interfering effect of the transfection reagent, 
leading to a detectable metabolic response. Thus, self-transfecting Accell siRNAs 
were tested in human fibroblasts by measuring transfection efficiency and effect in 
ATP levels. Since they avoid the use of a chemical or mechanical error, we expected 
a lower effect in the metabolic response of the cells.  
 
First, a control fibroblasts line was used to optimise this new method following 
the protocol from the provider. Three cellular densities, 2.5-3.5 x 103 cells/well were 
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selected. ATP levels were initially tested at the recommended 96 hrs after 
transfection (Figure 3.19 a). Cells were transfected with either scramble siRNA (red), 
GAPDH or Cyclophilin B positive controls and Non-targeting negative control. ATP 
levels within the three cellular densities with the different controls showed similar 
comparable ATP levels to the untreated condition (Figure 3.19, a). However, ATP 
levels seemed to be very sensitive to very high and very low cellular densities, that 
could result at the 96 hrs.  
 
Next set of experiments was assessed at the 72 hrs, changing the medium to 
galactose at the 48hrs of transfection (Figure 3.19, b). ATP levels were different 
within the three densities, where 2,500 cells/well showed only slight changes 
compared to the untreated condition, and the 3,000 cell/well showed a significantly 
increase with all the controls. Since an acute effect of the change of the media and 
lower time of the siRNA in the medium was suspected, we decided to assess at the 
effect at 96 hrs in the patient. (P4) line, which previously showed the highest 
variability, then tested. Similar results to the control (Figure 3.19 a) were obtained 
after media change to galactose at the 48 hrs of transfection and assessed at the 
96hrs (Figure 3.19 c). Since transfection efficiency and knockdown efficacy has not 
been tested previously in fibroblasts, knockdown percentage was assessed.   
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Figure 3.19. Accell siRNA Optimisation in fibroblasts. ATP levels in transfected fibroblasts at 1µM of each 
siRNA positive target genes (Cyclophilin B, GAPDH), negative (Non-targeting control 1) and Scramble siRNA 
controls after 96hrs in a control fibroblast (a), 72 hrs (b) and 96 hrs (c) in a parkin mutant fibroblasts.   
 
 Transfection efficiency and knock down assays were performed in a control 
fibroblast. Transfection efficiency was assessed by imaging Scramble Accell siRNA 
(Figure 3.20 c) showing ~60% transfection efficiency at the 72 hrs. mRNA 
knockdown resulted in ~65% knockdown (Figure 3.20 a) and only 15% at the protein 
level (Figure 3.20 b-c).  
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 Accell siRNA requires high concentrations of the reagent and more 
experiment were needed to finally optimise the assays and obtain a higher 
knockdown effect. In addition, fibroblasts cell line availability was becoming limited 
due to the fact of its utility in other projects, therefore we decided to stop this 
experiments and change approach to focus investigating the cellular localisation of 
TIGAR upon cellular stress and its role in PD.  
  
 
Figure 3.20. Accell siRNA in a control fibroblasts. Transfection in one control fibroblasts. Optimisation with 
positive and non-tagenting and measure mRNA percentage levels by qPCR (a), GAPDH protein levels by 
densitometry analysis(b) and WB image (d) compared to control untreated condition. Representative image of 
transfection efficiency using a scramble Accell siRNA. Scale bar 50µM. 
3.4.8  TIGAR cellular localisation 
3.4.8.1 Antibody optimisation 
For future cellular localisation assays, optimisation for TIGAR 
immunofluorescence was undertaken using different antibodies in human fibroblasts 
and HeLa cell line as a control cell line.  Different concentrations and blocking 
methods were assessed. From all the results, only two of the antibodies against 
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TIGAR (ab12933 and PA5-29152) showed consistent staining signal. However, ab 
12933 antibody had an intense perinuclear signal across the different treatments. In 
order to assess their specificity, we tested by knocking down TIGAR in the control 
fibroblasts.   
 
Figure 3.21. TIGAR immunofluorescence in fibroblasts optimisation. Representative images of the different 
staining using Anti-TIGAR antibodies: a) LCS-C286858 (1:100); b) AB10545 (1:250) c) ABCAM 129333 (1:800); 
d) (1:500). Antibody against TIGAR in fibroblasts where TIGAR was knockdown for 48 hrs, fixed and labelled with 
ab1239333 (e) and PA5-29152 (f). Control cellular morphology in figure c was different due to lower confluency. 
Scale bar 50µM.  
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From these results, only the PA-29152 antibody had a reduced expression 
without any other nonspecific signal, whereas ab129333 continued to show an 
intense perinuclear labelling in all the samples tested (Figure 3.21). Then, we verified 
and optimised in HeLa cell lines different treatments and rotenone toxic exposure. 
TIGAR labelling across the different treatments and experiments were consistent 
(Figure 3.22). 
 
Figure 3.22. Anti-TIGAR antibody PA5-29152 immunofluorescence in HeLa cells. Representative images of 
labelling of TIGAR (red) and TOM20 (green) to visualize the mitochondria in HeLa cells. Cells were treated with 
25nM Rotenone for 48hrs and visualize under the fluorescent microscope. Images showed an intense nuclear 
staining in some cells under the different conditions. Cytoplasm intensity was lower in most of the cells. Upon 
rotenone treatment, TIGAR showed a partial mitochondrial translocation in some cells. This event occurred as 
well in the untreated condition in less proportion. Glucose (Glu); Galactose (Gal); Rotenone (Rot); Untreated (UT). 
Scale bar 50µM 
Notably, TIGAR localisation in fibroblasts in glucose (Figure 3.21 d) seemed 
to be mainly in the nuclei, whereas in HeLa had a cytoplasmic localisation. However, 
this changed upon galactose treatment, where intense TIGAR nuclei localisation was 
remarkable. TIGAR showed a partial mitochondrial co-localisation upon rotenone 
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toxic exposure. Since there are no previous reports of TIGAR characterisation in 
human fibroblasts and the effect when stressed with rotenone might induce 
mitochondrial localisation we performed these experiments in three parkin-mutant 
patients and matching controls cell lines.      
3.4.9  Rotenone toxic exposure 
We assessed whether TIGAR could be recruited or translocated to the 
damaged mitochondria in cells with impaired Parkin expression. The first set of 
experiments were performed in three controls (C4-C6) and three parkin-mutant (P4-
P6) fibroblasts from the second group using Antibody against TIGAR PA5-29152 and 
the mitochondrial marker TOM20. After treating cell lines in glucose and galactose 
media for 48hrs after rotenone toxic exposure no evident effect on the overall TIGAR 
expression could be seen in either controls or patients (Figure 3.23). However, an 
intense nuclear staining was obtained across all the samples. Previous reports in 
different cell lines showed TIGAR cytoplasmic localisation.  
  
To confirm this, a monoclonal mouse antibody, courtesy of Dr. Karen 
Vousden, was tested. Since monoclonal antibodies have shown higher specificity 
and this was the group that described TIGAR initially (Bensaad et al., 2006), we 
were confident of the specificity of the antibody. Both antibodies recognise an 
epitope in exon 6 within the same region; however, PA5-192 comprises 50 
aminoacids (220-270), whereas the monoclonal antibody targets only 14 aminoacids 
(256-270) (Table 3.7).   
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Figure 3.23. Anti-TIGAR antibody PA5-29152 immunofluorescence in control fibroblasts exposed to 
Rotenone at the 48hrs. Representative images of a control fibroblast cell line. Cells were fixed and stained with 
antibody against TIGAR PA5-29152 (red) and Anti-TOM20 (green), to visualize cellular localisation and 
mitochondria. Experiments were performed after 48 hrs of rotenone toxic exposure in glucose and galactose 
media. Cells were visualized under a confocal microscope. Glucose (Glu); Galactose (Gal); Rotenone (Rot); 
Untreated (UT). Scale bar 50µM. 
 
 Then, the new antibody was tested in HeLa cells under the same treatment 
conditions (Figure 3.24) and compared the results obtained with the antibody anti-
TIGAR PA5-29152 tested in HeLa cells (Figure 3.22) and fibroblasts (Figure 3.23).   
 
TIGAR PA5-29152 showed intense nuclear staining with moderate 
cytoplasmic staining (Figure 3.23); whereas TIGAR monoclonal antibody showed a 
more intense cytoplasmic and a less evident nuclear staining (Figure 3.24). Between 
the untreated conditions in glucose and galactose, there was no difference in TIGAR 
expression. When rotenone treatment was added to cells led to mitochondrial 
fragmentation, mainly in galactose treatment, where TIGAR showed an apparent 
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mitochondrial co-localisation (Figure 3.24). Since these showed a higher antibody 
specificity and suggested TIGAR mitochondrial co-localisation upon rotenone toxic 
exposure, we conducted the same experiment and conditions in a control fibroblast 
cell line using the monoclonal antibody and compared the previous results obtained 
with PA5-29152 (Figure 3.23).  
 
Figure 3.24. Anti-TIGAR monoclonal mouse antibody immunofluorescence in HeLa cells. Representative 
images of labelling of TIGAR (red) and TOM20 (green) to visualize the mitochondria in HeLa cells. Cells were 
treated with 25nM rotenone in glucose or galactose for 48hrs and visualized under confocal microscope. Glucose 
(Glu); Galactose (Gal); Rotenone (Rot); Untreated (UT). Scale bar 50µM. 
 
TIGAR cellular localisation in control fibroblasts was investigated upon 
glucose and galactose treatment conditions, as well as to the exposure to rotenone 
(Figure 3.25). An evident TIGAR cytoplasmic localisation was obtained, however, 
there was no difference in TIGAR expression under the different treatments. 
Rotenone showed shortened mitochondria (TOM20), which was a reflection of 
mitochondrial fragmentation, mainly in cells grown in galactose. Mitochondrial 
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measurements (form factor (branching) and aspect ratio (length)) were not 
performed. However, TIGAR mitochondrial localisation was not evident. Intense 
small doted punctae were detected in specific cellular areas near the nuclei. 
 
 
Figure 3.25. Anti-TIGAR monoclonal mouse antibody immunofluorescence in a control fibroblast. 
Representative images of labelling of TIGAR (red) and TOM20 (green) to visualize the mitochondria in HeLa cells. 
Cells were treated with 25nM Rotenone in glucose or galactose for 48hrs and visualized under inverted 
microscope. Glucose (Glu); galactose (Gal); rotenone (Rot); untreated (UT). Scale bar 50µM. 
 
TIGAR mitochondrial localisation was then investigated. These experiments 
were performed in only one control (C4) and one parkin-mutant (P4) fibroblasts.  
 
Co-localisation analysis was performed by inverted microscopy analysis of 
cells labelled in single images acquired and the correlation between TIGAR and 
mitochondrial marker TOM20 was calculated (Figure 3.26). TIGAR expression 
between control (Figure 3.26, a) and patient (Figure 3.26, b), as well as within the 
different treatments, showed no difference. Mitochondria upon rotenone toxic 
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exposure showed fragmentation in both control and patient fibroblasts and in few 
regions the presence here of small puncta suggested a possible partial mitochondrial 
co-localisation. 
 
Figure 3.26. TIGAR localisation in fibroblasts from one control and one parkin-mutant patient. 
Representative images of fixed and stained cells with antibodies against TIGAR (red) and TOM20 (green) to 
visualize the mitochondria in a control (a) and a parkin-mutant (b) fibroblasts (P4, ARG42PRO het). Cells were 
treated with 25nM Rotenone in glucose or galactose for 48hrs and visualized under an inverted microscope. 
Glucose (Glu); galactose (Gal); rotenone (Rot); untreated (UT). Scale bar 50µM. 
Pearson’s analysis obtained from both, C4 and P4, showed partial 
colocalisation (0.4-0.6) with all the conditions (Figure 3.27). However, this coefficient 
is difficult to interpret and it is only reliable with high correlation. Pearson’s coefficient 
can easily be affected by additional non colocalising signals and a lack of 
perspective of both channels. Mander’s coefficients are easier to interpret and not 
sensitive to overlapping pixels (Dunn et al., 2011). Therefore, we decided to further 
analyse with Mander’s coefficients to determine the proportion coming from both 
channels and how they overlap with each other Mander’s coefficients (m1 and m2) 
169 
 
were both low in the control and patient in all the conditions. A minimal increase in 
the Mander’s coefficient for the green channel (m2, TOM20 over TIGAR) in 
fibroblasts was detected (Figure 3.27), showing that the high contribution is coming 
from the mitochondria rather than the actual presence of TIGAR within it.  
 
Figure 3.27. Colocalisation coefficients. Colocalisation analysis of TIGAR with TOM20 in a control (C4) 
and a parkin-mutant (P4) fibroblasts. a) Pearson’s coefficient; b) Mander’s 1 (m1) coefficient and c) Mander’s 2 
coefficient (m2) from each condition from C4 and P4. Overall, there was no difference between the control and 
patient in any of the treatments. Results are expressed as the mean +SD of samples from 3 different experiments    
 
Overall, these findings suggest that TIGAR do not co-localise in the 
mitochondria upon mitochondrial damage when CI is inhibited.  
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3.4.10 TIGAR and autophagy 
The role of TIGAR role in autophagy was investigated in patients with 
sporadic PD with mitochondrial defect.  We investigated the effect on TIGAR after 
cells were treated with bafilomycin (autophagy inhibitor) and CCCP (mitophagy 
inducer). TIGAR protein levels were determined in cell lines from two controls and 
two sporadic patient fibroblasts.  
 
There was no evident difference in TIGAR protein level amongst patients and 
controls (Figure 3.28). Results from these experiments showed a great variability in 
both controls and patients, which is reflected by the high SD obtained. This is 
perhaps a reflection of the variation occurring between the differences from the 
patients here tested. 
 
Figure 3.28. Western blot analysis effect on TIGAR after bafilomycin and CCCP treatment in fibroblasts 
from controls and sporadic PD patient cell lines. a) Representative blots probed in controls (Ct a; Ct b) and 
sporadic PD patient (Pt a; Pt b) cell lines with antibody against TIGAR. b) Densitometry analysis from each pre-
treament conditions (4hrs) in both controls and patients: Untreated (UT), Bafilomycin (B), CCCP (C) and 
Bafilomycin + CCCP (B+C). There was no statistical difference between controls and patients in any of the 
treatments. Results are expressed as the mean+SD of samples from three different experiments (2-way ANOVA, 
P>0.05).  
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3.4.11 TIGAR in other cellular models 
 Previously, we showed that TIGAR protein is present in human fibroblasts in 
order to assess its suspected function in this cell model system. In order to continue 
investigating TIGAR function and its role in PD, we then investigated the protein level 
in other cellular models that are commonly used in PD research for future 
experiments. Five different cell lines were assessed by WB under basal conditions 
and compared to each other. Endogenous TIGAR protein levels are similar between 
fibroblasts, HeLa and Luhmes, slightly higher in HeLa and significantly increased in 
HEK293 (Figure 3.29). Therefore, for future experiments, we decided to investigate 
TIGAR function in HEK293 cell model system.  
 
Figure 3.29. TIGAR protein levels in 5 different cell lines. WB image (a) and densitrometry analysis (b) using 
b-actin as a loading control. TIGAR protein levels showed to be similar between fibroblasts (F), Luhmes (L), SH 
SY5y and HeLa, whereas HEK cells showed a significant increase of TIGAR protein level when compared to the 
other cell lines. Bars represent the mean values +SD, from 3 independent experiments. (ANOVA, **p<0.005). 
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3.5 Discussion 
3.5.1 TIGAR in human fibroblasts 
As with every cellular model, there are few limitations when using this cellular 
model. Infrequently, a mixture of cells in proliferation or post-mitotic state can be 
found. Mycoplasma infection can occur, like in every cell culture, however regular 
testing and available treatments prevent further infection. As cells are from different 
individuals, growth rates, seeding density and confluency between individual cell 
lines, from controls and patients, is variable, but highly valuable to understand the 
mechanisms of the disease. Unlike neurons, fibroblasts have a different response to 
trophic factors and signals (Auburger et al., 2012).  
 
Comparison of TIGAR mRNA expression levels in the controls and patients 
with Parkin mutations, showed no difference. However, the assessment was 
performed only in a small sample cohort and the conclusions in the present study are 
limited by this factor.  
 
No significant difference was seen in TIGAR protein levels either when a 
group comparison of data obtained from parkin-mutant fibroblasts were compared 
with controls. However, in one patient the TIGAR protein level was increased by ~2.0 
fold, whereas in the remaining patients it was slightly decreased by ~0.5 fold. We 
therefore wanted to establish whether the protein level of TIGAR correlated with the 
level of Parkin in these fibroblasts cells lines. Notably, in the same patient in whom 
the level of TIGAR was the highest the Parkin remained the lowest, suggesting that 
there may be a correlation. Parkin protein level amongst controls and patients 
showed a variable amount of Parkin, except for P1, that interestingly has the highest 
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TIGAR protein level. Due to the shared PD related PINK1/Parkin pathway, these 
results might be related to the effect seen in the pink1-/- zebrafish, where a TIGAR 
overexpression correlation was demonstrated (Flinn et al., 2013). However, the small 
number of samples limits the validity of any conclusions, therefore increasing our 
cohort of controls and patients with Parkin and/or PINK1 mutations, may help to 
confirm these results. 
 
3.5.2  Mitochondrial function and bioenergetics status in parkin-mutant 
fibroblasts 
In previous research performed from our group, fibroblasts from patients with 
known parkin mutations have been shown to have mitochondrial dysfunction with 
ATP deficient production linked to CI. ATP assays assessed the proliferative and 
cytotoxicity response of cells, from PD patient tissue, to drug exposure or other 
biological compounds and/or conditions. Therefore, ATP assays are valuable, 
sensitive and effective method to investigate the underlying suspected energetic 
mechanisms involved in PD (Mortiboys et al., 2008, 2010b). 
  
ATP linked-complex I production is facilitated by changing the media growth 
conditions, since fibroblasts in culture produce their ATP through glycolysis. When 
media is changed from glucose to galactose, fibroblasts rely on the mitochondrial 
oxidative phosphorylation (OXPHOS) pathway to produce their energy. One of the 
patients had to be removed from the overall analysis (P3). ATP assays were 
performed according to the availability of the tissue. Current results show an ATP 
reduction of ~41.5% when comparing the group of controls with the patients with 
Parkin mutations, although not as pronounced as previously observed (Mortiboys et 
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al., 2008). This demonstrated an overall decrease of ATP production linked to a 
similar defect amongst the five parkin-mutant fibroblasts cell lines reported 
(Mortiboys et al., 2008).      
 
Although fibroblasts are a reliable, robust and useful model of research to 
study PD in patient tissue, PD is a disease that primarily affects the CNS. In vivo 
models, such as rodents, have been useful to investigate disease mechanisms, 
assess toxin exposure (i.e., rotenone, paraquat, herbicides) and to test newer 
treatments. They offer a great advantage by assessing their effect in motor 
symptoms and the SN after inducing neurotoxicity and genetic manipulation. Rodent 
models have shown Dopaminergic neuronal loss. Moreover, they have shown to be 
useful to study non-motor PD symptoms (i.e. sleep, cognition). However, they do not 
fully and consistently recapitulate human PD (Blesa et al., 2016; Campos et al., 
2013). An alternative approach will be to study TIGAR by reprogramming fibroblasts 
from patients with PD-related mutations, via induced pluripotent stem cells (iPSC), 
direct lineage of induced neural stem (iNS), induced neural precursor (iNP), induced 
neurons (iN), or dopaminergic neurons (iDA). iPSC with PD-related mutations can be 
differentiated into neurons, which have shown the pathological mechanisms already 
described in PD (Playne and Connor, 2017; Xu et al., 2017). Direct reprogramming 
from somatic cells to a specific type of neurons offers a new alternative method for 
cell modelling avoiding pluripotent state. The direct conversion offers many 
advantages: functional neurons can be obtained faster (within weeks); the risk of 
having pluripotent cells left is avoided; it promises to be an efficient and feasible 
model. However, there are also many disadvantages: less efficiency with scarce or 
no Tyrosine Hydroxylase positive (TH+) cells, it could still produce longer culture 
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periods for maturation and immature and non-functional neurons, cells are post 
mitotic and with limited availability. These new methods are still under optimisation, 
for which different reprogramming protocols have been assessed.  Indeed, the effect 
of TIGAR have been shown to be cell dependent, with complex and somehow 
contrary and arbitrary functions depending on the metabolic context of a specific 
cellular type (Bensaad et al., 2006, 2009; Madan et al., 2012). For this reason, any 
observations in parkin- or PINK1-mutant fibroblasts would need to be confirmed in 
further cellular, neuronal model systems or in PD brain tissue. 
3.5.3  Tigar RNAi mediated knockdown 
Initial transfections using siRNAs (Santa Cruz) against TIGAR were 
unsuccessful in achieving a satisfactory knockdown in controls. Several potential 
reasons should be considered for this. For instance, particular cell types can be 
more difficult to transfect, and this is well established for fibroblasts. Also, the growth 
and quality variability (i.e., cell confluency, density, passage, etc.) amongst the 
different fibroblast cell lines used, could affect the transfection process. However, 
even when transfections assays were performed at the same time with the same 
methodology, variation cannot be avoided due to cell culture behaviour. This 
variation in the results could also be caused by the fact that the reference genes are 
not stably expressed. Also, the factor of the transfection done under serum free 
media for six hours, might affect the expression of the genes when serum is added 
hours after the transfection. In Figure 3.10 b-c, the knockdown effect was seen to be 
reliable between β-actin and GAPDH, whereas at 24 hours (Figure 3.10 a) the 
knockdown effect showed the highest inconsistency of them all. 
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The siRNAs against TIGAR we used were also only targeting the 3’UTR 
region of the gene  (Figure 3.2). Furthermore, it has been reported that siRNA 
mediated gene knockdown is generally less effective when targeting only the 3’ UTR. 
A better silencing effect is achieved when targeting the interior region of the mRNA, 
we therefore used a new SMARTpool of 4 siRNA against TIGAR (Dharmacon) 
avoiding 50 nucleotides (nt) upstream and downstream region and within the exon 4, 
5 and 6 regions of the gene. Successful knockdowns of ~70% were achieved 
consistently across the different experiments within different cell lines (Figure 3.12), 
therefore we decided to assess its effect in the mitochondrial function in one LRRK2-
patient, which displayed a mitochondrial defect previously reported and was 
available. We wanted to see if the effect of TIGAR knockdown was robust and could 
be applied in PD tissue regardless the genotype.  
3.5.4  TIGAR knockdown in mitochondrial function 
 Transfection with either Lipofectamine only or siRNA against TIGAR, showed 
a significant increase of ATP levels in both treatments in the control and the patient. 
This means that the ATP increase is the result of the transfection treatment in the 
cell, therefore any effect of TIGAR knockdown is masked by the transfection. 
Seahorse assays showed the same problem, where Lipofectamine transfection is 
already affecting the results and having similar comparable readings with the cells 
where TIGAR is knockdown in both, control and patient. Therefore, further 
transfection reagents and methods were tested and optimized in order to assess 
TIGAR knockdown effect in mitochondrial function in fibroblasts from patients with 
PD. 
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3.5.5  Transfection reagents effect in ATP 
Transfection experiments in primary cell lines have been shown to be a good 
method to investigate cellular function, physiology, genomics and drug treatments. 
Current RNAi methods use physical and chemical reagents in order to deliver the 
gene or product into the cell. Chemical reagents are some of the most popular 
methods, they are commonly cationic lipids or polymers, that interact with the 
negatively charged nucleic acids, allowing their entrance to the cell via endocytosis 
and prevention to be degraded (Kaestner et al., 2015). In this study, all reagents 
belonging to this group were used for the transfections, were Lipofectamine 2000 
was used for initial transfections and knockdowns. Although fibroblasts are known to 
be a cell line difficult to transfect, we achieved good transfection efficiency (~77%) 
and gene knockdown (~69%), as previously seen by others (Mortiboys et al., 2008, 
2015; Rakovic et al., 2010). Despite the successful knockdown achieved, the effect 
of TIGAR silencing in the patient cell lines could not be assessed due to the 
overlapping effect of the transfection reagent per se. Although different transfection 
reagents, cellular densities and timings were modified, within the different cell lines; 
ATP levels continued to be affected by it. This can be explained by a combination of 
several factors, from the cells and the transfection procedure. With transfections, it is 
difficult to preserve cellular functionality when cells required to be transfected under 
serum-free conditions and the need to replace the media. Cells that are also 
effectively transfected, require to be in division (S or M phase), no overgrown and 
therefore metabolically active (Hsu and Uludağ, 2012). Consequently, metabolic 
activity would be affected and visualised in current metabolic measurements here 
used, such as ATP levels and mitochondrial respiration. Moreover, the growing rate 
of the cell, passage number and the overall health status and membrane trafficking 
processes might be another interfering factor, which contributed for the high 
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variability between the different densities and across the experiments, mainly in the 
patient cell line, since the mutation by itself might be conferring them an energetic 
and metabolic defect. 
 
 New RNAi methods include Accell siRNA, which has the advantage of be a 
“self-delivery” method, where no transfection reagent is required. Thus, lower 
cytotoxicity with good transfection efficiency can be achieved. In this study, the pilot 
optimisation studies showed indeed that ATP production is less affected at the 96hrs, 
where the media was changed at the 48hrs after transfection, in the control and the 
patient, within the different siRNAs, negative and positive controls, same as with the 
scramble siRNA. Further tests and optimisations are needed for this new promising 
method. However, due to the fact that fibroblasts cell lines were limited, Accell siRNA 
reagents needed at higher concentrations and with high price value, we decided to 
stop this experiments. We then decided to assess TIGAR in different cell lines and 
further related mechanisms in fibroblasts, such as response to toxic exposure and 
autophagy. TIGAR RNAi methods were further conducted in a stable inducible 
cellular model, namely HEK293 Flp In cells (see Chapter 4). 
3.5.6  Rotenone toxic exposure 
 Mitochondrial dysfunction, oxidative stress and defective bioenergetics status 
of the cells can all be triggered by rotenone. The aim of these experiments was to 
determine the effect of CI inhibition in TIGAR cellular localisation and expression 
when parkin is deficient. TIGAR cellular localisation and expression under the 
different conditions, glucose and galactose, with or without the rotenone treatment 
showed no difference in either the control or the parkin patient (Figure 3.26 and 
Figure 3.27). Despite the lack of TIGAR translocation, it does not mean that it is not 
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implicated in the pathological process. TIGAR mitochondrial translocation has been 
reported to be dependent on Hexokinase-II (HK-II) expression and presence in the 
mitochondria, which is highly dependent when glucose is available. Furthermore, 
TIGAR is affected in different ways by different stressors. Mitochondrial translocation 
occurs only when O2 levels are <0.1%, but not with moderate hypoxia or normoxia. 
Furthermore, the effect was seen in HeLa cells and several cancer cell lines, where 
metabolic and energetic demands are very different when compared to human 
fibroblasts. Moreover, TIGAR mitochondrial translocation was linked to cellular 
survival by protecting cells from ROS damage and regulation of mitochondrial 
membrane potential.  
3.5.7  Tigar and autophagy 
Autophagy has been suggested to be implicated in PD and TIGAR pathology. 
We therefore aimed to assess TIGAR role in treated fibroblasts from patients with 
sporadic PD with CCCP and bafilomycin. We found no difference between the 
controls and the patients in any of the conditions. This is in keeping with what results 
from our group reported in these cell lines, where no significant evidence was found. 
Many factors could explain this outcome.  
 
To date, altered autophagy remains as a prospective cause in sporadic PD. It 
remains unclear whether a lack of autophagic response and loss of UPS function or 
an abnormal accumulation of autophagosomes and lysosomes are behind the 
pathologic process. Both mechanisms have been shown to produce detrimental 
effects and finally cellular death. Future experiments aiming to determine TIGAR role 
in autophagy in human fibroblasts would need to be done in fibroblasts from patients 
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with sporadic, but also familial PD in order to fully address its role in autophagy PD-
related mechanisms.   
3.6 Conclusion 
This is the first study to investigate TIGAR expression in human fibroblasts 
derived from patients with familial and sporadic PD. We did not find difference in 
TIGAR gene expression and protein level between controls and parkin-mutant 
fibroblasts. Although one patient showed TIGAR increased levels, which correlated 
with decreased parkin levels, it was only one patient.  
 
Effective TIGAR knockdown was achieved in parkin deficient and LRRK2G2019S 
fibroblasts, but the effect of TIGAR deficiency on mitochondrial function could not be 
tested due to masking effect of the transfection. Therefore, further investigations of 
the effect of TIGAR in cellular and neuronal models with PD-related mutations 
should be attempted by alternative methods such as stable transduction. TIGAR 
cellular localisation is not affected in parkin mutant fibroblasts in response to 
rotenone toxic exposure and cellular stress. No evidence of TIGAR involvement in 
autophagy was seen in sporadic patients with PD under the conditions tested in this 
study. Further experiments should be attempted in a stable cell line to determine 
effect of TIGAR knockdown in PINK1 deficiency and confirm in dopaminergic 
neuronal cell lines.     
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4 Stable cell lines for PD research 
4.1 Introduction 
 
It is essential to fully understand the function of genes implicated in the 
development of the disease. Therefore, cellular and animal models with conditional 
gene expression and regulation need to be generated. The genetic function can be 
analysed by turning on or off the expression of mutated genes known to cause PD 
pathology, and therefore be able to recapitulate human health and disease. In the 
present, a wide variety of controlled gene expression systems are commercially 
available, including the tetracycline-inducible T-Rex™ Flp-IN™ cells from Thermo 
Fisher Scientific using common cell lines, such as HEK293T.  
 
As previously stated, mutations in PD-related genes can cause autosomal or 
recessive forms of the disease. Knowing causal gene mutations enables researchers 
to generate cellular and animal models via genomic manipulation, in order to 
investigate potential disease leading mechanisms. 
4.1.1  Gene silencing: molecular engineering  
 RNA interference (RNAi) methods allow the introduction of a double-stranded 
RNA (dsRNA) into a target cell. Small interfering RNAs (siRNAs), micro-RNAs 
(miRNAs) and short hairpin RNA (shRNAs) are some of the interfering RNA species 
used for gene silencing. MicroRNAs (miRNAs) are short transcripts encoded by 
endogenous genes, which activates repression at both, post-transcriptional and 
translational levels, of target genes. In mammalian cell lines, miRNA repression is 
fundamentally through translational repression (Guo et al., 2010; Wilczynska and 
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Bushell, 2014). miRNAs usually bind the 3’UTR in a partial but highly complementary 
manner. They are found in the nucleus, contained and transcribed in a cluster, 
known as long primary transcripts (pri-miRNAs), which are synthesised by the 
enzyme RNA polymerase II. Pri-miRNAs are subsequently cleaved by Drosha, a 
RNAse III protein located in the nucleus and important for miRNA processing. 
RNAse III proteins are specific endonucleases that cleave the RNA structure on 
each side. Drosha cleaves pri-miRNAs into small ~70 nucleotide hairpins known as 
pre-miRNAs. Pre-miRNAs are then exported from the nucleus through pores to the 
cytoplasm by Exportin-5. The pre-miRNAs are further processed into a 22-nucleotide 
mature RNA sequence (mRNA) by Dicer, another RNAse III protein located in the 
cytoplasm (Lee et al., 2003). The mRNA sequence binds the RNA-induced silencing 
complex (RISC), after which antisense strands align with the mRNA. The expression 
of the mRNA is repressed then by three mechanisms: a) preventing the translational 
initiation (repression), mRNA decay (decapping 5’ and 3’ ends) or direct RNA 
cleavage by RISC (Recasens et al., 2016). Plasmid and viral vectors usually contain 
small nuclear RNA pol III promoters, such as U6 and H1, widely used for shRNA and 
miRNAs construct design. Both are ubiquitously expressed promoters that promote 
efficient gene silencing effect, where U6 proved to be the most effective (Mäkinen et 
al., 2006; Zhou et al., 2007). 
  
RNA interference (RNAi) is a powerful tool to gain insight into the biological 
and physiological function of specific genes. By controlling the environmental 
conditions and through genetic manipulation, protein levels can be regulated within 
the physiological margin. However, long-term gene repression might potentially 
cause non-physiological and undesired cellular effects. Generation of inducible RNAi 
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cellular regulation (e.g tetracycline) is a way to avoid these potential undesired 
effects. One disadvantage of this system is that in some particular cell lines 
background gene expression might still be high and detectable in the non-induced 
cells and affect the overall outcome (Gupta et al., 2004).  
 
The Thermo Fisher Scientific engineered miRNAs, BLOCK-iT™ Pol II miR 
RNAi expression vector kit, is a new adapted method for expression of a specific 
designed miRNA sequence, which represent the target sequence of interest and 
RNAi research. This allows the generation of clones expressing double stranded (ds) 
oligos, encoding a pre-miRNA sequence generated by expression vector selection. 
These constructs can then be introduced into the cell of interest for transient or 
stable expression of the targeted miRNA sequence to study its effects within the cell 
(Werness and Anderson, 2010).   
4.1.2 Site-specific recombinase systems  
 The site-specific recombinase systems (SSR) have been widely used to 
achieve gene knockout. SSR can be combined with and inducible gene expression 
system, such as tamoxifen and tetracycline, which enables the generation of cellular 
and animal models at a specific stage in the tissue of interest. This conditional 
knockout approach allows researchers to study the gene function at different cellular 
stages. There are several SSR developed systems, where Cre-loxP, Flp-FRT and 
ᶲC31 are amongst the most commonly used. 
4.1.3  Flp In-FRT  
  The Flp-In FRT system was derived from the yeast Saccharomyces 
cerevisiae. In this system, the recombinase Flp recognises a 34-base pair (bp) 
nucleotide sequence known as the FRT site. Within this site two 13bp palindromic 
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sequences are contained and separated by an 8 bp spacer. These palindromic 
sequences will give the orientation of the site, bind to the recombinase and the 
spacer. This region is where the DNA breaks and homologous recombination occurs 
between the FRT sites. The Flp system therefore allows DNA exchange between 
genomes, at the site of gene of interest, and the transfected plasmid (Golic and 
Lindquist, 1989). This homologous recombination occurs in a single targeted site, 
preventing from gaining or losing nucleotides as well as avoiding clonal variability 
(Shah et al., 2015; Zhang et al., 2012). This is important as it enables the generation 
of isogenic stable cell lines, in which control and disease cell lines are genetically 
identical, except for the expression of the disease-mutated gene (Liu et al., 2006). 
4.1.4  Tetracycline system 
The tetracycline systems are based on the E. coli tetracycline resistance 
operon, an operator sequence (TetO) contained within the operon, the efflux pump 
genes and a tetracycline-repressor protein (TetR). The regulation of this allows the 
gene expression in a spatiotemporal manner. Under normal conditions, the 
expression of the operon is inhibited when TetR binds the TetO. When tetracycline is 
added, the TetR binding is interrupted leading to the operon release, which promotes 
the gene expression. Two controlled systems were derived from this system:  
• In the Tet-off (tTA) systems, the target gene is turned off after tetracycline is 
added, promoting TetR to bind the transcription activation domain VP6. Here, when 
tetracycline is absent, the tetracycline controlled transactivator protein (tTA), which is 
a repressor that binds the tTA responsive promoter (Ptet), enables the gene 
expression.  
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• In the Tet-ON system, the tTAT does not bind the Ptet. Once tetracycline is 
added, the tTA binds the Ptet, which subsequently leads to gene expression (Zhang 
et al., 2012).  
Tet-off and Tet-On systems have been widely used for modelling 
neurodegenerative disorders, such as Alzheimer’s Disease (AD) (Arif et al., 2014), 
PD (Bertolin et al., 2013; Carballo-Carbajal et al., 2010; Jiang et al., 2007; Kobayashi 
et al., 2006), Huntington’s Disease (HD) (Igarashi et al., 2003; Waelter et al., 2001) 
using different cellular and animal models (Khlistunova et al., 2006; Sun et al., 2007).  
4.1.5  FLP/FRT Inducible model 
The combination of both techniques, tetracycline and Flp In systems, enabled 
the development and construction of improved conditional cell lines. The gene of 
interest (GOI) can be then targeted in a spatiotemporal manner by adding 
tetracycline or, the analogue, doxycycline (Spitzer et al., 2013; Yahata et al., 2005).    
 
Thermo Fisher Scientific introduced the new Flp-In T-Rex Core Kit, for 
generation of stable cell lines with tetracycline-inducible expression. This system is 
controlled by the integration of the Flp Recombinase in a specific site, which 
mediates the expression of GOI in mammalian cell lines. This system follows three 
basic steps: generation of the Flp-In T-Rex™ host mammalian cell lines, followed by 
the integration of the vector expressing the GOI containing a tetracycline-controlled 
promoter and, gene induction by tetracycline addition (Spitzer et al., 2013) (Figure 
4.1).  
 
The Flp-In T-Rex System offers many advantages compared to many other 
cellular models. It is and efficient and rapid system for generation of Flp-In T-Rex cell 
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lines expressing the GOI after it has been integrated FRT site in the Flp-In T-Rex 
host cell line. Importantly, the generated inducible stable cell lines are isogenic 
(Yahata et al., 2005).  
 
The Flp-In T-Rex host cell line is generated when two plasmids are co-
transfected into the selected mammalian cell line:  
• The pFRT/lacZeo vector containing a SV40 promoter regulating the 
expression of the lacZ-Zeocin fusion gene. Downstream from the ATG initiation 
codon of the lacZ-Zeocin fusion gene, the FRT site is inserted. This is the recognition 
binding and excision site for the Flp endonuclease. The lacZ-Zeocin fusion gene 
encodes a fusion protein with a Zeocin resistance marker, which allows selection of 
stable cell lines by screening them for Zeocin sensitivity (Huang et al., 2007).  
• The pcDNA6/TR plasmid expressing the TetR gene provides Tetracycline 
resistance (Møller et al., 2016) under the control of the human cytomegalovirus 
(CMV) promoter (Kim et al., 1995). The blasticidin resistance gene, which is under 
the control of the SV40 early polyadenylation signal, allows the expression of the 
blasticidin resistance gene for stable cell line selection (IzuMi et al., 1991).  
 
Random independent genomic integration occurs when the pFRT/lacZ-Zeo and 
pcDNA6/TR plasmids are transfected and integrated into the mammalian cell line. 
Thus, the Flp-In™ T-Rex™ host cell line is then generated (Spitzer et al., 2013).  
 
An expression vector containing the GOI is built by the operator that wishes to 
create a new inducible cell line and will then be integrated into the cells by the Flp 
recombinase. The expressing vector is co-transfected with a plasmid expressing the 
187 
 
Flp recombinase into the host cell line. This allows the expression of the Flp 
recombinase, which enables the integration of the expressing vector containing the 
GOI into the genome of the host cell. The Flp recombinase then mediates the 
homologous recombination between the two FRT sites. The lacZ-Zeocin fusion gene 
is inactivated after the SV40 promoter and the ATG initiation codon are brought into 
frame with the hygromycin resistance gene. Stable cell lines can therefore be 
selected by screening them for blasticidin and hygromycin resitance and zeocin 
sensitivity. The expression of the GOI is then induced upon tetracycline addition 
(Figure 4.1).     
 
 
Figure 4.1.  FLP-In T-Rex System Thermo Fisher Scientific. Schematic representation of the Flp-In T-Rex 
system. The pcDNA 5/FRT/TO construct genomic integration into the host cell line is performed by its 
cotransfection with the recombinase plasmid.  Then, homologuos recombination occur between the FRT sites in 
the expression vector and the host cell line. The transcription of the Gene of interest (GOI) takes place once the 
expression is integrated. The host cell line is conferred with antibiotic resistance to Hygromycin and sensitivity to 
Zeocin. Tetracycline addition enables the expression and regulation of the inserted gene.  Adapted from Flp-In™ 
T-REx™ Core Kit Manual, Thermo Fisher Scientific.  
 
188 
 
4.1.6  Inducible models in Parkinson’s Disease 
 Autophagy has been suggested to be involved in the pathogenesis of many 
neurodegenerative diseases. Autophagy helps cellular clearance from misfolded 
proteins, its impairment could lead to accumulation and contribute to the 
pathogenesis in neurodegenerative diseases. When impaired, it could lead to 
accumulation of misfolded proteins within the cell. Stable doxycycline inducible PC12 
cell lines expressing WT alpha-synuclein, A30P or A53T mutants were used as PD 
cellular model to study the neuroprotective effects of resveratrol. The resveratrol 
beneficial effects against aging, inflammation and cancer have been widely 
investigated; however, the involved mechanisms are still unknown. In this model, it 
was demonstrated that it acts as an autophagy and mitophagy inducer through 
modulation and activation of the silent regulator 2 (SIRT1) and AMP-activated 
protein kinase (AMPK) (Wu et al., 2011). Resveratrol is a potential drug for PD 
treatment due to its potential beneficial effects demonstrated in several models   
 
The relation of alpha-synuclein and unfolded protein response (UPR) was 
studied in a PC12 alpha-synuclein overexpressing inducible cell line. Here, induced 
cells showed to have an impaired UPR, increased cellular vulnerability and death. An 
enhancement of cellular toxicity was correlated with cathecolamine, such as 
dopamine, function (Ito et al., 2010). The interaction between dopamine and alpha-
synuclein in a PC12-Tet off (tetracycline inducible) system was studied. The stable 
inducible cell lines were expressing WT alpha-synuclein, mutants M116A, M127A 
and M116/M127A (in which the methionine residue was mutated), Y12D and S12A. 
It is suggested that the alpha-synuclein methionine residues are oxidized by 
dopamine, which induces oligomerization of alpha-synuclein with subsequent 
neurocytotoxicity. Here the dopamine-related M127A modification was reported to 
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play the main role in the oxidation process. It was suggested that the mechanism is 
via dopamine binding the C-terminal region of alpha-synuclein, where dopamine 
might be the main source of reactive oxygen species (ROS). Furthermore, an 
increase of the M127 modification might result under the presence of the pathogenic 
serine (S129) and tyrosine (Y12) alpha-synuclein forms (Nakaso et al., 2013).  
Moreover, the synergistic interaction between alpha-synuclein and dopamine was 
also demonstrated in a stable inducible cell line expressing WT alpha-synuclein and 
the PD-related alpha-synuclein mutant A53T. An increase of aggregates within the 
cytoplasm was observed in cells with alpha-synuclein overexpression, whereas 
mutant A53T showed increased dopamine induced cytotoxicity and vesicular 
formation. Alpha-synucein is mainly expressed in cells with high levels of dopamine, 
where it is suggested to be regulating its release in the synaptic terminals. At long 
term, the cumulative effect of defective dopamine compartmentalization, instability 
and ROS generation might lead to alpha-synuclein aggregation, aggregates 
formation and neuronal death (Tabrizi et al., 2000).  
 
The pathophysiological cellular mechanisms of LRRK2 proteins remain poorly 
understood at the molecular, biochemical and biological levels. Thus, generation of 
reliable and robust cellular and animal models are valuable tools to study these 
mechanisms. Inducible dopaminergic MN9D cell lines (a fusion of embryonic ventral 
mesencephalic and neuroblastoma cells) expressing either WT LRRK2 or mutant 
LRRK2G2019S, were generated to serve for drug screening, testing therapeutic role of 
LRRK2G2019S RNAi mediated gene knockdown and its kinase inhibitors. It was found 
that the G2019S cells had lower metabolic activity, which was increased in the 
presence of WT LRRK2. The G2019S displayed also shortened neurite extension 
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without cytotoxicity, which was rescued by kinase inhibitors and by G2019S RNAi 
mediated knockdown (Huang et al., 2013). Previous research in a Drosophila model, 
suggested that the eukaryotic initiation factor 4E (eIF4E)-binding protein) (4E-BP), 
important in protein synthesis and translation, had role as a LRRK2 substrate. This 
Drosophila model showed that LRRK2 phosphorylated the 4E-BP, impairing 
translation of proteins and altered cellular homeostasis, which could lead to 
neurodegeneration (Imai et al., 2008). To investigate the suspected interaction 
between LRRK2 and 4E-BP, as well as the involved mechanisms, a tetracycline 
inducible HEK 293FT FLP-In cells with WT LRRK2 and mutant G2019S or R1441C 
were studied. Here, they showed that the 4E-BP was a weak substrate of LRRK2 in 
vitro. Its suspected role involved with LRRK2 functionality in human cellular models 
remain to be demonstrated (Kumar et al., 2010). The LRRK2 related cellular 
response to oxidative stress was studied in a lymphoblastoid LRRK2 inducible cell 
line. Here, cells were exposed to two oxidative stressors, namely arsenite and 
hydrogen peroxide (H2O2) and their effect in LRRK2 phosphorylation status. Both 
oxidative stressors induced the loss of phosphorylation at specific sites in LRRK2, 
which affected the GTP binding and kinase activity. This proposed LRRK2 as a 
modulator of the oxidative stress response linked to PD pathogenesis (Mamais et al., 
2014).   Further suspected mechanisms between WT LRRK2, LRRK2 PD-linked 
mutations and tubulin or microtubules dynamics have been investigated in non-
neuronal inducible lines. Here LRRK2 mutations showed to affect the tubulin 
phosphorylation status and lead to impaired microtubule function and stability, 
leading to cellular damage (Gillardon, 2009).   
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 The PINK1/Parkin pathway function in mitophagy is crucial for the cell to 
maintain healthy mitochondria. Impaired mitophagy has been suggested to be 
associated to PD. Many mechanisms have been studied, where mutations in the PD-
related, PINK1 and Parkin, genes play a major role. Stable inducible cell lines 
expression WT human Parkin (FLP-In GFP Parkin) and two mutants, K161N and 
G430D (PD-linked mutations); were used to screen a number of deubiquitinase 
(DUBs) enzymes by mass spectrometry. In the overexpressing Parkin cell line 
induced by carbonyl cyanide 3-chlorophenylhydrazone CCCP, USP30 showed to 
have opposite effects to Parkin. By overexpressing USP30 in Parkin cell lines, it was 
found that USP30 inhibits mitophagy by removing the ubiquitin attached by Parkin. 
Mitophagy was rescued in the GFP-Parkin, mutant G430D and K161N when USP30 
was knocked down in vitro and the in vivo model Drosophila. A protective effect 
against paraquat toxicity was also demonstrated in the flies (Bingol et al., 2014).   
 
 Parkin tetracycline-inducible SH-SY5Y cell lines have been reported useful to 
study the effect of WT and mutant forms of Parkin proteins (Arena et al., 2013; 
Geisler et al., 2010a, 2010b; Ozgul et al., 2014; Rothfuss et al., 2009). Some of the 
mechanisms studied using these models were:  
• Mitophagy: the involvement of PINK1, Parkin, ubiquitin, VDAC1 and p62 in 
the mitophagy pathway in a chronological manner after mitochondrial depolarization 
to remove damaged mitochondria. This pathway impaired by PD-related mutations, 
Parkin and PINK1 loss of function affect their interaction and solubility, mitochondrial 
localization, stabilization and Parkin translocation. Their functional impairment lead 
to defective mitophagy, suspected to be a key mechanism leading to 
neurodegeneration (Geisler et al., 2010a, 2010b). 
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• PINK1 neuroprotection: one of the PINK1 neuroprotection mechanisms was 
demonstrated to occur by preventing cellular death via Bcl-cL (anti-apoptotic protein) 
interaction in depolarized mitochondria. In the SH-SY5Y Parkin inducible cells, Bcl-Xl 
was not involved in depolarized mitochondria and mitophagy after Parkin 
recruitment. This proposed a Parkin-independent PINK1-Bcl-Xl pathway for 
mitochondrial mitophagy (Arena et al., 2013).  
 
• By using 2D-DIGE to study the proteomic profile of this cell lines, 22 proteins 
were identified to be regulated by Parkin, from which 13 of them were particularly 
regulated in the mutant forms (Q311R and A371T) assessed. Most of the hits for the 
mutant forms, were proteins involved in energy metabolism and protein folding. 
Here, UCHL-1, 14-3-3 and heterogeneous nuclear ribonucleoprotein (hnRNP) was 
the most affected. Functional analysis with WT and mutant cell lines showed that 
one of the main differences is post-translational modifications in which mutant forms 
display lower molecular weight. However, protein stability, ubiquitylation activity and 
cellular localisation were not affected in the mutant forms. Further studies are 
required to confirm and correlate the relation of the Parkin substrates identified and 
the mechanisms related to PD and neurodegeneration (Ozgul et al., 2014). 
 
PD cellular and animal models to study DJ-1 role in neurodegeneration, 
showed that its main function is by providing neuroprotection against ROS and by 
regulating gene transcription. In the SH-SY5Y inducible cell model where DJ-1 is 
silenced, microarray analysis showed that 166 genes were altered, where the 
rearranged during transfection (RET) gene showed the highest reduction of mRNA 
and protein levels. A direct correlation between RET and DJ-1 expression was found 
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in this cellular model. Further functional analysis in this DJ-1 deficient model showed 
that RET is acting as a ligand of the glial cell line-derived neurotrophic factor (GDNF), 
which is involved in the regulation of cellular death during early development and its 
vital for postnatal cellular survival and innervation. In addition to this, DJ-1 deficiency 
produced increased ROS levels, which stabilises the hypoxia inducible factor 1α 
(HIF-1α). Increased HIF-1a levels induced cellular hypoxia and apoptosis. This study 
suggested a neuroprotection role of DJ-1 via the GDNF pathway against hypoxia 
and ROS damaged in PD pathology (Foti et al., 2010).  
 
Cell lines in which PD-related genes and mutations have been induced, have 
been a valuable source to study PD-related mechanisms and unknown biochemical, 
physiological and molecular pathways involved.  
4.1.7  CRISPR/Cas9  
Modern techniques have allowed us to use a wide range of molecular 
engineering methods in which a diversity of molecular, biological, biochemical 
pathways can be studied. CRISPR/Cas9 is a new identified genome editing 
technique, which depends on the bacterial Cas9 endonuclease activity. The 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 
(CRISPR-associated endonuclease) is a system, in which the Cas9 endonuclease 
targets and cleaves specific DNA sequences directed by a small guide RNA 
(sgRNA). The system requires the target recognition by Cas9, via a seed sequence 
in the sgRNA and the adjacent GG-dinucleotide PAM sequence (Garneau et al., 
2010; Jinek et al., 2012; Ran et al., 2013). Blunt DNA cleavage generates a double-
strand break (DSB) by two endonucleases domains, which cut the complementary 
strand (Cas9 HNH nuclease domain) and the complementary strand (Cas 9 RuvC-
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like nuclease domain) (Jinek et al., 2012). Cas9 nickase cut only one DNA strand 
(single-strand break, SSB). DSBs and SSBs are then repaired via the homology-
directed repair (HDR) or the Non-homologous end-joining (NHEJ) pathways (Rubio 
et al., 2016).  
 
Insertions and/or deletions can be generated by the NHEJ pathway, which 
result in truncated proteins and premature stop codons (Su et al., 2016). Gene 
Knock-in is generated via the HDR, displaying point mutations, insertions and 
epitope tags (Zhang et al., 2017). Cas9 nickase and SSB repair avoids indels; to cut 
both strands a double-nicking approach is required and DSBs are generated. Thus, 
the off-target effect is highly reduced. This approach requires co-transfection of two 
plasmids, Cas9 nickase, sgRNAs and markers, which affect transfection efficiency 
and efficacy (Yoshioka et al., 2016). The All-in-One (AIO) plasmid approach tackles 
this obstacle by carrying the Cas9 coupled to the fluorescent marker and the two 
sgRNAs. The two cuts or “nicks” (double nicking) are in opposite strands close to 
each other. This approach achieves slightly less efficiency and efficacy but with very 
low off-target effects (Chiang et al., 2016). 
 
Targeting a specific gene and its alteration mimics mutations in humans in 
cellular and animal models. Gene knock-in or knock-out allows to investigate the 
defects from a particular disease and recapitulate pathology.  
 
CRISPR/Cas9 has been used as a therapeutic tool for different conditions and 
diseases. Recombinant adeno-associated viral vectors (AVV) are currently used in 
some cellular (Kennedy and Cullen, 2015) and animal disease models (Ohmori et al., 
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2017) as well as some clinical trials in gene therapy with promising outcomes 
(Rincon et al., 2015). However, the continue need of re-dosing due to loss of gene 
function and potential toxic effect in peripheral organs remain a problem secondary 
to viral sequestration. The combination of CRISPR/Cas9 and AAV genome 
modification, has successfully engineered an effective aav2G9 chimeric aav strain. 
The modified engineered strain possesses the ability to enter the cell by anchoring 
either the heparan sulphate or galactose receptors. This new strain promises an 
effective and specific cellular delivery in the central nervous system (CNS), avoiding 
off-target effects and with lower transgene expression (Murlidharan et al., 2016). 
 
4.1.7.1 CRISPR/Cas9 and PD models 
The anatomy, physiology and genome of pigs are very similar to the human, 
making them suitable as an animal model for a diversity of human pathologies. 
Moreover, their cerebral cortical folding is highly similar to the human brain, making 
them an ideal model to study neurodegenerative diseases. Recently, PD pig model 
has been generated via CRISPR/Cas9, in which Parkin, DJ-1 and PINK1 are 
simultaneously targeted. This new reliable, robust and promising animal model for 
PD was generated by introducing the multiplexing sgRNA into the pronuclear 
embryos via Cas9 mRNA injection. Despite the high possibility of antagonistic, off-
target effects and mutagenesis due to multiple sgRNAs introduction; whole-genome 
sequencing showed no off-target effects and no mosaic mutations (Wang et al., 
2016d).   
 
Risk variants of PD-related genes have been associated with the sporadic 
form of PD. Alpha-synuclein was identified by Genome Wide Association Studies 
(GWAS) as the strongest risk loci for sporadic PD (Simón-Sánchez et al., 2009). 
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Isogenic human pluripotent stem cell lines with genetically modified PD-associated 
regulatory elements were generated via CRISPR/Cas9 system. Heterozygous 
deletion or exchange of associated elements in the risk and protective alleles were 
analysed in the progenitor cells and derived neurons. Here, the binding efficiency of 
the transcription factors was modified having a modulation effect in the enhancer 
activity. The cis-acting effect of the protective A allele at rs356168 in the genomic 
sequence showed lower expression of alpha-synuclein, reducing the risk for PD. 
Contrary, the risk G allele at rs356168 showed increased alpha-synuclein expression 
and higher risk for PD. This system showed to be a reliable and robust cellular model 
to study human disease and the effect of gene variations disease-related (Soldner et 
al., 2016).        
 
It remains unclear the mechanism of the vacuolar protein sorting 35 gene 
(VPS35) in PD. A question of whether its pathology mechanism is due to a gain or 
loss of function has motivated researchers to create models to elucidate the cause. 
Recently, a knock-in mice model was generated via CRISPR/Cas9, in which 
endogenous expression patterns with Vps35 deletion 1 (Del1) are expressed 
alongside the mutant protein (Vps35 D620N KI). The Vps35 D620N KI was able to 
rescue the Vps35 del1 mice from lethality during embryonic stages, but with less 
survival rates. Therefore, the normal functionality of the wild-type protein was never 
achieved. Dopaminergic neurotransmission in the caudate putamen was impaired, 
but without evidence of neurodegeneration in the homozygous mice (Vps35 D620N 
KI). Due to these effects in the mice models, it has been proposed that VPS35 
causal PD-related mechanisms are due to loss of function. However, further 
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functional mechanisms are required to confirm and identify the actual biological 
process implicated in the pathogenesis (Ishizu et al., 2016). 
 
CRISPR/Cas9 offers the opportunity to generate cellular and animal models 
to simulate human diseases, alongside the opportunity to be use as a therapeutic 
tool to target specific genes and correct the genetic defect. Recently, a CRISPR-
based genetic screen was designed in induced pluripotent stem cells (iPSC) derived 
neurons. This CRISPR-iPSC derived neuronal models offers a new platform, in 
which neurodegeneration and vulnerability of a specific neuron can be studied by 
manipulating a range of associated disease risk factors. This approach offers a new 
cellular model to study pathogenesis and related mechanisms, alongside the 
opportunity test new therapeutic techniques and drugs (Kampmann, 2017).     
 
Despite all the advantages CRISPR tools offer, the system is still in early 
stages, where undesired effects hinder its utility. Some of the major disadvantages 
remain the off-target effects and chromosomal rearrangements, which in some 
instances can be difficult to detect (Mohr et al., 2014). This is due to mismatches 
occurring within the short 20 nucleotide sequence that are tolerated within the 
protospacer region (Ran et al., 2013). Furthermore, the larger size of the Cas9 
protein makes it difficult as a delivery method via either viral vectors or as RNA 
molecule. CNS delivery techniques need to cross the blood-brain barrier, making it 
particularly difficult for use as a therapeutic tool in Neurological disorders. Moreover, 
the HDR requires an effective DNA damage repair, which is particularly less active 
and efficient in the post-mitotic neurons, where the likelihood of mutagenesis is 
enhanced (Yan et al., 2017). Current research is working to tackle this problem by 
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sequencing and looking into more prokaryotes genomes, new CRISPR or CRISPR-
like systems, Cas9 modifications and designing algorithms in order to improve the 
DNA cleavage specificity and effectors (Haeussler et al., 2016; Yoshioka et al., 
2016).  
4.2 Aims and objectives 
 Assess the effect of TIGAR knockdown in a stable inducible human cellular 
model with PINK1 deficiency. HEK 293 and HEK Flp In cells were chosen as the 
cellular model and expression system for this study. These cells are easy, 
inexpensive to grow and maintain, with rapid reproduction, easy to transfect, efficient 
protein production, ideal for viral vector production and gene therapy, amenable for 
recombinant protein production, express exogenous proteins and commercially 
available. They offer a robust and reliable cellular model. Furthermore, transfection 
procedures are easy and fast, achieving high efficiency and efficacy.  
 In this study we aimed to: 
• Design RNAi methods for TIGAR and PINK1 knockdown in mammalian cells. 
• Achieve a consistent effective and efficient knockdown of TIGAR and PINK1 
in HEK 293 cells. 
• Build isogenic stable inducible human cell models with TIGAR and PINK1 
deficiency to assess mitochondrial function by measuring ATP cellular production 
and the mitochondrial morphology. 
• Compare two different molecular engineering techniques to assess gene 
silencing effect and function. 
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4.3 Materials and methods 
4.3.1  Stable inducible cell line 
4.3.1.1 HEK293T Flp In 
Oligonucleotides design: microRNAs 
In order to generate inducible knockdown lines, we used the BLOCK-iT™ Pol 
II miRNAi Expression kit (Invitrogen) to generate CMV promoter-based vectors that 
will allow genome-integration at the FRT site. The integration of the vectors enables 
the expression of miRNAs in the HEK293 Flp-IN host cell lines. miRNA are 
oligonucleotides that target a specific against a genomic region, namely TIGAR and 
PINK1. Such constructs are composed by: 
• Single stranded oligonucleotide (ss oligos) for each gene were designed by 
using the online tool from Invitogen’s RNAi Designer 
(http://rnaidesigner.lifetechnologies.com/rnaiexpress/) (Table 4.1 and Table 4.2). 
Pre-miRNA sequences for TIGAR (Table 4.1; Table 4.2) and PINK1 (Table 4.3 and 
Table 4.4) were designed for cloning into pcDNA™ 6.2-GW/+ EmGFP-miR vector. 
The Pre-miRNA (miR) sequences are inserted in the 3’UTR of the fluorescent GFP.  
 
The designed ss oligos or pre-miRNA (miR) for TIGAR (Table 4.2) and PINK1 
(Table 4.4) inserts have the following characteristics:  
• Five derived-nucleotide (TGCTG) from endogenous miR-155. 5’ overhang 
compatible with a four nucleotide overhang in the pcDNA 6.2-GW™/+ EmGFP-miR 
vector 
• Reverse complement of the 21 nucleotide target sequence 
• 19 nucleotide derived from miR-155 to form a terminal loop  
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No. Start Sequence(DNA) GC% Rank1 
1 334 GAAGAGTGCCCTGTGTTTACA 47.62 
 
2 563 GATTAGCAGCCAGTGTCTTAG 47.62 
 
3 567 AGCAGCCAGTGTCTTAGTTGT 47.62 
 
4 634 GACCTTAAGTGTTCCTTACCA 42.86 
 
5 677 TTATGTCAGTCACTCCCAATA 38.1 
 
6 695 ATACAGGGATGAGTCTCTTTA 38.1 
 
7 696 TACAGGGATGAGTCTCTTTAT 38.1 
 
8 738 AGAAGTTAAACCAACGGTTCA 38.1 
 
9 743 TTAAACCAACGGTTCAGTGTA 38.1 
 
10 782 ATCATCTAAATGGACTGACTG 38.1 
 
Table 4.1. TIGAR (NM_020375.2) top 10 target sequences. 1“Star scoring system” reflects the probability of 
knockdown, where the one with the highest probability is given 5 stars and the one with the lowest only 3 stars. 
Only duplexes that are most likely to be successful with higher quality are shown. Target sequences highlighted 
in yellow and were selected for miRNA design. 
 
No. Start Oligo Type Oligo Sequence 
1 334 T S 5'- TGCTGTGTAAACACAGGGCACTCTTCGTTTTGGCCACTGACTGACGAAGAGTGCTGTGTTTACA -3' 
B S 5'- CCTGTGTAAACACAGCACTCTTCGTCAGTCAGTGGCCAAAACGAAGAGTGCCCTGTGTTTACAC -3' 
2 634 T S 5'- TGCTGTGGTAAGGAACACTTAAGGTCGTTTTGGCCACTGACTGACGACCTTAAGTTCCTTACCA -3' 
B S 5'- CCTGTGGTAAGGAACTTAAGGTCGTCAGTCAGTGGCCAAAACGACCTTAAGTGTTCCTTACCAC -3' 
3 743 T S 5'- TGCTGTACACTGAACCGTTGGTTTAAGTTTTGGCCACTGACTGACTTAAACCAGGTTCAGTGTA -3' 
B S 5'- CCTGTACACTGAACCTGGTTTAAGTCAGTCAGTGGCCAAAACTTAAACCAACGGTTCAGTGTAC -3' 
Table 4.2. TIGAR oligonucleotide primers. 3 miRs (column 1) were designed against TIGAR. They target 
different regions within the gene (column 2). Top Strand, TS; Bottom Strand, BS.  
 
No. Start Sequence(DNA) GC% Rank1 
1 459 GGAGGAGTATCTGATAGGGCA 52.39 
 
2 464 AGTATCTGATAGGGCAGTCCA 47.62 
 
3 465 GTATCTGATAGGGCAGTCCAT 47.62 
 
4 470 TGATAGGGCAGTCCATTGGTA 47.62 
 
5 496 TGCAGTGCTGCTGTGTATGAA 47.62 
 
6 509 TGTATGAAGCCACCATGCCTA 47.62 
 
7 681 TTCCTCCAGCGAAGCCATCTT 52.39 
 
8 686 CCAGCGAAGCCATCTTGAACA 52.39 
 
9 690 CGAAGCCATCTTGAACACAAT 42.86 
 
10 936 GACGCTGTTCCTCGTTATGAA 47.62 
 
Table 4.3. PINK1 (NM_032409.2) top 10 target sequences. 1”Star scoring system” reflects the probability of 
knockdown, where the one with the highest probability is given 5 stars and the one with the lowest only 3 stars. 
Only duplexes that are most likely to be successful with higher quality are shown. Target sequence is highlighted 
in yellow and were selected for miRNA design. 
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No. Start Oligo Type Oligo Sequence 
1 464 
TS 5'- TGCTGTGGACTGCCCTATCAGATACTGTTTTGGCCACTGACTGACAGTATCTGAGGGCAGTCCA -3' 
BS 5'- CCTGTGGACTGCCCTCAGATACTGTCAGTCAGTGGCCAAAACAGTATCTGATAGGGCAGTCCAC -3' 
2 509 
TS 5'- TGCTGTAGGCATGGTGGCTTCATACAGTTTTGGCCACTGACTGACTGTATGAACACCATGCCTA -3' 
BS 5'- CCTGTAGGCATGGTGTTCATACAGTCAGTCAGTGGCCAAAACTGTATGAAGCCACCATGCCTAC -3' 
3 936 
TS 5'- TGCTGTTCATAACGAGGAACAGCGTCGTTTTGGCCACTGACTGACGACGCTGTCTCGTTATGAA -3' 
BS 5'- CCTGTTCATAACGAGACAGCGTCGTCAGTCAGTGGCCAAAACGACGCTGTTCCTCGTTATGAAC -3' 
Table 4.4 PINK1 oligonucleotide primers. Three microRNAs (miRs) (column 1) were designed against PINK1. 
They target different regions within the gene (column 2). Top Strand, TS; Bottom Strand, BS. 
 
4.3.2  Flag tagged TIGAR and pEFGPn1-PINK1 
 Flag-tagged TIGAR was designed and generated by PCR using the primers in  
Table 4.5. The pEGFPn1-PINK1 plasmid expressing PINK1 fused to a GFP tag was 
provided by Dr. Kurt de Vos. 
 
Primer  Sequence  
Sense / Forward GGCGGGGGATCCATGGCTCGCTTCGCTCTGACG 
Antisense / Reverse ACCTGACTGACTTTGAGCGATTGAGCTCCCGCCC 
 
Table 4.5. Flag-tagged TIGAR plasmid design. Sequences rich in GC (green); BamHI restriction site (purple); 
start codon (dark blue); nucleotide target sequence (italics); stop codon (brown) and XhoI restriction site (light 
blue). 
4.3.3  Agarose gel 
Restriction digests or DNA fragments were resolved on 0.8-2% w/v agarose 
gels according to the DNA product size. Gels were run for 45 min - 1 hr at 80 V and 
visualised using a Generuler DNA ladder mix (Thermo Fisher Scientific). 
4.3.4  Restriction digests 
PCR products and plasmids were digested with the appropriate restriction 
enzymes. For this purpose, samples were digested using fast digestion restriction 
enzymes (Thermo Fisher Scientific) with 10x fast digest green restriction buffer 
(Thermo Fisher Scientific) diluted in dH2O at 37º C for 2 hrs.  
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4.3.5  Vector preparation 
 The vector was digested with the appropriate restriction enzymes, which 
prevent non-compatible ends in order to prevent self-ligation. 5µg were digested and 
dephosphorylated with Calf Intestinal Phosphatase (CIP) and incubated at 37ºC for 5 
min. Then, the vector was precipitated by using Phenol-chloroform and centrifuged 
at 15871 g for 3 min. Supernatant was discarded without disturbing the pellet. Pellet 
was air dried and diluted with 25 µl of dH2O. 
 
Plasmid Description Bacterial resistance Source 
pcDNA5 FRT/TO 
FLP Recombination Target 
(FRT) site for Flp 
recombinase-mediated 
integration of the vector into 
the Flp-In™ T-REx™ host cell 
line 
Ampicillin  Invitrogen 
pPGKFLPobpA Expression of recombinase Ampicillin Addgene 
pcDNA™6.2-
GW/EmGFP-miRs* 
TIGAR 
Expression of miRs* against 
TIGAR  Spectinomycin 
Invitrogen/ 
generated in this 
study 
pcDNA5 FRT/3XFLAG 
TIGAR 
Expression of 3XFLAG 
tagged TIGAR  Ampicillin 
Generated in 
this study 
PcDNA5 FRT/EmGFP 
miRs* PINK1 
Expression of miRs* against 
PINK1 Spectinomycin  
Generated in 
this study 
pEGFPn1-PINK1 Expression of EGFP tagged PINK1 Kanamycin Dr. Kurt de Vos 
Table 4.6. Plasmids for HEK FLP in construction. *For each gene, three microRNAs (miRs) were designed 
and tested for knockdown. 
4.3.6  Annealing single stranded oligos  
The synthesized complementary DNA oligos (Sigma Aldrich) were annealed 
to generate a double-stranded (ds) oligo. The annealing reaction was heated at 95ºC 
for 4 min and let cool down at RT for 10 min. The obtained sample was diluted 5,000 
fold by serial dilutions to get a final concentration of 10nM. ds Oligos were cloned 
into the linearized vector.   
4.3.7  Flagged TIGAR cloning 
 TIGAR DNA fragment was amplified by PCR. PCR samples consisted 
of 100 ng DNA obtained from human fibroblasts, 100ng forward primer, 100ng 
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reverse primer, 2.5nM dnTPs (Bioline) and 1 µl of TAQ enzyme. PCR samples were 
held at 94°C for 3 min, then 30 cycles consisting of 94 °C for 30 sec, 53°C for 30 sec 
and 72°C for 1 min 30 sec, followed by final step at 72°C for 10 min. Products were 
resolved in a 1% w/v agarose gel at 80V for 45min – 1 hr using a Generuler DNA 
ladder mix (Thermo Fisher Scientific).  Observed DNA fragments were cut and 
extracted from the gel using QIAquick Gel Extraction Kit (Qiagen) and following the 
manufacturer´s protocol. Purified DNA was cloned into the dephosphorylated and 
restricted vector.  
4.3.8  Ligation  
The plasmids and DNA inserts were cloned by using a T4 DNA ligase (Roche) 
and 10X ligase Buffer (Roche). The ligation reaction was mixed and incubated for 
>16hrs at RT.  
4.3.9  Plasmid Transformation 
10 µl of the ligation reaction was combined with 100 µl of E.coli DH5α 
competent cells with gentle and swift movements. Then, samples were incubated on 
ice for 10 min and submitted to a heat-shock at 37º C for 5 mins. Samples were then 
taken out and 1 mL of sterile LB Buffer was added and further incubated at 37º C for 
1 hr. After the incubation, samples were centrifuged at 17000 g for 1 min. and the 
supernatant was discarded. The obtained cell pellet was re-suspended in 100 µl of 
LB buffer and distributed in an agar plate with ampicillin or spectinomycin. Agar 
plates were then incubated at 37º C for >16 hrs.  
 
Antibiotic resistant colonies were screened for suitable clone selection. 
Recombinant vectors were purified with QIAquick Gel Extraction Kit purification kit 
(Qiagen) and confirmed by sequencing.  
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4.3.10 Restriction 
 Restriction digest were performed by using the corresponding restriction fast 
digest enzymes (Thermo Fisher Scientific) with 10x fast digest restriction buffer 
(Thermo Fisher Scientific) at 37ºC for 2 hr. 
4.3.11 DNA purification 
Single bacterial colonies from the transformation step were collected and 
inoculated in 3ml of LB broth containing the corresponding selective antibiotic and 
grown at 37 ºC with vigorous shaking overnight. Successful DNA integration 
verification was carried out by using the Plasmid Mini Kit and following the 
manufacturer’s instructions. 
   
Bacterial cells were harvested by centrifugation at 17000 g for 1min at RT. 
Bacterial pellet was re-suspended in 200µl of Buffer P1 (Lysis buffer) followed by 
adding 200µl of Buffer P2. Samples were then inverted five times and incubated for 5 
min at RT. 300 µl of Buffer P3 was then added and samples were mixed thoroughly 
by inverting ten times and centrifuged for 10 min at 17000 g. Supernatant was then 
transferred to a new collection tube. 700µl of Isosopropanol was added to the 
samples, mixed by inverting five times and further incubated for 10 min at RT. 
Samples were then centrifuged at 17000 g for 10 min, the obtained supernatant was 
then discarded without disturbing the pellet. Obtained pellets were air dried and re-
suspended in 50 µl of dH2O. Successful DNA inserts and vectors were verified by 
size of the restriction digests analysed in an agarose gel. 
 
200 µl of the culture from the successful transformants were collected, grown 
in 5ml of LB containing the selective antibiotic and incubated at 37º C on a vigorous 
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shake overnight. Purification was performed using the Plasmid Plus Midi Kit 
according the manufacturer’s instructions.       
4.3.12 Chaining pre-miRNAs (miRs) 
 In order to express more than one miRNA in one primary transcript and 
ensure co-cistronic expression, TIGAR and PINK1 miRNAs were chained into a 
single vector. Restriction digestions were performed by: 1) the combination of two 
specific restriction enzymes to cut the pre-miRNA (miR) insert and; 2) the 
combination of two specific restriction enzymes to cut the expression vector. The 
obtained fragments from the restriction, were run on a 2% agarose gel; then 
backbone and inserts were cut from the gel and purified. The purified fragments and 
backbone were then ligated and transformed. The obtained clones were analysed by 
Sanger sequencing and tested for future experiments.  
4.3.13 Removing EmGFP coding sequence from designed miRNAs to 
destination vector 
To avoid EmGFP expression in functional analysis of TIGAR and PINK1 
knockdown, EmGFP sequence was removed from successful pcDNA6.2-
GW/EmGFP-miR2 TIGAR 2, miR2 PINK1 and the chained miR2 TIGAR- miR2 
PINK1 clones. EmGFP sequence was removed by DraI digestion for 2 hrs at 37ºC 
and run in a 0.8% agarose gel. The insert fragment was excised from the gel and 
purified. The purified fragment was ligated and inserted into the destination vector 
pcDNA5 FRT/TO. Competent cells were transformed and the obtained clones were 
selected and checked by DraI restriction digests, where the 750bp EmGFP fragment 
was not visible.    
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4.3.14 RNAi knockdown 
 Gene knockdown from the successful TIGAR and PINK1 constructs were 
verified by western blotting and qPCR.    
4.3.14.1 Western blotting 
To determine and compare gene knockdown performed by each miR 
constructs, transfected HEK cell pellets were dissolved with Lysis buffer containing 
RIPA (Radio-Immunoprecipitation Assay) buffer (Sigma Aldrich), diluted 
phosphatase inhibitors (1% v/v) (Sigma Aldrich) and protease inhibitors cocktail 
(1%v/v) (PIC). Cell lysates were incubated on ice and centrifuged for 30 min at 
15871 g at 4°C. Supernatant was collected and the total protein was measured using 
the Bradford assay to select the appropriate amount of protein. 
 
A standard curve was obtained and the sample protein concentration was 
calculated using the linear equation (See Chapter three). The volume of cell lysate 
was determined and equivalent amount of Laemmli buffer 2x was added. Samples 
were heated for 3 min. at 100°C and centrifuged for 1 min at 2347 g. Proteins 
equivalents from each sample were loaded on a 12% polyacrylamide gel (SDS-
PAGE). Separating gels were run at low voltage (50 V) and running gel at a higher 
voltage (120 V). Proteins were transferred applying a wet electrophoretic transfer to 
a PVDF membrane for 1.5 hrs at 250 mA. The membranes were blocked with 5% 
non-fat dried milk diluted in TBS-T, after which, membranes were incubated 
overnight at 4ºC with primary antibodies against TIGAR (Santa Cruz) and GFP-
PINK1 (Clonetech) (Table 4.7). Then, membranes were incubated with secondary 
antibody horseradish peroxidases (HRP) (Table 4.7) and bands were detected using 
chemiluminescence with ECL Western Blot detection kit. α-Tubulin and GAPDH 
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were used as loading controls (Table 4.7). Quantification was done by densitometry 
analysis using G-Box Syngene Image software. 
 
Antibodies Catalogue number Company Dilution 
Molecular weight 
(kDa) Host 
Primary antibodies 
TIGAR antibody 
TIGAR(G2)  
sc-74577 
Santa Cruz 
Biotechnology 
1:1000 30  M  
Monoclonal anti-α-
Tubulin 
T9026 Sigma 1:10000 50  M 
Anti-Actin antibody 
ACTN05 (C4) ab3280 Abcam 1:1000 42 R 
Anti-GADPH 
monoclonal antibody 
(6C5)  
CB1001 Calbiochem  1:5000 36 M 
Anti-GFP 
monoclonal antibody 
(JL-8) 
632380 Clonetech 1:4000 /  M 
Secondary antibodies 
Anti-rabbit HRP IgG 1706515 Biorad  1:5000 / G 
Anti-mouse HRP IgG 1706516 Biorad  1:10000 / G 
Table 4.7. Antibodies used for knockdown assessment. Goat (G), Mouse (R); Rabbit (R). 
4.3.14.2 qPCR 
Gene knockdown in HEK Flp-In successful clones was evaluated by Real-
Time qPCR. Total RNA was extracted from cell pellets, using QIAGEN RNeasy kit 
(Qiagen) and cDNA was synthesised using SuperScript III cDNA first strand-
synthesis Kit (Invitrogen), following the manufacturer’s instructions. Target gene 
expression level was normalised using U1 snRNA as reference gene.  
 
The gene quantitation was done relative to the reference genes by subtracting 
the cycle threshold (Ct) of U1 snRNA, from the Ct of TIGAR and PINK1(∆∆Ct=∆Ct 
sample - ∆Ct reference gene). The resulting value of Ct (∆Ct) is the exponent of the 
base 2 (2-∆∆Ct). This was represented as the fold difference of template for the genes 
(Table 4.8). Efficiency of the qPCR reactions of all gene primers were 95-99%. The 
normalised relative TIGAR and PINK1 gene expression was calculated for each 
condition and normalised against the untreated control. Percent of knockdown was 
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calculated by subtracting the normalised ∆∆Ct expression of the control and 
multiplying by 100. The following formula was used in Excel for the calculation: 
(Power(10,-((∆Ct target-∆Ct reference)/3.333)))*100. 
 
GENE SEQUENCE 5’ > 3’ 
TIGAR F CCAAAGCAGCCAGGGAAGAGTG R CCGCTTCTTTCAGGATTAGTTGAC 
PINK1 F TGGACACCTCTGGGGCCATC R GCCGGACGCTGTTCCTCGTT 
U1 snRNA F CCATGATCACGAAGGTGGTT R ATGCAGTCGAGTTTCCCACA 
Table 4.8. Primers used for gene knockdown analysis. Primers used for TIGAR and PINK1 gene expression 
by qPCR. F, Primer forward; R, Primer reverse. Efficiency of the qPCR reactions of all gene primers were 95-
100%. 
4.3.15 Sequencing 
All miR constructs and overexpressing vectors were checked by Sanger 
sequencing using the Big Dye Terminator 3.1 (Applied Biosystems) protocol. Each 
sequencing reaction consisted of 1µg of DNA combined with the corresponding 
primer (Table 4.9), sequencing buffer and reaction mix diluted in dH2O using the 
following PCR sequencing program: 1) 30s at 95ºC for 45 cycles, 2) 15s at 50ºC and, 
3) 4 min at 60ºC. 
 
The PCR products were precipitated and sent to Source Bioscience 
(Nottingham, UK) for analysis. Sequences in abi format were checked by using Finch 
TV software (Geopiza). 
 
PRIMER  SEQUENCE  
CMV (pcDNA5) CGCAAATGGGCGGTAGGCGTG 
BGH reverse TAGAAGGCACAGTCGAGG 
GFP seq forward CGAGAAGCGCGATCACATGGTC 
Table 4.9. Primers used for sequencing in this study. 
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4.3.16 Building Stable Inducible Cell Lines 
4.3.16.1 HEK293T and HEK293T Flp-In 
Cell culture and transfections 
HEK 293T and HEK 293 FRT cell lines were grown in Dulbecco’s modified 
Eagle’s medium (DMEM, Sigma-Aldrich) supplemented with either 10% Fetal Bovine 
Serum or Tetracycline free fetal bovine serum (FBS), penicillin/streptomycin 
(100U/ml) at 37 C under 5% CO2 atmosphere and a relative humidity of 95%. 
HEK293T FRT was maintained in media supplemented with Blasticidin S 
(Calbiochem) and Zeocin (Invitrogen) for mantainance. Stable cell line selection was 
performed by substituting Zeocin with Hygromycin B (Thermo Fisher Scientific)  
(Table 4.10).  
 
For pcDNA6.2™6.2-GW/EmGFP-miRs TIGAR and PINK1 clones screening, HEK 
293 cells were plated in a 24-well plate at 50,000 cells/well. Co-transfections of 
pcDNA6.2™-miRs and overexpressing vectors were carried out using 
polyethylenimine (PEI; Sigma) 1µg/ml and 500ng of total DNA and 50µl of OptiMEM® 
(Life Technologies). The mixture was added to each well with gently swirls and left 
for 48-96 hrs to assess knockdown.   
 
For stable inducible cell line construction, the Flp-In T-Rex kit (Thermo Fisher 
Scientific) was used. After miRs contructs for both genes were checked and selected, 
they were transferred and cloned into the destination vector pcDNA5™/FRT/TO 
designed to be used with the Flp-In T-Rex system. The inducible expression vector 
contains:  
• The hybrid human cytomegalovirus (CMV)/TetO2 promoter, with gene 
expression regulated by Tetracycline. 
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• Flp Recombination Target (FRT) site, for vector stable integration into the 
selected mammalian host cell line. 
• Hygromycin resistant gene for cell line selection.  
 
The integration and expression of the pcDNA 5/FRT/miRs TIGAR, PINK1 and 
chained TIGAR-PINK1 into the genome, occurs by intermolecular DNA 
recombination mediated by the Flp recombinase.  
 
Stable inducible cell lines were generated for knockdown of the two genes 
TIGAR and PINK1, and the combination of both. Cells were seeded at 1 x 106 cells 
on a 10 cm dish in 15 ml culture medium containing Blasticidin to obtain a cellular 
confluency of >50%. 24 hrs after seeding, cells were co-transfected with the 
pPGKFLPobpA:pcDNA5FRT/TO DNA plasmid at a 6:4 ratio using 50 µg PEI  (1 mL). 
48hrs after transfection cells were harvested and split into 10 cm dish with 5 mL of 
conditioned medium (media from cells that have been in culture) and 5 mL of fresh 
culture medium without antibiotics.  24hrs after cells were plated, medium was 
supplemented with Hygromycin B and Blasticidin for selection. Cells were grown 
under selective growth conditions for seven days, after which, media was replaced 
with fresh selection medium until visible clones were identified. Hygromycin resistant 
clones were screened for Zeocin sensitivity to confirm pcDNA5/FRT/TO integration 
into the FRT site. Cells with successful recombination and stable integration will 
grow in selection medium with Hygromycin and Blasticidin. These cells do not grow 
in medium Zeocin and Blasticidin. Successful clones, where the cDNA construct had 
been recombined into the FRT site in the Flp-In-293 cells, were isolated, propagated 
and screened for gene knockdown by qRT-PCR for confirmation. Confirmation of 
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clones with the highest percentage of knockdown at 72 hrs after tetracycline 
induction were selected and expanded. All control cell lines were induced and 
assessed alongside HEK Flp In CRNAi negative control obtained from Dr. Guillaume 
Hautbergue. 
 
Cell model  
stage Antibiotic 
Stock 
concentration 
Working 
concentration 
HEK FRT 
Before transfection 
Blasticidin 10 mg/mL 15 µg/mL 
Zeocin 100 mg/mL 100 µg/mL 
HEK Flp GOI 
After transfection 
Blasticidin 10 mg/mL 15 µg/mL 
Hygromycin 50 mg/mL 100 µg/mL 
HEK Flp In 
Induction Tetracycline 10 mg/mL 1 µg/mL 
Table 4.10. Antibiotic concentrations for HEK FRT and HEK Flp in.  
 
4.3.17 Mitochondrial function and morphology assessment   
4.3.17.1 ATP assays  
ATP assays were performed to assess the effect of TIGAR, PINK1 and 
double-knockdown in the mitochondrial function and whether there is a rescue effect 
in cells with PINK1 deficiency when TIGAR is knockdown. Cultured cells generate 
their ATP mainly through glycolysis if grown in glucose-rich medium. Once the 
medium is replaced with galactose, they rely on the oxidative phosphorylation 
pathway to produce ATP (Mortiboys et al., 2008). The ATP assays were performed 
over three consecutive passages as biological triplicates of each cell line. Each cell 
line was maintained with selection medium containing Blasticidin and Hygromycin. 
Once cells were confluent, they were trypsinised and plated at 3x103 cells/well in a 
96-well plate with glucose or galactose selection media with or without tetracycline. 
48hrs after tetracycline addition, media was replaced with fresh selection media 
containing tetracycline.  For each cell line, four conditions were tested:   
• Glucose selection media: Not Induced and Induced with tetracycline. 
• Galactose selection media: Not Induced and Induced with tetracycline. 
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ATP cellular level was measured using the ATPliteTM Luminescence Assay 
System (Perkin Elmer). In brief, reagents were warmed to RT before starting the 
assay. Cells were washed with 100 µl of PBS, after which 100µl of PBS was added 
with 50 µl of mammalian cell lysis solution per well and the plate was placed on a 
plate shaker at 700 rpm for 5 min. Then, 50 µl of substrate solution was added and 
plate was shaken for further 5 min at 700 rpm. The plate was then left to adapt to the 
dark for 10 min. and the luminescence was assessed using a FLUOstar Omega 
microplate reader (BMG LABTECH). Cell density was measured with CyQUANT Cell 
Proliferation Assay Kit (Life technologies). After ATP was measured, 50 µl were 
added per well and incubated for 1 hour at 37ºC. The fluorescence was measured at 
530 nm using a FLUOstar Omega plate reader. The normalised data was obtained 
when the total ATP was divided by the CyQUANT measurement per well in triplicate. 
Averages from controls were taken as a 100% and the ratio corresponding to each 
condition per cell line was calculated. 
4.3.17.2 Mitochondrial morphology 
In order to assess the effect of TIGAR, PINK1 and double-knockdown effect in 
mitochondrial morphology, HEK 293T Flp in cells and controls were stained with the 
mitochondrial marker Tom20 (Table 3.7). We assessed four different conditions of 
each cell line with selection media: glucose not induced, glucose/tetracycline 
induced, galactose not induced and galactose/tetracycline induced. Cells were 
seeded at a 5x104 cells/well density in a 24-well plate containing a glass coverslip, in 
selection medium with or without tetracycline. After 48hrs, media was removed from 
wells and replaced with fresh medium with tetracycline. Cells were induced for 72 hrs 
and fixed for immunofluorescence. Briefly, cells were rinsed with PBS and 
permeabilised with 0.3% Triton-X followed by incubation with 5% bovine serum 
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albumin (BSA, Sigma) in PBS (Blocking buffer) for 1 hr at RT. Cells were then rinsed 
with PBS, mouse anti-Tom20 antibody (1:1000, BD Biosciences) in blocking buffer 
was applied to all the wells and incubated overnight at 4ºC. Cells were rinsed with 
PBS and incubated with secondary goat anti-mouse antibody Alexa Fluor 488 
(1:1000; Life technologies) for 1 hr in the dark at RT. Images were captured with 
Opera Phenix Laser based Confocal High Throughput Cell Imaging System (Perkin 
Elmer). A total of nine Images per field per condition per cell line were captured and 
processed by high-content analysis using the Harmony PhenoLOGIC software 
(Perkin Elmer).  
4.3.18 CRISPR/CAS9  
Recently, new approaches in molecular biology towards genome editing 
continue to emerge with improved and promising results. The Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) Type II system is one of them. 
This is a bacterial immune system modified and designed for genome engineering. 
The system is composed of a “guide” RNA (gRNA) and a non-specific CRISPR-
associated endonuclease (Cas9). The gRNA contains a scaffold sequence for Cas9-
binding and an upstream PAM site conformed by a 20 nucleotide targeting sequence. 
The nuclease targets a precise target DNA sequence producing double-strand 
breaks (DSBs), which are repaired through non-homologous end-joining (NHEJ) or 
homology directed repair (HDR). The NHEJ is prone to error but highly efficient, 
whereas the DSB confers high fidelity but with low efficiency. Due to this, Cas9 can 
produce frame-shifts indels and gene loss of function, without modifying the genomic 
sequence.      
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4.3.18.1 Expression system 
Plasmid based 
 For this study, the plasmid expression system was selected. The All-in-One 
plasmid (AIO, #74630) contains two cloning sites that encode dual U6 promoter to 
express dual synthetic guide RNAs. The Cas9-D10A nickase is linked by a 2A 
peptide with the selectable puromycin resistant marker to enhance efficient and 
accurate genome editing (Figure 4.2). 
 
Figure 4.2. Plasmid expression system. AIO-Puro (#7430) nickase plasmid targeting each gene. BbsI and 
BsaI allow dual cloning of synthethic guides RNAs (sgRNA) and dual U6 promoter expression.  Puromycin 
coupled to Cas9 via 2A peptide linker. Terminator (pA).   
 
4.3.18.2 Target sequence selection and sgRNA design  
 The complete sequence with isoforms for TIGAR and PINK1 was obtained 
from NCBI. To select the most efficient 20-nucleotide sequences for nickase 
targeting, the online program (http://crispr.mit.edu/) was used (Table 4.11). It 
provides the nickase design and predicts its “off-target” sites and effects (Figure 
4.15). To maximise gene disruption, we aimed for the first exons within each gene. 
However, for TIGAR, due to the first thee exons having a very short sequence 
(Figure 3.2), guides were only available for exons 4-6. For the nickase design, the 
PAM sequence lies upstream the target sequence and it was removed to leave only 
20 nucleotide sequence. If target sequence did not begin with G, this was added in 
order to allow transcription by the U6 promoter. The space between the two gRNAs 
are variable and without exceeding 20 bp from each other (Table 4.11). The guides 
with the highest scores were selected and two paired gRNAs were chosen for each 
gene. 
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Gene Exon Guide Sequence 5’ > 3’ Pair Sense 
PINK1 1 
1A F ACCGACCCTGCGAGGCTCCGCGCC R AAACGGCGCGGAGCCTCGCAGGGT 
1B F ACCGTCTCCGCTTCTTCCGCCAGT R AAACACTGGCGGAAGAAGCGGAGA 
2A F ACCGCCGCCTGTTTTTCCTCGATG R AAACCATCGAGGAAAAACAGGCGG 
2B F ACCGGCGGGCGGTCTCGGCCTGTC R AAACGACAGGCCGAGACCGCCCGC 
TIGAR 
4 
1A F ACCGTCTCTCCAAAATTCCATGCA R AAACTGCATGGAATTTTGGAGAGA 
1B F ACCGAAAGTATGACTCAAGACTTC R AAACGAAGTCTTGAGTCATACTTT 
5 
2A F ACCGTTCCCTGGCTGCTTTGGCCA R AAACTGGCCAAAGCAGCCAGGGAA 
2B F ACCGCCTGTGTTTACACCGCCCGG R AAACCCGGGCGGTGTAAACACAGG 
Table 4.11. Designed primers for TIGAR and PINK1. Each paired guide are designed in opposite strands. 
Highlighted in green (F, forward) and yellow (R, reverse) are the cloning overhangs for BbsI or BsaI ligation. Pair 
guides are 1A and 1B, and 2A and 2B for each gene.  
 
4.3.18.3 Molecular cloning  
AIO-Puro vector was digested with BbsI, dephosphorylated and purified as 
previously described ( Vector preparation). All the complimentary DNA oligos were 
annealed by heating at 90-95ºC for 4 min and allow slow cooling at RT. Then, the 
oligo pairs were individually phosphorylated with T4 Polynucleotide Kinase (PNK4). 
Each oligo pair was cloned into the BbsI digested vector using T4 Ligase. Each 
construct was transformed and purified using the Spin Miniprep Kit (QIAgen) and 
following the manufacturer’s instructions. Resulting clones were checked and 
successful ones were selected and purified as previously described (See section 
4.3.11).  
4.3.18.4 Verification of inserts 
 Clones were screened by restriction digests using BamHI. Successful clones 
lose the BamHI recognition site and a linearised vector was then visualised.  
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4.3.18.5 Sequencing 
All sgRNA cloned into BbsI-digested AIO-Puro plasmid were analysed by 
Sanger sequencing using the hU6 promoter primer 
(F:TTTCCCATGATTCCTTCATATTTG) and the Big Dye Terminator 3.1 (Applied 
Biosystems) protocol. Each sequencing reaction was performed as described 
previously (See section 4.3.18.5).  
4.3.18.6 Cell culture and transfection 
 HEK 293T cell lines have been successfully used with CRISPR/Cas9 and 
optimised protocols have been already stablished. HEK293 were grown in 
Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, 
penicillin/streptomycin (100U/ml) at 37º C under 5% CO2 atmosphere and a relative 
humidity of 95%. The day before the transfection, 5x104 cells/well were seeded in a 
24 well plate. On the day, 70% confluent cells were transfected with 500ng of AIO-
TIGAR and AIO-PINK1, each containing the respective paired dRNAs, using 
Lipofectamine 2000.  
 
 Then, 24 hrs after transfection, medium was replaced with fresh warm media 
and 3.5µg of Puromycin was added to each well. Cells were further incubated for 
72hrs for selection. Cells that survived under the Puromycin condition, have 
maintained the plasmid expression, which integrates into the genome of the cell. 
Puromycin resistant cells were then harvested and cultured in regular medium for 
clonal selection. 
4.3.18.7 Clonal selection 
 Clonal cell lines were isolated by limited dilution. Puromycin resistant cells 
were dissociated into single cells 72 hrs after transfection. Each transfected well with 
cells were counted and serially diluted in fresh medium. 60 cells per 10 mL in 
medium were obtained and plated for each 96-well plated, to obtain 0.5 cells/100 µL 
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media per well. Accurate dilution, calculation and single cell seeding is critical for 
single clone selection. Each transfected population for each paired gRNA for each 
gene was plated in duplicate. Cells were checked and inspected with media 
replacement for a period of 2-3 weeks, until clonal appearance with colonies were 
visualized. Cells were left growing in the incubator for a period of ~2 weeks for 
expansion. Clones from cells transfected with paired guides A and B for TIGAR 
knockdown were tested by WB to assess knockdown at the protein level. Clones 
from cells transfected with paired guides A and B for PINK1 knockdown were tested 
by qPCR for gene expression.   
4.3.19 Statistical Analysis  
Statistical analysis was carried out with Prism 7 GraphPad software. P value 
significance was obtained using 2-way and one-way ANOVA with multiple 
comparisons with post hoc correction wherever it is indicated.   
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4.4 Results 
4.4.1  Building the Flp In stable model 
4.4.1.1 Flag tagged TIGAR 
 TIGAR was successfully cloned into pcDNA5 FRT/TO (Figure 4.3, a) and 
overexpressing vector verified in transfected HEK cells (Figure 4.3, b).   
 
Figure 4.3. TIGAR cloning. a) TIGAR PCR product obtained from human fibroblasts; b) WB image of TIGAR in 
the Untreated (UT) and the overexpressing FRT-TIGAR construct in transfected HEK cells.   
4.4.1.2  TIGAR and PINK1 miRNAs 
miR constructs for TIGAR (Figure 4.4) and PINK1 (Figure 4.5) were 
successfully synthethised and cloned into the pcDNA™6.2-GW/EmGFP vector, 
which allow the expression of the miR inserts against TIGAR (Figure 4.4) and PINK1 
(Figure 4.5). The cloned miRs size was expected to be ~200 bp. They were 
transfected into HEK cells for transient RNAi analysis. One miR construct for each 
gene, with the most effective and efficient knockdown, was selected for the 
generation of the HEK Flp In stable cell line.  
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Figure 4.4. TIGAR miRs constructs. Agarose image of cloned TIGAR miR1, miR2 and miR3 inserts that were 
cloned into pcDNA™6.2-GW/EmGFP digested with BamHI and XhoI. Insert expected at ~200bp.   
 
 
 
Figure 4.5. PINK1 miRs constructs. Agarose image of cloned TIGAR miR1, miR2 and miR3 inserts cloned into 
pcDNA™6.2-GW/EmGFP digested with DraI and XhoI. Insert expected at ~180pb.   
 
4.4.1.3  miRNA mediated knockdown 
TIGAR miR constructs screening 
 In order to assess TIGAR knockdown and to select the best miR construct for 
future assays, HEK cells were transfected with or without pcDNA5 FRT/FLAG 
TIGAR and the three cloned pcDNA™6.2-GW/EmGFP-miRs TIGAR knockdown 
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effect was assessed by by WB at 72hrs post-transfection (Figure 4.6). To see 
whether a combination of two miRs showed a higher knockdown, the three miRs 
were combined in two pairs and cloned into pcDNA™6.2-GW/EmGFP. The co-
transfected cells with the overexpressing FLAG-TIGAR and the miR TIGAR 
constructs (Figure 4.6 a left panel) showed a reduction at the protein level of ectopic 
TIGAR, were miR2 TIGAR achieved the highest percentage of all (Figure 4.6 b). 
However, endogenous levels of TIGAR protein remained the same compared to the 
untransfected cells. When cells were transfected with single miR TIGAR constructs, 
TIGAR protein level was reduced in almost all of the transfected cells except for the 
cells transfected with chained miR2 and miR3 TIGAR. Overall, miR2 showed the 
highest knockdown percentage (~86%) (Figure 4.6). Constructs containing two miRs 
for TIGAR did not showed an increase in the knockdown effect, therefore miR2 
TIGAR was selected for future assays and functional analysis. 
 
 
Figure 4.6. TIGAR knockdown in HEK 293T cells. a) Representative WB image of transfected HEK 293T with 
(left panel) or without (right panel) FLAG TIGAR and pcDNA6.2/miR1, miR2, miR3 and chained miRs TIGAR (left 
panel). A knockdown can be seen in all the single constructs and only in one chained. The highest knockdown 
(~86%) was obtained with miR2 against TIGAR.  Ectopic (red arrow) and endogenous (blue arrow) TIGAR.   
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PINK1 miRs constructs screening 
 Cloned miRs for PINK1 were transfected in HEK and knockdown effect was 
assessed at the 48hrs. To asses PINK1 knockdown at the protein level, eGFP-
PINK1 was co-transfected with the three pcDNA™6.2-GW/EmGFP-miRs PINK1. 
Since there are no reliable PINK1 antibodies, GFP-PINK1 knockdown was assessed 
at the 48hrs post-transfection. The three constructs showed high levels of 
knockdown, where miR2 PINK1 showed ~100% knockdown (Figure 4.7). Therefore, 
the construct containing miR2 PINK1was selected for stable inducible cell line 
generation and future functional analysis.    
 
Figure 4.7. PINK1 knockdown in HEK cells. a) Representative Western Blot image of HEK cells co-transfected 
with eGFP-PINK1 and three pcDNA6.2/miR1, miR2 and miR3 against PINK1. Blots (upper panel) were probed 
with antibody against GFP, to detect eGFP-PINK1. The three miR2 PINK1 construct achieved the highest effect 
with ~100% knockdown. 
 
4.4.1.4 GFP removal 
Before the HEK FLP IN cellular model for each gene was established, the 
GFP 750bp sequence was removed from all miR constructs and transferred into the 
destination vector pcDNA5™/FRT/TO (Figure 4.8).  
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Figure 4.8.  Restriction analysis of miRNAs after GFP removal. Image of digested miRNAs with DraI of the 
three miRNAs in pcDNA6.2 vector. First six lanes correspond to miR2 TIGAR. Lanes in the middle correspond to 
miR2 PINK1, where the first 2 lanes correspond to pcDNA6.2/EmGFP-miR2 TIGAR (asterix) and 
pcDNA6.2/EmGFP-miR2 TIGAR/miR2 Pink1 (dash), which were used as GFP controls respectively (single or 
chained inserts). Last six lanes correspond to chained miR2 TIGAR and miR2 PINK1.  
 
 Then, after GFP removal, miR2 TIGAR, miR2 PINK1 and miR2 TIGAR/miR2 
PINK1 were successfully cloned into the pcDNA5/FRT/TO expression vector (Figure 
4.8), TIGAR and GFP-PINK1 levels were assessed at the 48hrs by WB to verify 
knockdown effect (Figure 4.9). GFP-PINK1 continue to show ~100% knockdown in 
transfected cells with miR2 PINK1 (Figure 4.9) and miR2 TIGAR/miR2 PINK1. 
However, miR2 TIGAR showed a lower knockdown effect alone (Figure 4.9) (30%) 
and when co-transfected with eGFP-PINK1 and chained with miR2 PINK1 (Figure 
4.9) (23%). When two miRs are co-transfected, it has been shown that percentage of 
knockdown might decrease (Werness and Anderson, 2010).    
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Figure 4.9. TIGAR Protein levels.  a) Representative Western Blot image of HEK cells untransfected (lane 1), 
co-transfected with eGFP-PINK1 and pcDNA™5/FRT/miR2 TIGAR (lane 3), pcDNA™5/FRT/miR2 PINK1 (lane 4) 
and pcDNA™5/FRT/miR2 TIGAR/miR2 PINK1 (lane 5). Blots (upper panel) were probed with antibody against 
GFP, to detect eGFP-PINK1 The constructs showed a knockdown, in which miR2 PINK1 achieved a ~100% 
knockout; whereas TIGAR showed a knockdown of 30% alone and 23% when both inserts are expressed. 
4.4.2  HEK Flp In TIGAR and PINK1 assessment  
 Once knockdown was achieved, the miR constructs were selected for further 
functional assays in the HEK Flp In cell lines. The miR constructs were transferred 
and cloned into the pcDNA™5/FRT/TO expression vector containing the hybrid 
human cytomegalovirus (CMV)/TetO2 promoter and Hygromycin resistance gene. 
This system allows inducible regulation after tetracycline addition and antibiotic 
selection.  
 
 Stable inducible cell lines for TIGAR and PINK1 were generated after HEK 
FRT cells were transfected with the pcDNA5™/FRT/TO vector containing the pre-
miRNA (miR) insert in the 3’UTR, directed against TIGAR, PINK1 or both, using the 
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Flp-In T-Rex kit. The integration of the vector is mediated by the Flp recombinase, 
which allows the DNA recombination at the FRT sites.  
 
The HEK FRT host cell line contains the pFRT/lacZeo target site vector, 
containing the lac-Z-Zeocin fusion gene regulated by the SV40 promoter. The ATG 
initiation codon of the lac-Z-Zeocin fusion gene lies upstream the FRT site. HEK FRT 
cells express the lacZ-Zeocin resistance gene, which makes them Zeocin-resistant.  
The pcDNA5/FRT/TO constructs contain the hygromycin resistance gene within the 
5’ coding region, as well as a FRT site, which is lacking from the ATG initiation 
codon and a promoter. Once the constructs were co-transfected with pPGKFLPobpA 
plasmid, homologous recombination occurred between the FRT sites. Stable 
insertion into the genome of the pcDNA5/FRT/TO, the ATG initiation codon and the 
SV40 promoter are brought in frame within the hygromycin resistance gene, leading 
to lacZ-Zeocin fusion gene inactivation. Therefore, we were able to select the stable 
inducible cell lines via hygromycin and blasticidin resistance and Zeocin sensitivity. 
After the pcDNA5/FRT/TO vector containing the miR2 TIGAR, miR2 PINK1 and 
miR2 TIGAR/miR2 PINK1 is integrated, gene repression is achieved via tetracycline 
induction. 
 
The pcDNA/FRT/TO vector contains the CMV/TetO2 promoter, in which the 
miR inserts expression are regulated via tetracycline induction. The HEK FRT cells 
contained the blasticidin resistance gene and Tet repressor elements (TetR). This 
allowed blasticidin selection of cell lines expressing the tetracycline repressor protein. 
These cells are maintained under the regulation of the Tetracycline Operator 2, 
which inhibits the expression of the miR insert. Once tetracycline is added, it binds 
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the TetR, it changes it conformation and releases it from the Tet operator sequences. 
This leads to miRs transcription and expression. 
 
After cells were transfected and single colonies were obtained, successful 
clones were selected for screening for each cellular model. Single visible colonies 
were picked and grown in a 24-well plate. Single colonies were then grown under the 
following selection conditions: a) medium with Hygromycin and Blasticidin.and b) 
medium with Zeocin and Hygromycin. Successful clones were grown in medium 
Hygromycin and Blasticidin, where cellular death occurred in medium containing 
Zeocin and Blasticidin. A total of three cell lines were selected from each cellular 
model. After tetracycline induction, knockdown was assessed by comparing the 
mRNA levels obtained by qPCR for each cell lines, (Figure 4.10, Figure 4.11 and 
Figure 4.12).    
4.4.2.1  RNAi mediated knockdown 
Three clones for screening from the HEK Flp In for each cell model were 
selected. Each cell line was harvested and plated into 10 cm dish with or without 
tetracycline addition. Next, the knockdown percentage was analysed for each of the 
clones by assessing the gene expression of TIGAR and PINK1 at 48hrs post 
induction and using qPCR.  
HEK Flp TIGAR cell lines.  
All three Flp TIGAR cell lines were compared with the cells without 
tetracycline induction (control). Based on the obtained results from the 72 hrs post-
induction, two of the three cell lines showed decreased TIGAR expression compared 
to their respective control (Figure 4.10 a). Flp TIGAR cell line T2 had a reduction of 
55.3% (2-way ANOVA, ****P<0.0001) and A2 of ~30% (2-way ANOVA, ****P 
<0.0001), whereas T1 showed a 2-fold increased expression (2-way ANOVA, 
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****P<0.0001)  (Figure 4.10 a). The T2 and A2 cell lines were then chosen to check 
for consistent decreased TIGAR expression after 72 hrs post induction. TIGAR 
expression showed was consistently knocked down after 48 hrs post induction in 
further assessments, where A2 showed a 65% decreased expression and T2 50% 
relative to their controls (2-way ANOVA, ****P <0.0001) (Figure 4.10 b and c). A2 
demonstrated consistency with high reduction of TIGAR expression, therefore this 
cell line was selected for further functional analysis.        
  
 
Figure 4.10. TIGAR Knockdown in HEK FLP IN cell lines. TIGAR mRNA level of HEK FLP TIGAR cell lines at 
72 after of tetracycline induction. A) Three cell lines were selected for screening and selection for TIGAR 
knockdown, where a reduction of TIGAR expression was obtained for T2 (50%) (****P<0.0001) and A2 (30%) 
(****P<0.0001) and a 2-fold increased TIGAR expression was obtained for T1 (****P<0.0001). Two cell lines were 
selected for knockdown validation: A2 (b) and T2 (c), where a constant knockdown was achieved with both cell 
lines of 64.3 % (****P<0.0001) for A2 and 55% (****P<0.0001) for T2. 2-way ANOVA, Dunnett’s test (n=3).    
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HEK Flp PINK1 cell lines  
Initial assessment of HEK Flp PINK1 cell lines after 72 hrs of tetracycline 
induction, two from the three cell lines showed a reduction in PINK1 expression 
when compared to their respective controls (Figure 4.11 a). Here, a decrease in 
PINK1 expression of ~50 % (2-way ANOVA, ****P<0.0001) was observed in PB11 
and 40% (2-way ANOVA, ****P<0.0001) for P2 and an increase of ~19% (2-way 
ANOVA, ****P<0.0001) in P5 (Figure 4.11 a). Further analysis performed in PB11 
and P2 demonstrated a consistent decrease of PINK1 expression of 80% (2-way 
ANOVA, ****P<0.0001) and 50% respectively (2-way ANOVA, ****P<0.0001) relative 
to controls (Figure 4.11, b and c). PB11 achieved the highest knockdown, therefore 
this cell line was selected for future functional analysis.            
 
Figure 4.11. PINK1 knockdown in HEK FLP IN cell lines. PINK1 mRNA level of HEK FLP PINK1 cell lines at 
72 after tetracycline induction. A) Three cell lines were selected for screening for PINK1 knockdown, where a 
reduction in PINK1 expression was obtained for PB11 (50%) (****P<0.0001) and P2 (40%) (****P<0.0001) and a 
~19% increase in PA5 (****P<0.0001). B11 (b) and A2 (c) were selected for further validation of knockdown, 
where a constant knockdown was seen with both cell lines of 80% in PB11 for and 50% in P2. 2-way ANOVA 
Dunnett’s test (n=3).    
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HEK Flp TIGAR/PINK1 cell lines  
After 72 hrs of tetracycline induction, the three obtained cell lines showed a 
decreased expression in both genes of approximately 55% for TIGAR (2-way 
ANOVA, ****P<0.0001) and 72% for PINK1 (TP8) (2-way ANOVA, ****P<0.0001); 
63% for TIGAR and 78% for PINK1 (TP9) (2-way ANOVA, ****P<0.0001); and 24% 
for TIGAR and 35% for PINK1 (TP2) (2-way ANOVA, ****P<0.0001) (Figure 4.12 a). 
Two cell lines were selected for further confirmation, where TP8 showed consistent 
decrease expression of approximately ~94% in both genes (2-way ANOVA, 
****P<0.0001) (Figure 4.12 b); and TP9 of ~53% in both genes (2-way ANOVA, 
****P<0.0001) (Figure 4.12 c). TP8 achieved consistent high reduction for TIGAR 
and PINK1 expression and was selected for functional analysis.    
 
  
Figure 4.12. TIGAR and PINK1 knockdown in HEK FLP IN cell lines. PINK1 knockdown in HEK FLP IN cell 
lines. PINK1 and TIGAR mRNA level of HEK Flp TIGAR/PINK1 cell lines at 72 after tetracycline induction. a) 
Three cell lines were selected for screening for gene knockdown, where a reduction in TIGAR and PINK1 
expression was obtained for TIGAR of 55% (****P<0.0001) and 72% (****P<0.0001) for PINK1 in TP8; 63% and 
78% (****P<0.0001) in TP9 and 24% and 35% in (****P<0.0001) TP2 respectively. These two cell lines were 
selected for further validation of knockdown TP8 (b) and TP9 (c), where a constant knockdown for both genes of 
94% (****P <0.0001) in TP8 and 53% (****P <0.0001) in TP9. 2-way ANOVA Dunnett’s test (n=3).    
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4.4.2.2 HEK Flp In mitochondrial function  
Since tigarb knockdown was demonstrated to have a mitochondrial rescue 
effect in pink1 deficient zebrafish model (Flinn et al., 2013); we aimed to assess this 
effect in human cell lines. 
Effect of TIGAR and PINK1 deficiency in ATP production 
 ATP production was assessed in the three selected cell lines for each cellular 
model (Figure 4.13). In the presence of glucose, after 48 hrs induction, we found a 
reduction of 58% (2-way ANOVA, *P=0.0309) in the HEK Flp TIGAR A2 induced 
cells compared to HEK Flp CRNAi induced cells (Figure 4.13 a). However, no 
statistical difference was found in HEK Flp TIGAR A2 compared to the not induced 
control (2-way ANOVA, P=0.703) (Figure 4.13a). ATP levels were increased in HEK 
Flp PINK1 B11 induced cells compared to not induced cells (20%), without reaching 
statistical difference (2-way ANOVA, P=0.52) (Figure 4.13a). ATP production was 
decreased in HEK Flp TIGAR A2 induced cells (58%) (2-way ANOVA, *P=0.0353) 
when compared to HEK Flp PINK1 B11 induced cells (Figure 4.13). ATP levels were 
reduced in TIGAR/PINK1 TP8 induced cells (~16%) compared to not induced 
controls, however they did not reach statistical significance (2-way ANOVA, P=0.95) 
(Figure 4.13 a). 
 
 In glucose-free medium at 48 hrs post tetracycline induction, HEK Flp TIGAR 
A2 and HEK Flp PINK1 PB11 induced cells showed an ATP reduction of 60% (2-way 
ANOVA, *P=0.0141) and 62% (2-way ANOVA, *P=0.0115) respectively, when 
compared to control HEK Flp CRNAi induced cells. HEK Flp TIGAR A2 and PINK1 
BII showed a decrease of ATP levels ~20% (2-way ANOVA, P>0.05), without 
reaching statistical difference when compared to their respective not induced 
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controls. ATP levels showed a slight increase in HEK Flp TIGAR/PINK1 TP8 induced 
cells when compared to the not induced control (~5%) (2-way ANOVA, P>0.05), 
however this did not reach statistical difference (Figure 4.13 b).  We demonstrated 
that TIGAR and PINK1 deficiency produced a decrease in the ATP independently in 
the absence of glucose; whereas in glucose media TIGAR deficiency showed a 
decrease in ATP levels, opposite to an ATP increase when PINK1 is deficient. In 
glucose-free medium, although there was an increase in ATP production when both 
genes were deficient in the same cell line, it was minimal and no significant. Overall, 
there is a statistical difference in TIGAR and PINK1 cell lines when compared to 
negative control, but not to the respective not induced cell lines.     
 
Figure 4.13. ATP assays in stable inducible cell lines for TIGAR and PINK1 knockdown. ATP assays were 
performed in HEK Flp In of each cellular model in two different medium conditions after 48 hrs of Tetracycline 
induction. a) In glucose medium, a reduction of ATP levels of induced cell lines of about 58% in HEK Flp TIGAR 
A2 relative to HEK Flp CRNAi induced cells (*P=0.0309). An ATP reduction of ~58% in HEK Flp TIGAR A2 when 
compared to HEK Flp PINK1 B11 (*P =0.0353); b) in glucose-free medium, induced cells showed an ATP 
reduction in HEK Flp TIGAR A2 (60%) (*P=0.0141) and HEK Flp PINK1 B11 (62%) (*P=0.0115) when compared 
to HEK Flp CRNAi induced cells. All cellular models showed no statistical difference in any of the conditions 
when compared to their respective not induced control. 2-way ANOVA, Turkey’s test (n=3).  
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4.4.2.3 HEK Flp In mitochondrial morphology 
 Morphological changes have been reported in other cellular models linked to 
a defect in the ATP production in PINK1 deficiency. We therefore investigated 
whether mitochondrial morphology was altered in the HEK Flp TIGAR, HEK Flp 
PINK1 and HEK Flp TIGAR/PINK1 induced cells. All cell lines were submitted to the 
same conditions as the ones assessed for ATP levels. Cells were stained with 
mitochondrial marker Tom 20 and visualised with the Opera Phoenix Laser based 
Confocal High Throughput Cell Imaging System. Nine Images per field per condition 
per cell line were captured and processed by high-content analysis using the 
Harmony PhenoLOGIC software to obtain mitochondrial length measurements. 
Qualitative analysis of individual cell lines was performed in the presence or absence 
of glucose. Overall, after 48 hrs of tetracycline induction, we did not find any 
significant difference in the mitochondrial length or branching in any of the conditions 
and any of the HEK Flp In cellular models. Overall, in our hands and under the 
conditions tested, these results suggested that TIGAR and PINK1 deficiency does 
not alter the mitochondrial morphology in the HEK Flp In cellular model.  
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Figure 4.14. Mitochondrial morphology in stable inducible cell lines for TIGAR and PINK1 knockdown. 
Cells were stained with the mitochondrial marker Tom20 and assessed at the 48hr after tetracycline induction in 
the presence (a) or absence (b) of glucose. Mitochondrial were visualised with the Opera Phoenix Laser based 
Confocal High Throughput Cell Imaging System. Mitochondrial length measurements were obtained by high-
content analysis using the Harmony PhenoLOGIC software. No statistical difference was obtained in any of the 
cell lines in any of the conditions assessed (P>0.05). 2-way ANOVA multiple comparisons (n=3).  
4.4.3  CRISPR/Cas9  
The design for each gene using the CRISPR online tool (http://crispr.mit.edu/) 
produced 2 paired sgRNAs for PINK1 in the exon 1, whereas for TIGAR one paired 
guide was design targeting the exon 4 and one within the exon 5, an example of the 
design is featured in Figure 4.15. The first three exon sequences of the TIGAR gene 
are too small, which result in no available suitable sgRNA for this regions due to their 
size (Table 4.11).  
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Figure 4.15. gRNA design and nicking strategy. Representative image of each paired guide gRNA designed in 
opposite strands, based on target sequences against human TIGAR and PINK1. gRNAs are separated from each 
other by 20 bp within the respective exon. When gRNAs are paired, the off-target effect is predicted to be null by 
the online CRISPR Design tool for all the paired guides against both genes (crispr.mit.edu). Each guide cuts after 
the PAM sequence (red arrow), creating the biallelic disruption.   
 
4.4.3.1 TIGAR and PINK1 colony screening 
All gRNAs were cloned into BbsI-digested AIO-Puro vector. From the 
obtained transformants, 2-3 colonies were picked and checked by restriction digests 
with BamHI and EcoRV. Successful clones with the insert lose the BamHI site, from 
which the linearized vector was detected (Figure 4.16). Successful clones were 
selected and transformed. Afterwards, plasmids were purified, assessed and 
checked for right insertion without any mutations by Sanger sequencing. Four 
plasmid constructs, for the two paired guides corresponding to each gene, were 
selected for transfections.       
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Figure 4.16. Colony screening for PINK1 and TIGAR. Restriction analysis of cloned gRNAs for PINK1 and 
TIGAR. The oligonucleotide duplex was ligated into BbsI-digested AIO-Puro vector; restriction digests with 
BamHI and EcoRV of successful clones showed only the linearized vector (~10000bp) (asterix).  
 
 After cells were transfected with the correct paired guides for each gene and 
puromycin selected, successful clones were expanded and selected for knockdown 
or knock-out confirmation against TIGAR and PINK1.  
TIGAR screening 
  TIGAR protein level was assessed by WB from the selected clones. A total of 
fourteen clones were obtained from each transfected gRNA pair, from which eight 
were selected for screening. Quantitative analysis from the blots showed a reduction 
in TIGAR protein level in five of the clones between 33-85% (Figure 4.17 a-b). 
Although clone 2A showed the highest reduction (One-way ANOVA, ***P<0.001), it 
was also the one with the least protein amount loaded, where Actin protein level was 
remarkably affected (Figure 4.17 a-b). Clones 5A, 6A and 11A showed an increase 
in TIGAR protein levels at almost 2-fold in one clone (Figure 4.17). The four clones 
1B, 3B  (33.5%) (ns P>0.05, n=2), 4B (58%) (*P<0.05, n=2) and 5B 52% (*P<0.05, 
n=2) demonstrated similar reduction of TIGAR protein levels (33-58%) (Figure 4.17 
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b). Since some of the clones were not assessed in triplicate, further verification of 
TIGAR knockdown is suggested in the remaining clones. In addition, quantifying 
mRNA levels would be an alternative method to assess if TIGAR was knocked down 
at the transcriptional level.  
     
 
Figure 4.17. TIGAR CRISPR Cas9 screening. A) WB image of clones obtained from cells transfected with 
paired guides A and B; b) Densitometry analysis where protein level was quantified and normalised against the 
untransfected cells (WT). TIGAR knockdown was obtained for pair 2A of 85% (***P<0.001; n=2), pair 1B of ~50% 
(*P<0.05; n=2), pair 3B of 33.5% (ns P>0.05, n=2), pair 4B of 58% (*P<0.05, n=2) and for pair 5B of 52% 
(*P<0.05, n=2). One-way ANOVA Dunnett’s test.        
 
PINK1 screening  
 Since there is a lack of reliable antibodies against PINK1, we assessed PINK1 
mRNA levels by qPCR in five of the ten clones obtained for this cell model. From the 
results obtained, only two of the five clones assessed showed a reduction of PINK1 
mRNA levels. Clone 4B and 3B showed a reduction of 87% (One-way ANOVA, 
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**P<0.01, n=2) and 85% (One-way ANOVA, **P<0.01, n=3) respectively compared 
to WT cells. A non-significant reduction in PINK1 mRNA levels was detected in 6B 
(33.7%) (One-way ANOVA, ns p>0.05, n=3) and 3A (One-way ANOVA, P>0.05, n=2) 
(Figure 4.18). Some of the clones were tested in duplicate, therefore further 
screening in triplicate and for the remaining clones should be performed in order to 
verify the knockdown effect in order to select a suitable cell line for functional 
analysis in PINK1 deficient cells.  
   
 
Figure 4.18. PINK1 CRISPR Cas9 screening. Quantification of the mRNA level of transfected cells with paired 
guides A and B for PINK1 knockdown, where level of expression was normalised against the untransfected cells 
(WT), where a significant knockdown was obtained for PINK1 3B (85%) (**P<0.01, n=3), and PINK1 4B (87%) 
(**P<0.01) (n=2) cell lines only. Although PINK1 6B and PINK1 3A cell lines showed a reduction, it was no 
statistical different. One-way ANOVA Dunnett’s test.  
 
All cell lines from both cellular models were only screened for knockdown or 
knockout efficacy and efficiency. Detection of indel mutations and polymorphism 
should be verified by functional testing and genotyping for fully validation of the 
system, detect mutations and off-target effects. Further functional testing assays 
should be performed by isolating the DNA of each cell model.  
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4.5 Discussion 
 Previous research performed in the zebrafish pink1 deficient model from our 
group, suggested an unknown implication of TIGAR in PD neurodegenerative 
process (Flinn et al., 2013). The proper mechanisms related to the development of 
the disease were still elusive and needed to be validated in a human model. The aim 
of the current project was to confirm and verify TIGAR PD-related mechanisms in a 
reliable and robust cellular model with PINK1 deficiency. Thanks to modern 
molecular engineering techniques, we achieved to build a stable inducible model, 
which allow us to study the implications and effects of TIGAR when PINK1 is 
deficient.  
4.5.1  Gene knockdown 
 Previous attempts to assess the effects of TIGAR knockdown in human 
fibroblasts were not successful and inconclusive. Although, they proved to be a very 
valuable model with potential promising results, effects of transient transfections and 
chemical reagents prevented us from assessing the knockdown effect. In order to 
overcome and tackle this problem, we build an isogenic stable inducible cell line, 
which allow us to study the functional effects in a PINK1 deficient stable inducible 
model. 
 
 In our study, using RNAi by microRNAs, we achieved a 40-50% TIGAR 
knockdown at the protein and gene level consistently. PINK1 showed to have almost 
a ~100% knockdown at the protein level, achieving almost a knock-out. The fact that 
TIGAR knockdown effect was lower in HEK transfected cells might be for a number 
of reasons. First, TIGAR protein levels have been reported to be higher in HEK cells 
(See chapter three), whereas mRNA levels has been shown to be lower 
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(http://www.proteinatlas.org). So, even when TIGAR is knockdown, it is a lower 
percentage due to its abundancy or a long protein half-life time in HEK cells. Second, 
even when transient transfections help to study the effect of a target gene and 
protein production, they do it in a limited temporal manner due to the fact that the 
genome is not integrated to the host cell line. For this, knockdown effect should be 
then assessed over a period of time from 24-96 hrs to see whether the maximum 
effect is achieved at shorter or longer period. Third, chemical and physical methods 
might interfere with the physiological response of the cell, produce chemical 
modifications of the microRNA (unlikely) and the overall outcome. The efficiency of 
the knockdown also depends on the targeted sequence site within the gene, which 
can result in a high variability. Although, there are no reported TIGAR isoforms, there 
is the probability that there are produced, not targeted by the miRNA (miR) and 
therefore detected by WB. A higher TIGAR knockdown was expected with chained 
microRNAs (miRs) targeting only one gene, but the results showed that the 
percentage was similar or lower than when using miR2 TIGAR alone. miR1 targets 
exon number 5, whereas miR2 and 3 target the middle and distal part of the exon 
number 6 of the gene (Table 4.1). These different sites explain the differences of the 
knockdown effect, suggesting that effective TIGAR knockdown occurs when miR are 
targeting the centre region of exon number 6, the largest of the gene. Contrary to this, 
the chaining of miRNAs targeting two or more different genes can usually result in 
lower knockdown effect of both genes, explaining the difference in the knockdown 
percentage between the two genes in the co-construct (Werness and Anderson, 
2010).  
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Both, TIGAR and PINK1, protein products are present within the cell in the 
cytoplasm or the mitochondrial membrane. Current antibodies against all forms of 
endogenous PINK1 lack reliability, where many of them recognise different cleaved 
products or do not recognise them at all, displaying unspecific background bands 
that are likely to be detected at different molecular levels (Deas et al., 2009). PINK1 
protein is processed and displayed in three different species within the cell: 1) as full 
length (~63 kDa), that upon mitochondrial depolarization it is cleaved by, 2) the 
mitochondrial processing peptidase into a 60-kDa intermediate form, and 3) a 52 
kDa mature form processed by the presenilin-associated rhomboid-like protein 
(PARL) (Greene et al., 2012; Jin et al., 2010). Therefore, the PINK1 protein has a 
short half-life due to its rapid cellular turnover and modifications (Liu et al., 2017), 
which explains the higher protein reduction when it is knocked down and detected 
when tagged with the eGFP protein. PINK1 mRNA levels remain to be a more 
reliable source for PINK1 detection, since they are ubiquitously stably expressed 
within the cell (Blackinton et al., 2007; Duan et al., 2014).  
 
TIGAR and PINK1 knockdown results by WB were both confirmed and 
verified in the stable inducible cell lines by detection of mRNA levels by qPCR. We 
were confident of our results and the silencing effect mediated by the miRNAs (miRs) 
to study the effect in the mitochondrial function and morphology in the cellular 
inducible models.    
4.5.2  Stable inducible models 
There are a wide variety of techniques for transient RNAi, such as: 
microinjection of the desired specific nucleotide sequence, viral and plasmid vectors 
carrying genes and probes that target specific cell. However, one shortcoming with 
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the microinjection is that only a very limited number of cells are transfected (Hsu and 
Uludağ, 2012). Viral vectors have the characteristic to be very useful for 
transfections in primary cells, which are difficult to transfect. Another advantage of 
viral and plasmid vectors is that they often carry a marker for cellular selection of 
cells successfully transduced. Viral vectors require the transcriptional machinery 
from the host to express integrated DNA material. Thus, the host is exposed to 
random integration of the DNA material alongside the bio-hazard risk implied when 
using a viral vector (Ramachandran and Ignacimuthu, 2013). 
 
Stable inducible cell lines offer several advantages for investigating the 
biological and molecular processes not only for PD but for a number of human 
diseases (Falkenburger et al., 2016; Kappel et al., 2007). They can be grown for 
longer periods of time and be produced in larger quantities. The gene function can 
be assessed in a spatiotemporal manner, where gain or loss of function mutations 
are avoided. By turning on and off the gene expression, it helps to understand the 
involvement in the development and progression of the disease. Gene over-
expression can be also studied through this approach and assess gene dose cellular 
effect and toxicity. More than one gene can be easily introduced by the carrying 
vector; allowing to assess protein levels as well as to investigate the clonal 
functionality when different genes are integrated in the same cell. The system also 
prevents the risk of random integration, undesired, not predictable and not 
reproducible gene and cellular effects are minimal (Yahata et al., 2005). 
 
 The Tetracycline-Inducible Flp In T-Rex System from Thermo Fisher 
Scientific provides the tools for generation of stable, isogenic and inducible cell lines 
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with a unique FRT integration site. All of which will contain identical backgrounds and 
cellular models can be generated to knockdown or introduce mutations of a 
particular gene of interest. By using this system, we were then able to generate three 
stable inducible cellular models: HEK Flp TIGAR, PINK1 and co-construct TIGAR-
PINK1 for PD research. The generated cell lines from each model showed a good 
knockdown for both genes, particularly PINK1. The clones with the highest 
percentage reduction at the mRNA level were used to assess the mitochondrial 
function and morphology. However, for Flp TIGAR and the co-construct Flp 
TIGAR/PINK1 cell model, TIGAR silencing showed to be more variable and < 50% at 
the mRNA and protein level. This could be due to the fact that it is a metabolic 
protein and any cellular insult may modify its expression, which is also highly 
dependent in the cellular type. Moreover, HEK cells have a higher TIGAR expression 
than PINK1, which also affects the knockdown effect.    
4.5.3  Limitations  
Opposed to neurons, where the pathology occurs, the HEK cellular model is 
continuously dividing. The ongoing division could be providing the cell the 
opportunity to repair and compensate the damage by alternative mechanisms. 
Stable HEK cells have shown similar physiological effects as neuronal cells, however 
stable expression and phenotype maintenance had been difficult in some cellular 
types, with irreproducible results subjected to different culture conditions. Moreover, 
HEKs are cells with a different phenotype and metabolism different to neurons 
(Stepanenko and Dmitrenko, 2015). To overcome this problem, inducible models 
could be transformed into dopaminergic neurons by converting them either into iPSC, 
or directly into induced human neuronal progenitor cells (iNPCs). Mitochondrial 
translation, glycolysis, mitochondrial functions, protein balance between 
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mitochondrial and nucleus, and molecular changes are suggested to occur in cells 
induced with doxycycline mainly and less likely with tetracycline. (Houtkooper, 2015).  
4.5.4  Mitochondrial morphology and function  
 Mitochondrial function and morphology are impaired in PINK1 deficiency. In 
this study we assessed the changes obtained in the mitochondrial morphology in the 
HEK Flp cells with either PINK1 and/or TIGAR and with TIGAR/PINK1 deficiency. 
Our current results suggested that they might not be affecting the mitochondrial 
morphology in HEK cells.  
 
There are a number of reasons for our current results. First, HEK cells have a 
small particular size (20-30µm length). The detection by the high throughput 
microscopy analysis, OPERA Phoenix, provides better results in larger cells with flat 
morphology. This is explained by the fact the mitochondrial morphology 3D images 
are represented by the obtained 2D image. Moreover, some proteins that are 
constitutively highly expressed might be influencing the expression of the exogenous 
or introduced gene (Thomas and Smart, 2005). Since HEK Flp In are not neuronal 
cells, some genes and protein products might have different levels of expression and 
post-translational modifications. Their rapid growth, clusters or clumps formation and 
cell to cell variation might also contribute to obtained results  
 
A link between mitochondrial function, mitochondrial complexes, mitochondrial 
complexes, ATP production and morphology has been demonstrated in a diversity of 
non-neuronal cellular models. This has been mainly reported in cell lines and tissue 
from patients with PINK1, Parkin and LRRK2 (G2019S) mutations. The zebrafish 
study demonstrated a clear deficit in mitochondrial complex I and III, which 
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correlated with increased tigarb (zebrafish homologue) expression in pink1 
deficiency (Flinn et al., 2013). Here, we aimed to investigate whether the 
mitochondrial function and ATP production is affected in TIGAR and PINK1 
deficiency models, and if there is a rescue effect when both genes are silenced in 
the cell.  
 
 In this study, the three HEK Flp In cellular models showed that ATP cellular 
levels were different within the two growth medium conditions. In glucose presence, 
HEK Flp TIGAR and TIGAR/PINK1 cells showed a drop in ATP levels, which was 
only significant when compared to the negative control (HEK Flp CRNAi) but not the 
not induced control cells. Interestingly, HEK Flp PINK1 cells showed higher ATP 
cellular levels compared to its not induced control (Figure 4.13 a). This could be due 
to the fact that higher cellular ATP levels in cells in culture rely on glucose and 
glycolysis. Thus, in PINK1 deficiency, cells still rely on glycolysis and generate ATP, 
whereas cells with TIGAR deficiency produce ATP via OXPHOS which is less active 
but more productive. PINK1 deficient cells in glucose free media had slightly lower 
ATP, whereas ATP in TIGAR deficient cells remained lower. Although cells have to 
switch to OXPHOS metabolism, cells with lower ATP production have been shown to 
have severe defects of the mitochondrial respiratory chain complexes. Therefore, 
TIGAR deficient cells continued to generate energy through OXPHOS. PINK1 
deficient had a tendency to produce lower levels of ATP, which could be due to 
remaining active mechanisms for energy production. Furthermore, cells with 
TIGAR/PINK1 deficiency, had lower ATP levels in glucose presence, but not 
significant, whereas a tendency for an increase was seen in glucose free media. The 
overall results showed that ATP levels had a tendency to be affected in all three 
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cellular models, although we were expecting a higher effect in all of them. One of the 
most likely explanations for the obtained results is a relation between the knockdown 
percent in each cell line. TIGAR knockdown was achieved at ~50% and ~80% for 
PINK1, with similar results in the cell line with TIGAR/PINK1 deficiency. The fact that 
there are still cells able to express either TIGAR or PINK1, explains the impact on 
the ATP levels obtained for each model. Furthermore, not induced cells could be 
also expressing the miRNA and repressing the targeted genes, thus interfering with 
the outcome. Moreover, since cells were induced, split and plated 24 hrs for the 
assay, acute compensatory mechanisms could be triggered within the cells. 
Therefore, a still active glycolytic pathway and other sources of energy (eg. 
Glutamine) that could be triggered by the cell as a compensatory mechanism might 
increase the ATP production levels in the cells.  
 
Recently, PINK1 levels have been directly correlated with ATP cellular levels 
dependent in glucose as a source. Low levels of PINK1 expression were found in 
cultures with low levels of glucose, likely due to impaired translation. Furthermore, 
PINK1 expression levels were found to depend in an active glycolytic pathway rather 
than the glucose content. A link between glucose metabolism, PINK1 mitochondrial 
damage sensing mechanisms and PINK1/Parkin mitophagy pathway have been 
suggested (Lee et al., 2014b) and with opposed results in other some lines (Yao et 
al., 2011) . TIGAR role in neuronal metabolism is still unclear, it has been suggested 
only to be a neuroprotector only after ischemia-reperfusion events (Cao et al., 2015; 
Li et al., 2014; Sun et al., 2015; Zhou et al., 2016). The suspected role of TIGAR in 
PINK1 deficiency related mechanisms in PD still remain unclear. Interestingly, in 
glioblastoma cells TIGAR and PINK1 have opposed effects, in which the linked 
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mechanisms are by their effect in cellular growth and survival. Both genes are 
regulators of the Warburg effect, in which cellular main source of energy is through 
glycolysis. TIGAR positive regulator provides cellular survival (Peña-Rico et al., 2011; 
Sinha et al., 2013; Wanka et al., 2012) , whereas PINK1 negative regulation impairs 
cellular growth (Agnihotri et al., 2016). However, both act as ROS scavengers 
preventing cellular death (Agnihotri et al., 2016; Peña-Rico et al., 2011; Sinha et al., 
2013; Wanka et al., 2012). These mechanisms could be the link between TIGAR and 
PINK1-related PD pathology. However, it is still unknown how exactly TIGAR is 
involved in PD PINK1 related pathology.  
 
The present study remains to be confirmed and further optimised to detect 
significant changes in the mitochondrial function and morphology, as well as further 
related mechanisms such as autophagy/mitophagy, which have been both related to 
TIGAR and PINK1. Moreover, higher knockdown needs to be achieved for both 
models, which could be performed by optimising the protocol and studied the effect 
at different time-points. ATP defects are highly correlated to defects in the 
mitochondrial respiratory chain. The mitochondrial chain complexes should also be 
assessed since the original zebrafish pink1 deficient model showed complex I and III 
defect. Energy demands and metabolism are different depending on the cellular type, 
which has been also demonstrated true for the function of TIGAR and PINK1. 
Therefore, the link between both genes need to be studied in a dopaminergic 
neuronal model, which could be achieved by converting the cells into induced human 
neuronal progenitor cells (iNPCs).     
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4.5.5  CRISPR/Cas 9: TIGAR and PINK1 
 The new era in genomic engineering brought the CRISPR/Cas9 approach for 
genome editing. This new method offers many advantages compared to previous 
systems like zinc-finger nucleases (ZFN) and transcription activator-like effector 
nucleases (TALENs), which are highly complex and expensive. With CRISPR/Cas9 
a specific gene sequence is targeted, yielding a higher efficiency. Moreover, it allows 
the introduction of two or more sgRNAs targeting different sites in the genome.     
 
One of the main limitations of this technique is the possible occurrence of off-
target effects. Random integration and repair can also result in different cellular 
mosaic mutations. One of the recent developed approaches to avoid those effects is 
by the “double nicking” method using nickase endonucleases. In this study, we used 
the combination of an All-In One vector and Nickase approach to generate 
CRISPR/Cas9 cell lines with TIGAR and PINK1 deficiency. Generation and selection 
of the clones were done without any FACS and only by antibiotic selection and clone 
isolation. This could explain the variability obtained in the TIGAR protein level and 
the PINK1 expression between and within the same clones.  As previous results with 
the FLP-In T-Rex system from Invitrogen, TIGAR showed to have less effective 
knockdown in HEK cells (Figure 4.10 and Figure 4.17), whereas almost a complete 
knockout of PINK1 (~80-90%) (Figure 4.11 and Figure 4.18) was achieved by using 
both methods. One of the main caveats is that without FACS sorting and any assay 
for checking the correct integration and screening for mutations (eg. Surveyor or 
T731 assays) before clonal expansion. However, recently a study by Manikoth 
Ayyathan et al., 2017; showed that the main difference obtained in knockout 
efficiency is due to the cell line rather than the method approached (Manikoth 
Ayyathan et al., 2017).  
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CRISPR/Cas 9 TIGAR tested clones also showed an effect in Actin protein 
level, which could be due to an off-target effect within the clones. Another main 
limitation with CRISPR/Cas9 is that the cell lines are not isogenic, compared to the 
FLP-In cells, and mosaic mutations within the different cell lines might still occur. 
Although CRISPR/Cas9 PINK1 cell lines showed higher knockdown, some clones 
were only tested in two biological replicates. Further confirmation awaits by 
assessing the protein level and gene expression in three biological replicates for 
both genes to confirm effective gene knockdown/knockout, from all the obtained 
clones to select the best one. Before any functional analysis, sequence the full 
genome looking also for candidate off-target sites occurring within either TIGAR or 
PINK1 clones.    
 
In order to study the mechanisms involved in PD-related pathogenesis in the 
main affected region of the disease, the generated isogenic cell lines should be 
converted directly into induced neural stem cells or neural precursor cells to 
generate dopaminergic neurons.  
4.6 Conclusions 
Comparing both systems in the current study, it is clear that here the best 
approach for gene knockdown is by the FLP-In T-Rex system. Limited time for the 
generation of the CRISPR/Cas9 cell models for TIGAR and PINK1 is one of the 
reasons of the lower efficiency and efficacy of this system in this approach. 
Optimisation of the method should be performed in a suitable cell model in which a 
knockout for both genes could be successfully achieved. The dopaminergic neurons, 
248 
 
in the SN, are the main site affected in PD, where the pathology results in neuronal 
death and disease phenotype.  
 
To fully understand the underlying mechanisms leading to PD and related to 
TIGAR and PINK1, studies need to be conducted in a dopaminergic neuronal model 
and in vivo. Overexpression of TIGAR in PINK1 deficient neurons could help to 
understand if TIGAR has a toxic effect within the cells. It would be interesting and 
valuable to understand the role of PINK1 overexpression in dopaminergic neurons 
with TIGAR deficiency.  Overall, we were able to establish a stable inducible cell 
model for TIGAR and PINK1. We showed a tendency to an effect on mitochondrial 
function, but this was not significant. These results require to be optimised over 
different time points and be studied together with the mitochondrial respiratory 
complexes.  
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5 General Discussion and Conclusions 
5.1 TIGAR expression in different cellular models 
TIGAR is a multifunctional protein with a number different binding regulators 
and targets. Its expression is tightly regulated and depends on the cell type and the 
nature of the stimuli. In our study, there was widespread TIGAR expression in the 
different brain regions studied, as well as in human fibroblasts, HEK293, LUHMES 
and SHSY-5Y cells. This supports the proposed role of TIGAR to maintain cellular 
homeostasis across different cell types and tissues. The main function of TIGAR is to 
inhibit glycolysis and promote the metabolic shunt to the Pentose Phosphate 
Pathway (PPP). The function of TIGAR as a pro-survival protein is reflected by its 
capacity to provide antioxidant defence against ROS, cellular stress and hypoxia, 
and nucleotides for DNA synthesis (Bensaad et al., 2006).  
 
How TIGAR-related pathways might be contributing to PD and 
neurodegeneration are still unclear. Since it is a glycolysis inhibitor, in cells that are 
highly depending on energy production from the glycolytic pathway, such as neurons, 
this function might be deleterious for them. PINK1 deficiency causes OXPHOS 
impairment, making the cell rely on ATP production by other sources different from 
the mitochondria, but from glycolysis. TIGAR overexpression impact on glycolysis 
might therefore have a particularly marked effect in PINK1 mutant tissue.  
 
However, TIGAR expression similar in the sporadic PD brains as well as in 
fibroblasts from patients with parkin mutations compared to controls. PINK1 and 
Parkin share many cellular functions. However, there is also evidence of them acting 
in independent pathways (Kageyama et al., 2014; Lazarou et al., 2015; Murakawa et 
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al., 2015). This suggests that TIGAR up-regulation may be a specific feature of 
PINK1-related disease. Unlike in familial cases, a complex interplay between 
environmental and genetic factors will contribute to the development of the disease 
in patients with sporadic PD. Thus, different genes and pathways might explain the 
wide variation of TIGAR levels in our study. Unfortunately, we did not have access to 
PINK1 mutant PD patient tissue.      
 
TIGAR was found to co-localise with alpha-synuclein in the Lewy bodies, 
which could be due to a synergetic interaction, altering their conformation and 
leading to further aggregation. The interaction between alpha-synuclein and TIGAR, 
alongside the previous finding of TIGAR overexpression in the pink1 deficient model, 
suggests new shared mechanisms in sporadic and familial PD. However, proof of 
interaction awaits further investigation, using co-immunoprecipitation assays in the 
PD and DLB brain extracts, stable cell lines overexpressing alpha-synuclein with and 
without additional stressors such as oxidative stress. Since oxidative stress has been 
suggested to be one of the mechanisms in PD and demonstrated to be related to 
alpha-synuclein, TIGAR and PINK1, it would be interesting to study TIGAR and 
alpha-synuclein interaction in the generated stable cell lines, as well as in induced 
neurons under oxidative stress conditions. Many proteins including the PD-related 
LRRK2, PINK1 and Parkin proteins showed impaired conjugation under oxidative 
stress and have also been detected in Lewy bodies (Brudek et al., 2016b; Murakami 
et al., 2007; Volpicelli-Daley et al., 2016). Notably, only antibodies against the C-
terminal did recognise TIGAR in the neuronal bodies and Lewy bodies, which 
suggests that the protein might be fragmented or has undergone a conformational 
change. This could result in misfolding, reduced solubility and aggregation of TIGAR 
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protein in the inclusions.  
5.2 The suspected role of TIGAR in PD 
The zebrafish pink1 deficient model showed a defect in the mitochondrial 
complex I and III, with a slight defect in the mitochondrial morphology but no ATP 
assays were carried out (Flinn et al., 2013).   
 
 In this study, we assessed the effect of TIGAR and PINK1 knockdown in a 
stable inducible cell culture model, where we did not see a mitochondrial defect. We 
found some promising results carried out in the human fibroblasts with TIGAR 
knockdown, but overall the results were inconclusive due to the transfection affecting 
the mitochondrial function. Therefore, our results obtained in fibroblasts and HEK 
cells suggest that mitochondrial function and morphology might not be affected by 
TIGAR levels. However, these results are inconclusive and require further 
optimisation. Fibroblasts and HEK cells are not neuronal cells and their metabolic 
demands differ from neurons. Neuronal metabolisms and energetic demands have 
been demonstrated to depend on glucose metabolism, where the Pentose 
phosphate pathway (PPP) was suggested to be essential. Continue damage in 
neurons has been reported to occur from oxidative stress. TIGAR has been 
demonstrated to function as a pro-survival (Bensaad et al., 2006; Cheung et al., 
2013b; Ma et al., 2017; Martinez-Outschoorn et al., 2010; Peña-Rico et al., 2011; 
Wanka et al., 2012; Yin et al., 2012b), as well as an apoptotic mediator in different 
cell types (Hoshino et al., 2012; Kimata et al., 2010). Moreover, a dual function in 
autophagy and apoptosis has been demonstrated in cancer cell lines (Cheung et al., 
2015; Xie et al., 2014). So, TIGAR might be acting as a neuroprotector by 
dampening the ROS levels and maintaining NADPH and glutathione levels to 
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prevent further damage (Bolaños and Heales, 2010; Herrero-Mendez et al., 2009). 
As a glycolysis inhibitor, TIGAR might also promote cellular death by inhibiting 
glycolysis, leading vulnerable cells and unable to meet energetic demands. 
Furthermore, TIGAR has been demonstrated to protect neurons and other cell types, 
by preventing damage from ischemic injury (Al-Maghrebi and Renno, 2016; Cao et 
al., 2015; Hoshino et al., 2012; Li et al., 2014; Sun et al., 2015; Zhou et al., 2016). 
However, several studies have suggested a dysregulation of the PPP pathway and 
glucose metabolism as one of the earliest events occurring in the pathogenesis of 
neurodegeneration (Bouzier-Sore and Bolaños, 2015; Dunn et al., 2013; Hilker et al., 
2012) providing a tentative but largely hypothetical link with TIGAR.  
 
TIGAR was only detected in Lewy bodies but not in other intracellular 
inclusion bodies, which further reinforces the hypothesis of its disease specificity. 
Therefore, since we TIGAR was present in pathological inclusions of PD and DLB 
patients, it will be interesting to study the effect of its overexpression in induced 
neurons (iN) from fibroblasts with familial and sporadic PD as well as in the 
generated stable cell lines (Hek Flp In) with PINK1 deficiency. TIGAR was found to 
co-localise with alpha-synuclein, therefore, we propose to study the effect of alpha- 
synuclein overexpression when TIGAR is either absent or overexpressed in cultured 
neuronal models.   
 
TIGAR is one of the target proteins of p53, but we did not find evidence of p53 
upregulation in in the post-mortem tissue of the PD and DLB brains. A number of 
p53-independent TIGAR mechanisms have been demonstrated in several cellular 
models under different physiological and stress conditions, which could explain this 
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finding (Sinha et al., 2013; Venkatanarayan et al., 2016; Zou et al., 2012, 2013). The 
p53-independent pathways might provide insight into the suspected role of TIGAR in 
PD. However, p53 was not investigated in the generated stable cell lines and in the 
PD patient fibroblasts.  
 
Reduced ROS levels have been suggested to be associated to autophagy 
inhibition (Bensaad et al., 2009; Ye et al., 2013), where TIGAR opposes autophagy 
(Bensaad et al., 2009). Autophagy has also been suggested to play an important role 
for the development of PD. Therefore, defects in the autophagy pathway, have been 
suggested in PD and other neurodegenerative diseases (Rahman and Rhim, 2017). 
Lewy body pathology may be a consequence of cellular self-defence for clearance of 
cytotoxic proteins (Fecchio et al., 2013) TIGAR presence in Lewy bodies could be 
the result of the same cellular mechanism and suggests an acquired cytotoxic 
property of TIGAR. Both TIGAR and alpha-synuclein have been suggested to have a 
role in autophagy impairment, so increased production of both proteins may lead to 
impaired autophagy and promote protein aggregation. The role of TIGAR in 
autophagy was demonstrated in unstressed cells and independent from mTOR 
pathway. In this study we also investigated the role in TIGAR for autophagy in 
sporadic PD fibroblasts. In our hands, we did not find any impairment in autophagy in 
the patient tissue. However, the study was performed in only two patient cell lines. 
Moreover, unlike familial PD, the evidence of impaired autophagy in sporadic PD still 
remains inconclusive (Ryan et al., 2015).  
 
Further experiments in neuronal cellular models are required to study this 
hypothesis. 
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TIGAR pathways involving HK-I and HK-II were investigated in the brains of 
PD patients in the SN. We found a slight increase in HK-I expression but the 
difference did not reach statistical significance. TIGAR was reported to translocate to 
the mitochondria and interact with HK-II in cells upon hypoxic conditions and 
metabolic stress, providing survival to the cells (Cheung et al., 2012). No difference 
in the HK-II expression was found in our experiments, which might be explained by 
the fact that it has low levels of expression in the human brain. Moreover, we did not 
observe TIGAR translocation to the mitochondria after rotenone exposure. 
Furthermore, we only study the effect of rotenone exposure in one PD patient 
fibroblast cell line and did not study the association of TIGAR with HK-II in the stable 
cell lines. In order to verify TIGAR association with HK-II, further experiments need 
to be performed in a larger cohort of fibroblasts, in the stable cell lines and preferably 
in induced dopaminergic neurons.  Furthermore, microarrays in post-mortem tissue, 
stable inducible cell lines, human fibroblasts, derived neurons, exposed to metabolic 
stress would also provide insight into the disease pathomechanisms related to 
TIGAR. 
5.3 PD models: from zebrafish to post-mortem tissue and 
cellular models 
 In this study we used different cellular models to investigate TIGAR suspected 
role in PD.  They help to unravel TIGAR-related mechanisms leading to the disease, 
with their own advantages and disadvantages. Combining them provided us with a 
good insight of the suspected role of TIGAR in PD.  
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Zebrafish models are a valuable model to study human disease because they 
are in vivo models that are transparent, small size and with fast development. 
Moreover, they are a robust platform for genetic manipulation and drug screening, as 
well as to study development during embryogenesis and at different stages. Contrary 
to fly models, zebrafish are vertebrate animals, where many genes are highly 
conserved, and their findings can be translated into humans (Matsui, 2017).  
However, zebrafish also have some limitations. For example, they do not completely 
resemble the human brain. Morpholino antisense (MO) and TILLING approaches 
can sometimes lead to off-target effects (MO); depending on the size and sequence 
of the coding exons (Sood et al., 2013).   
 
In this study, we aimed to translate the findings in pink1 deficient zebrafish into 
human PD tissue. Post-mortem tissue offers great advantages over other models, 
and help us to gain insight into the pathogenesis of the disease. Their correct 
processing and handling help their preservation and provides an invaluable model 
for DNA, RNA and protein studies.  Fibroblast cultures are also derived from patient 
tissue. However, fibroblasts mirror the biochemical defect occurring in the neurons 
only partially., Investigations in post-mortem brain tissue can nevertheless be 
complemented by performing functional and enzymatic assays in living cells with or 
without a PD gene mutation. Confirmation of their function and interaction can be 
further investigated in a generated stable cell line, which is isogenic and genetically 
manipulated to study the gene/protein function of interest. Although post-mortem 
brain tissue studies are important for research in neurodegeneration, it has some 
limitations.  
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In vitro cellular models allow us to study the process and dynamics leading to 
impaired cellular function and cell death. Fibroblasts and HEK are both, cheap, 
commercially available, easy to handle and maintain, and well established models 
for disease research. HEK cell lines are easy to transfect, whereas fibroblasts are 
slightly more difficult to transfect cells. These cell lines were used when attempting 
TIGAR knockdown, showing different efficiency and efficacy due to their different 
behaviour. We found that TIGAR expression was higher in HEK cells compared to 
human fibroblasts, which resulted in a lower knockdown effect in HEK cells when 
compared to the fibroblasts. Moreover, the siRNA smart pool targets four regions in 
the gene, whereas the miRs target only one region of the gene. This suggests that 
due to the diversity amongst the cell lines and methods, to achieve the desired 
knockdown, an optimised general protocol had to be established for each cellular 
model.  
5.4 Concluding remarks 
TIGAR was found to be present in Lewy bodies in the SN of PD and DLB patients. 
Notably, TIGAR co-localises with alpha-synuclein. These findings suggest TIGAR 
role in neurodegeneration and Lewy body formation. TIGAR-positive pathological 
inclusions were only found in the SN. TIGAR-positive inclusions were not found in 
spinal cords of MND, or in the glial cytoplasmic inclusions of MSA cases. This 
suggests TIGAR specificity for Lewy-type pathology. p53 localization and expression 
was not found when comparing PD cases to controls. TIGAR is translated in human 
fibroblasts derived from patients with familial and sporadic PD. TIGAR gene 
expression and protein level was not significantly different in parkin-mutant 
fibroblasts when compared to controls.  
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TIGAR knockdown was successful in parkin-deficient and LRRK2G2019S 
fibroblasts, however its effect could not be assessed due the transfection secondary 
effects. TIGAR cellular localisation is not affected in parkin-mutant fibroblasts 
exposed to rotenone toxicity and cellular stress. No evidence of TIGAR involvement 
after autophagy/mitophagy induction in sporadic PD patients in this particular study. 
 
A stable inducible cell model for TIGAR and PINK1 deficiency was established to 
investigate TIGAR-pathology in PD. An effect on mitochondrial function was seen, 
but without statistical difference. These results require further optimisation and to be 
studied together with the mitochondrial respiratory complexes.  
5.5 Future studies 
Further cellular and post-mortem tissue studies need to be conducted to 
elucidate the TIGAR-related pathological mechanisms and pathways leading to 
neurodegeneration. These studies should be performed in more controls and PD 
patients with Parkin and/or PINK1 mutations. Moreover, further TIGAR up and 
downregulators (i.e., SP-1, CREB, mTOR, ATM) should be assessed to elucidate 
TIGAR related mechanisms. Further assays, such as co-immunoprecipitation assays, 
are needed in the PD and DLB brain extracts, stable cell lines overexpressing alpha-
synuclein and neuronal cellular models, with and without additional stressors such as 
oxidative stress and severe hypoxia. Future experiments aiming to determine TIGAR 
role in autophagy in human fibroblasts would need to be done in more patients with 
sporadic and familial PD, ideally with PINK1 mutations, in order to fully address its 
role in mitochondrial function and autophagy/mitophagy PD-related mechanisms.   
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TIGAR effect and mechanisms need to be performed in cellular and neuronal, 
in vitro and in vivo models, with PD-related mutations should be attempted by 
alternative methods such as stable transduction. Neuronal models with TIGAR 
and/or alpha-synuclein overexpression are required to study its effect in the 
mitochondrial function, autophagy/mitophagy and cellular survival. 
 
Although CRISPR/Cas9 achieved good knockdown, mainly for PINK1, a small 
limited number of clones were tested. Further confirmation needs to be done by 
assessing the protein level and gene expression in three biological replicates for 
both genes to confirm effective gene knockdown/knockout. Before any functional 
analysis, sequence the full genome looking also for candidate off-target sites 
occurring within either TIGAR or PINK1 clones. Once achieved, this new promising 
technique will be ideal to develop and establish stable neuronal lines to verify and 
investigate further TIGAR-PD related mechanisms and pathways. 
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